NHS Connecting for Health

NHS Data Model and Dictionary Service

Type:Patch
Reference:1338
Version No:1.0
Subject:November Release Patch
Effective Date:Immediate
Reason for Change:Patch
Publication Date:20 November 2012

Background:

This patch updates the NHS Data Model and Dictionary in preparation for the November 2012 Release and includes:

To view a demonstration on "How to Read an NHS Data Model and Dictionary Change Request", visit the NHS Data Model and Dictionary help pages at: http://www.datadictionary.nhs.uk/Flash_Files/changerequest.htm.

Note: if the web page does not open, please copy the link and paste into the web browser.

Summary of changes:

Central Return Forms
KC62 A 1   Changed Description
KC62 A 2   Changed Description
KC62 A 3   Changed Description
KC62 ANNEX 1   Changed Description
KC62 B 1   Changed Description
KC62 B 2   Changed Description
KC62 B 3   Changed Description
KC62 C1 1   Changed Description
KC62 C1 2   Changed Description
KC62 C1 3   Changed Description
KC62 C2 1   Changed Description
KC62 C2 2   Changed Description
KC62 C2 3   Changed Description
KC62 D 1   Changed Description
KC62 D 2   Changed Description
KC62 D 3   Changed Description
KC62 E 1   Changed Description
KC62 E 2   Changed Description
KC62 E 3   Changed Description
KC62 F1 1   Changed Description
KC62 F1 2   Changed Description
KC62 F1 3   Changed Description
KC62 F2 1   Changed Description
KC62 F2 2   Changed Description
KC62 F2 3   Changed Description
KC62 T 1   Changed Description
KC62 T 2   Changed Description
KC62 T 3   Changed Description
 
Supporting Information
ABOUT US HELP   Changed Description
GLOSSARY OF TERMS   Changed Description
INDEX   Changed Description
SAME SEX ACCOMMODATION   Changed Description
SECURITY ISSUES AND PATIENT CONFIDENTIALITY   Changed Description
SUPPORTING INFORMATION MENU   Changed Description
WHAT'S NEW: NOVEMBER 2012 renamed from WHAT'S NEW: SEPTEMBER 2012   Changed Name, Description
 
Attribute Definitions
ACTIVITY DATE AND TIME TYPE   Changed Description
ATTENDED OR DID NOT ATTEND   Changed Description
CURRENCY TYPE   Changed Description
LIVE OR STILL BIRTH   Changed Description
MEASUREMENT VALUE TYPE CODE   Changed Description
ORGANISATION CODE   Changed Description
ORGANISATION SITE CODE   Changed Description
PATIENT DIAGNOSIS TYPE FOR NHS HEALTH CHECK   Changed Description
 
Data Elements
ABSENCE WITHOUT LEAVE END DATE (RETIRED) renamed from ABSENCE WITHOUT LEAVE END DATE   Changed Name, status to Retired, Description
ABSENCE WITHOUT LEAVE START DATE (RETIRED) renamed from ABSENCE WITHOUT LEAVE START DATE   Changed Name, status to Retired, Description
ACTIVITY TREATMENT FUNCTION CODE   Changed Description
ASSESSMENT DATE (FOR TRANSPLANT SUITABILITY)   Changed Description
CDS RECORD IDENTIFIER   Changed Description
COMMISSIONER OR PROVIDER STATUS INDICATOR   Changed Description
COMMISSIONER REFERENCE NUMBER   Changed Description
COMMISSIONING SERIAL NUMBER   Changed Description
EARLIEST CLINICALLY APPROPRIATE DATE   Changed Description
END TIME (SUPERVISED COMMUNITY TREATMENT RECALL)   Changed Description
LEAVE OF ABSENCE END DATE (RETIRED) renamed from LEAVE OF ABSENCE END DATE   Changed Name, status to Retired, Description
LEAVE OF ABSENCE START DATE (RETIRED) renamed from LEAVE OF ABSENCE START DATE   Changed Name, status to Retired, Description
OPERATION STATUS CODE   Changed Description
PASSPORT NUMBER (OLD)   Changed Description
PERSON BIRTH DATE   Changed Description
PERSON BIRTH DATE (BABY)   Changed Description
PERSON BIRTH DATE (MOTHER)   Changed Description
PERSON HEIGHT IN CENTIMETRES   Changed Description
PERSON HEIGHT IN METRES   Changed Description
RENAL TREATMENT MODALITY NO TREATMENT REASON DATE   Changed linked Attribute
 
Packages
NE renamed from NE   Changed Name
OC renamed from OF   Changed Name
 

Date:20 November 2012
Sponsor:Richard Kavanagh, NHS Connecting for Health

Note: New text is shown with a blue background. Deleted text is crossed out. Retired text is shown in grey. Within the Diagrams deleted classes and relationships are red, changed items are blue and new items are green.

Click here for a printer friendly view of this page.


KC62 A 1

Change to Central Return Form: Changed Description

Central Return Form Guidance
 

KC62: Adult Screening Programmes - Breast Screening

  1. Table A: 1st Invitation for Routine Screening

    This table reports the persons in a Screening Programme (see PERSON IN PROGRAMME) for Breast Screening whose SCREENING STATUS is first call.

    Part A1: Invitations and Outcomes
  2. Table A: 1st Invitation for Routine Screening
    Part A1: Invitations and Outcomes
    • This is a summary of the outcomes of screening and assessment of all women invited and/or screened.

      Age at first offered appointment (first column)
    • This is derived from the BIRTH DATE of the PERSON. Line 01 includes all women who were aged 44 or less at the time of the date of their first offered appointment for screening in the period covered by the return. Lines 02 to 09 include women in specified age groups. Line 10 includes all women who were aged 75 or over. Line 11 gives the total of all women in lines 03 to 08, giving a summary of the women in the NHS Breast Screening Programme target age range of 50 to 70 - the Screening Population. Line 12 gives the total of all women in lines 01 to 10 regardless of age.

    • This is derived from the PERSON BIRTH DATE of the PERSON. Line 01 includes all women who were aged 44 or less at the time of the date of their first offered appointment for screening in the period covered by the return. Lines 02 to 09 include women in specified age groups. Line 10 includes all women who were aged 75 or over. Line 11 gives the total of all women in lines 03 to 08, giving a summary of the women in the NHS Breast Screening Programme target age range of 50 to 70 - the Screening Population. Line 12 gives the total of all women in lines 01 to 10 regardless of age.

    • Lines 13 - 24 in Part A2 Assessment and lines 25 - 36 in Part A3 Cancer diagnosed follow the pattern described above.

      Number of women invited (column 1)
    • Count of Screening Test Invitations where the first Screening Test Invitation has a first test date offered (see APPOINTMENT DATE OFFERED) in the period covered by the return.

      Lost to follow-up after technically inadequate screening mammogram (column 2)
    • Count of women whose SCREENING TEST RESULT classification was Inadequate test, and for whom no REFERRAL REQUEST for breast assessment was made.

      Number screened (technically adequate) (column 3)
    • Count of women with a Screening Test Date in the period covered by the return whose SCREENING TEST RESULT classification was not Inadequate test.

      Outcome of initial screen : Not known (column 4)
    • Count of women with a valid Screening Test Date but where no breast cancer screening test outcome (see BREAST ASSESSMENT OR TEST OUTCOME) has been recorded.

      Outcome of initial screen: Routine recall (column 5)
    • Count of women with a breast cancer screening test outcome classification of Routine recall.
      Outcome of initial screen: Early recall (column 6)
    • Count of women with a breast cancer screening test outcome classification of Early recall but without a REFERRAL REQUEST for breast assessment.

      Outcome of initial screen: Referred for assessment (column 7)
    • Count of women with a REFERRAL REQUEST for breast assessment. This covers all the women reported in columns 8 to 12.

      Final outcome of assessment: Failed to attend for assessment (column 8)
    • Count of women with a REFERRAL REQUEST for breast assessment who failed to attend for all required assessment appointments and for whom there is no breast assessment final outcome (see BREAST ASSESSMENT OR TEST OUTCOME).

      Final outcome of assessment: Outcome of assessment not known (column 9)
    • Count of women with a breast assessment date (see ACTIVITY DATE) but where no breast assessment final outcome has been recorded.

      Final outcome of assessment: Routine recall (column 10)
    • Count of women with a breast assessment date and a breast assessment final outcome classification of Routine recall.

      Final outcome of assessment: Early recall (column 11)
    • Count of women with a breast assessment date and a breast assessment final outcome classification of Early recall.

      Final outcome of assessment: Cancer (column 12)
    • Count of women with a breast assessment date and a breast assessment final outcome classification of Cancer diagnosed. The total recorded in this column will equal the total recorded in columns 13, 18 and 24.

      Part A2: Assessment
    • This part breaks down the outcomes of assessment by the procedures involved for all women assessed as a result of screening.

      Cancer diagnosed without cytology or histology (column 13)
    • Count of women with a breast assessment date and a breast assessment final outcome classification was Cancer diagnosed, but who had no REFERRAL REQUEST for biopsy or a REFERRAL REQUEST for biopsy where the PATHOLOGY INVESTIGATION TYPE CODE classification was not Cytology and the BIOPSY REFERRAL OUTCOME classification was Inconclusive.

      Referred for cytology and/or core biopsy (column 14)
    • Count of women with a breast cancer screening test outcome classification of Referred for assessment and a subsequent REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE CODE classification of Cytology or Core biopsy.
      Not referred for open biopsy: No result recorded/inadequate result (column 15)
    • Count of women with a breast cancer screening test outcome classification of Referred for assessment and a subsequent REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE CODE classification of Cytology or Core biopsy but without any PATHOLOGY INVESTIGATION TYPE CODE classification of Histology (open biopsy). These women did not complete any or all procedures within 6 months of the date of the screen or had no breast assessment final outcome recorded.

      Not referred for open biopsy: Routine recall (column 16)
    • Count of women with a breast cancer screening test outcome classification of Referred for assessment, a subsequent REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE CODE classification of Cytology or Core biopsy but without any PATHOLOGY INVESTIGATION TYPE CODE classification of Histology (open biopsy). These women have a breast assessment final outcome classification of Routine recall.

      Not referred for open biopsy: Early recall (column 17)
    • Count of women with a breast cancer screening test outcome classification of Referred for assessment, a subsequent REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE CODE classification of Cytology or Core biopsy but without any PATHOLOGY INVESTIGATION TYPE CODE classification of Histology (open biopsy). These women have a breast assessment final outcome classification of Early recall.

      Not referred for open biopsy: Cancer (column 18)
    • Count of women with a breast cancer screening test outcome classification of Referred for assessment, a subsequent REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE CODE classification of Cytology or Core biopsy but without any PATHOLOGY INVESTIGATION TYPE CODE classification of Histology (open biopsy). These women have a breast assessment final outcome classification of Cancer diagnosed.

      Referred for open biopsy (column 19)
    • Count of women with a REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE CODE classification of Cytology or Core biopsy followed by a REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE CODE classification of Histology (open biopsy).

      Total referred for open biopsy (column 20)
    • Total count of women with a REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE CODE classification of Histology (open biopsy).

      Up to and including open biopsy: No result/inadequate result (column 21)
    • Count of women with a REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE CODE classification of Histology (open biopsy). These women have a BIOPSY REFERRAL OUTCOME classification of Inconclusive or Biopsy not done or result not yet known or did not attend for the biopsy within 6 months of the date of the Screening Test having no recorded date biopsy taken (see ACTIVITY DATE) .
      Up to and including open biopsy: Result: Benign/normal: Routine recall (column 22)
    • Count of women with a REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE CODE classification of Histology (open biopsy). The BIOPSY REFERRAL OUTCOME classification is Benign or negative. The breast assessment final outcome classification for these women is Routine recall.

      Up to and including open biopsy: Result: Benign/normal: Early recall (column 23)
    • Count of women with a REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE CODE classification of Histology (open biopsy). The BIOPSY REFERRAL OUTCOME classification is Benign or negative. The breast assessment final outcome classification for these women is Early recall.

      Up to and including open biopsy: Cancer (column 24)
    • Count of women with a REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE CODE classification of Histology (open biopsy). The BIOPSY REFERRAL OUTCOME classification is Positive; i.e cancer diagnosed. The breast assessment final outcome classification for these women is Cancer diagnosed.

top


KC62 A 2

Change to Central Return Form: Changed Description

Central Return Form Guidance
 

KC62: Adult Screening Programmes - Breast Screening

  1. Table A: 1st Invitation for Routine Screening
    • Table A: 1st Invitation for Routine Screening
      Part A3: Cancers Diagnosed
    • This part of the return describes the cancers formally diagnosed in women assessed as a result of screening. Only breast cancers should be reported, as defined in the Information and Training Manual for England and Wales.

      Age at first offered appointment (first column)
    • This is derived from the BIRTH DATE of the PERSON and the test date offered (see ACTIVITY DATE) of the first Screening Test Invitation within the period of the return.

      Total number of women with cancer (column 25)
    • This is derived from the PERSON BIRTH DATE of the PERSON and the test date offered (see ACTIVITY DATE) of the first Screening Test Invitation within the period of the return.

      Total number of women with cancer (column 25)
    • Count of all women in columns 18 and 24 of Part 2 Assessment i.e. those women with a proven diagnosis of breast cancer.

      Invasive status not known (column 26)
    • Count of women included in Part 3 with a BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected invasive status not known.

      Non-invasive or possibly micro-invasive (column 27)
    • Count of women included in Part 3 with a BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected non-invasive or possibly micro-invasive.

      Definitely micro-invasive (column 28)
    • Count of women included in Part 3 with a BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected definitely micro-invasive.

      Invasive size (columns 29 - 33)
    • These columns count all cancers classified as invasive, separated according to the pathological size of the cancer (INVASIVE LESION SIZE). The BIOPSY REFERRAL OUTCOME classification is Positive; i.e. cancer detected invasive size known.

      Invasive size (of cancer)<10mm (column 29)
      Invasive size (of cancer)>=10mm & <15mm (column 30)
      Invasive size (of cancer)>=15mm & <20mm (column 31)
      Invasive size (of cancer)>=20mm & <50mm (column 32)
      Invasive size (of cancer)>=50mm (column 33)
      Invasive size: Size not known (column 34)
    • These columns count all cancers classified as invasive, separated according to the pathological size of the cancer (INVASIVE LESION SIZE). The BIOPSY REFERRAL OUTCOME classification is Positive; i.e. cancer detected invasive size known.

      Invasive size (of cancer)<10mm (column 29)
      Invasive size (of cancer)>=10mm & <15mm (column 30)
      Invasive size (of cancer)>=15mm & <20mm (column 31)
      Invasive size (of cancer)>=20mm & <50mm (column 32)
      Invasive size (of cancer)>=50mm (column 33)

      Invasive size: Size not known (column 34)
    • This column counts invasive cancers where the BIOPSY REFERRAL OUTCOME classification is Positive; i.e. cancer detected invasive size not known.

      Total invasive (column 35)
    • This column counts the total number of cancers classified as invasive, that is with a BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected invasive size known or Positive; i.e. cancer detected invasive size not known.

top


KC62 A 3

Change to Central Return Form: Changed Description

Central Return Form Guidance
 

KC62: Adult Screening Programmes - Breast Screening

  1. Part A4: Outcome measures
    • Part A4: Outcome measures
    • Part 4 presents a selection of outcome measures related to NHS Breast Screening Programme (NHSBSP) quality targets.

      Please note that where a column number is given within an outcome calculation, it relates to a specified column within the KC62 form for example:

      Number screened (technically adequate) (column 3) divided by Number of women invited (column 1) multiplied by 100 (for the appropriate age group).

      In this example (column 3) relates to Part 1 Invitations and Outcomes column 3.

      Age Groups of women (first column)
    • Outcome measures are assessed within three groups: the first being those within the previous target age range of 50-64, the second within the current target age range of 50-70 and the third, the total of those reported, regardless of age.

      Age Group (50-64) (line 37)
    • These are the outcome measures for women in the age group 50-64

      Age Group (50-70) (line 38)
    • These are the outcome measures for women in the age group 50-70

      Total all ages (line 39)
    • These are the outcome measures for women of all ages.

      Uptake rate (% of invited) (column 36)
    • This column gives the uptake rate (also known as the acceptance rate) for screening. It is defined as the percentage of women who receive a technically adequate and complete screen as a result of an invitation for routine screening, and is calculated as:

      Number screened (technically adequate) (column 3) divided by Number of women invited (column 1) multiplied by 100 (for the appropriate age group).

      Referral rate (% of screened) (column 37)
    • This column gives the rate of referrals to assessment from screening. It is defined as the percentage of women screened who are referred for any assessment procedure and is calculated as:

      Outcome of initial screen: Referred for assessment (column 7) divided by Number screened (technically adequate) (column 3) multiplied by 100 (for the appropriate age group).

      Non-invasive or micro-invasive cancers (per 1,000 screened) (column 38)
    • This column gives the cancers detected which are non-invasive, possibly micro-invasive, or definitely micro-invasive, per 1,000 screened calculated as:

      Non-invasive or possibly micro-invasive (column 27) plus Definitely microinvasive (column 28) divided by Number screened (technically adequate) (column 3) multiplied by 1000 (for the appropriate age group).

      Benign biopsy rate (per 1,000 screened) (column 39)
    • This column gives the women screened who have an open biopsy with a result of benign or normal per 1,000 screened, calculated as:

      Up to and including open biopsy: Result: benign/normal (columns 22 + 23) divided by Number screened (technically adequate) (column 3) multiplied by 1000 (for the the appropriate age group).

      Benign Therapeutic operation: Number (column 40)
    • This column gives the women screened who have an open biopsy with a result of benign or normal per 1,000 screened, calculated as:

      Up to and including open biopsy: Result: benign/normal (columns 22 + 23) divided by Number screened (technically adequate) (column 3) multiplied by 1000 (for the appropriate age group).

      Benign Therapeutic operation: Number (column 40)
    • This column gives the number of women screened who had a REFERRAL REQUEST for breast treatment and who had a BENIGN THERAPEUTIC OPERATION by the appropriate age group.

      Benign Therapeutic operation: Rate (per 1,000 screened) (column 41)
    • This column gives the women screened who have a BENIGN THERAPEUTIC OPERATION per 1,000 screened, calculated as:

      Number of BENIGN THERAPEUTIC OPERATIONS for the period (column 40) divided by Number screened (technically adequate) (column 3) multiplied by 1000 (for the appropriate age group).

      Invasive cancer detection rate (per 1,000 screened) (column 42)
    • This column gives the rate of invasive cancers detected per 1,000 women screened, calculated as:

      Total invasive (column 35) divided by Number screened (technically adequate) (column 3) multiplied by 1000 (for the appropriate age group).

      Detection rate of invasive cancers <10 mm (per 1,000 screened) (column 43)
    • This column gives the rate of invasive cancers smaller than 10mm detected per 1,000 women screened, calculated as:

      Invasive size < 10mm (column 29) divided by Number screened (technically adequate) (column 3) multiplied by 1000 (for the appropriate age group).

      Detection rate of invasive cancers <15 mm (per 1,000 screened) (column 44)
    • This column gives the rate of invasive cancers smaller than 15mm detected per 1,000 women screened, calculated as:

      Invasive size < 15mm (columns 29 + 30) divided by Number screened (technically adequate) (column 3) multiplied by 1000 (for the appropriate age group).

      Referral rate for cytology and/or core biopsy (% of screened) (column 45)
    • This column gives the percentage of women screened who are referred for fine needle aspiration cytology and/or core biopsy as part of the assessment process, calculated as:

      Referred for cytology and/or core biopsy (column 14) divided by Number screened (technically adequate) (column 3) multiplied by 100 (for the appropriate age group).

      Referral rate for open biopsy (% of screened) (column 46)
    • This column gives the percentage of women screened who are referred for an open biopsy, either directly from screening or following other assessment procedures, calculated as:

      Total open biopsy (column 20) divided by Number screened (technically adequate) (column 3) multiplied by 100 (for the appropriate age group).

      Pre-operative diagnosis rate (% of cancers diagnosed) (column 47)
    • This column gives the percentage of cancers diagnosed cytologically or histologically without surgery, calculated as:

      Not referred for open biopsy Cancer (column 18) divided by (Not referred for open biopsy Cancer (column 18) plus Open biopsy: Cancer (column 24)) multiplied by 100 (for the appropriate age group).

      Early recall rate following assessment (% of screened) (column 48)
    • This column gives the percentage of women screened who are recommended for early recall following any assessment procedure, calculated as:

      Early recall (column 11) divided by Number screened (technically adequate) (column 3) multiplied by 100 (for the appropriate age group).

      Number of invasive cancers observed (column 49)
    • This column gives the total number of detected cancers classified as invasive, calculated as:

      Total invasive (column 35) (for the appropriate age group).

      Number of invasive cancers expected (column 50)
    • This column is derived from the Number of invasive cancers observed (column 49) and a predefined incidence rate (calculated every three years for the appropriate age group).

      Please note KC62 is issued as an electronic spreadsheet and the predefined incident rate is contained within the spreadsheet for use within this calculation.

      Standardised Detection Ratio (SDR) (column 51)
    • This column is derived from column 49 and column 50.

      Please note KC62 is issued as an electronic spreadsheet and the formula to calculate this ratio is contained within the spreadsheet.

      Part A5: Data Completeness Indicators
    • Part A5 gives an indication of the completeness of data recorded on information systems in a variety of key areas.

      Please note that where a column number is given within an outcome calculation, it relates to a specified column within the KC62 form for example:

      Number screened (technically adequate) (column 3) divided by Number of women invited (column 1) multiplied by 100 (for the appropriate age group).

      In this example (column 3) relates to Part 1 Invitations and Outcomes column 3.

      Age Groups of women (first column) in Part A5.
    • Data Completeness Indicators are assessed within three groups: the first being those within the previous target age range of 50-64, the second within the current target age range of 50-70 and the third, the total of those reported, regardless of age.

      Age Group (50-64) (line 40)
    • These are the outcome measures for women in the previous target age group 50-64.

      Age Group (50-70) (line 41)
    • These are the outcome measures for women in the current target age group 50-70.

      Total all ages (line 42)
    • These are the outcome measures for all women reported, regardless of age.

      Assessment result not known (% of referred) (column 52)
    • This column gives the percentage of women assessed for whom the final outcome of assessment is not recorded, calculated as:

      Outcome of assessment not known (column 9) divided by Referred for assessment (column 7) minus Failed to attend for assessment (column 8) multiplied by 100 (for the appropriate age group)

      Cytology and/or core biopsy result not known (% of referred) (column 53)
    • This column gives the percentage of women referred for one or more cytology and/or core biopsy procedures, for whom a definitive result is not recorded and an open biopsy is not indicated. The column is calculated as:

      No result recorded/inadequate result (column 15) divided by Referred for cytology and/or core biopsy (column 14) multiplied by 100 (for the appropriate age group)

      Open-biopsy result not known (% of referred) (column 54)
    • This column gives the percentage of women referred for an open biopsy for whom a definitive result is not recorded, calculated as:

      No result /inadequate result (column 21) divided by Total open biopsy (column 20) multiplied by 100 (for the appropriate age group)

      Invasive status of cancer not known (% of all cancers diagnosed) (column 55)
    • This column gives the percentage of cancers diagnosed by cytology or histology in which the invasive status is not recorded. The column is calculated as:

      Invasive status not known (column 26) divided by Total number of women with cancer (column 25) multiplied by 100 (for the appropriate age group)

      Size not known (% of invasive cancers) (column 56)
    • This column gives the percentage of cancers diagnosed by cytology or histology which are recorded as invasive, but have no size recorded. The column is calculated as:

      Size not known (column 34) divided by total number of women with invasive cancer Total invasive (column 35) multiplied by 100 (for the appropriate age group)

      Lymph node status not known (% of invasive cancers) (column 57)
    • This column gives the percentage of cancers diagnosed by cytology or histology which are recorded as invasive, but the lymph node status is unknown. The column is calculated as:

      The number of women where no LYMPH NODE STATUS has been recorded and where the BIOPSY REFERRAL OUTCOME classification is Positive; i.e. cancer detected, invasive size known or Positive; i.e. cancer detected, invasive size not known divided by total number of women with invasive cancer: Total invasive (column 35) multiplied by 100 (for the appropriate age group)

      Grade not known (% of invasive cancers) (column 58)
    • This column gives the percentage of cancers diagnosed by cytology or histology, which are recorded as invasive, but the cancer grade is not known. The column is calculated as:

      The number of women where the BIOPSY REFERRAL OUTCOME is Positive; i.e. cancer detected, invasive size not known, grade not known or Positive; i.e. cancer detected, invasive size known, grade not known divided by total number of women with invasive cancer: Total invasive (column 35) multiplied by 100 (for the appropriate age group)

      Special type not known (% of invasive cancers) (column 59)
    • This column gives the percentage of cancers diagnosed by cytology or histology which are recorded as invasive, but the special type is not known. The column is calculated as:

      The number of women where no INVASIVE CANCER SPECIAL TYPE INDICATOR has been recorded and where the BIOPSY REFERRAL OUTCOME classification is Positive; i.e. cancer detected, invasive size known or Positive; i.e. cancer detected, invasive size not known divided by Total invasive (column 35) multiplied by 100 (for the appropriate age group)

      Grade not known (% of DCIS) (column 60)
    • This column gives the percentage of cancers diagnosed by cytology or histology, which are recorded as ductal carcinoma in-situ (DCIS), but the grade is not known. The column is calculated as:

      The number of women where the BIOPSY REFERRAL OUTCOME is Positive; i.e. cancer detected, non-invasive or possibly micro-invasive, grade not known (DCIS only detected) or Positive; i.e. cancer detected, definitely micro-invasive, grade not known (DCIS only detected) divided by total number of women with Non-invasive or possibly micro-invasive (column 27) plus Definitely micro-invasive (column 28) multiplied by 100 (for the appropriate age group)

      Part A6: Status of cancer
    • Part A6 gives status and grades of cancers detected.

      Age Groups of women (first column) in Part A6.
    • The status of cancers are assessed within three groups: the first being those within the previous target age range of 50-64, the second within the current target age range of 50-70 and the third, the total of those reported, regardless of age.

      Age Group (50-64) (line 43)
    • This is the outcome measure for women in the previous target age group 50-64

      Age Group (50-70) (line 44)
    • This is the outcome measure for women in the current target age group 50-70

      Total all ages (line 45)
    • This is the outcome measure for all women reported, regardless of age.

      Women with an invasive cancer detected: number with lymph nodes sampled (column 61)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known or Positive; i.e. cancer detected, invasive size not known with a <<a alias="name" href="ref:cc5368fa-21d1-11d9-b461-eb616f776d08"> where a LYMPH NODE STATUS has been recorded.

      Women with an invasive cancer detected: number positive (column 62)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known or Positive; i.e. cancer detected, invasive size not known where a LYMPH NODE STATUS has been recorded.

      Women with an invasive cancer detected: number positive (column 62)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known or Positive; i.e. cancer detected, invasive size not known where at least one Request for Pathology Investigation with a LYMPH NODE STATUS of lymph node positive has been recorded.

      Note where more than one Request for Pathology Investigation with a LYMPH NODE STATUS has been recorded for a woman and any one of the LYMPH NODE STATUSES is lymph node positive, then the woman should be included in column 62, but should not be included in column 63.

      Women with an invasive cancer detected: number negative (column 63)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known or Positive; i.e. cancer detected, invasive size not known with a Request for Pathology Investigation with a LYMPH NODE STATUS of lymph node negative.

      Note where more than one Request for Pathology Investigation with a LYMPH NODE STATUS has been recorded for a woman, then every LYMPH NODE STATUS should be lymph node negative for inclusion in count for column 63. If any of the LYMPH NODE STATUSES is lymph node positive, then the woman should be included in column 62 and not included in column 63.

      Women with an invasive cancer detected: number with 4 or more nodes assessed (column 64)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known or Positive; i.e. cancer detected invasive size not known with four or more Requests for Pathology Investigation where a LYMPH NODE STATUS has been recorded.

      Women with an invasive cancer detected: number with 4 or more nodes sampled: number positive (column 65)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known or Positive; i.e. cancer detected, invasive size not known with four or more Requests for Pathology Investigation with a LYMPH NODE STATUS, any one of which is lymph node positive.

      Women with an invasive cancer detected: number with 4 or more nodes sampled: number negative (column 66)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known or Positive; i.e. cancer detected, invasive size not known with four or more Requests for Pathology Investigation with a LYMPH NODE STATUS, any one of which is lymph node negative.

      Women with an invasive cancer detected: number grade 1 (column 67)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known ,Grade I or Positive; i.e. cancer detected, invasive size not known, Grade I.

      Women with an invasive cancer detected: number grade 2 (column 68)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known ,Grade II or Positive; i.e. cancer detected, invasive size not known, Grade II.

      Women with an invasive cancer detected: number grade 3 (column 69)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known, Grade III or Positive; i.e. cancer detected, invasive size not known, Grade III.

      Women with an invasive cancer detected: number special type (column 70)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known or Positive; i.e. cancer detected, invasive size not known with a Request for Pathology Investigation with a INVASIVE CANCER SPECIAL TYPE INDICATOR of special type.

      Women with an invasive cancer detected: number not special type (column 71)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known or Positive; i.e. cancer detected, invasive size not known with a Request for Pathology Investigation with a INVASIVE CANCER SPECIAL TYPE INDICATOR of not special type.

      Women with DCIS only detected: number low or intermediate grade (column 72)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, non-invasive or possibly micro-invasive low (DCIS only detected) or Positive; i.e. cancer detected, non-invasive or possibly micro-invasive, intermediate (DCIS only detected) or Positive; i.e. cancer detected, definitely micro-invasive, low (DCIS only detected) or Positive; i.e. cancer detected, definitely microinvasive, intermediate (DCIS only detected).

      Women with DCIS only detected: number high grade (column 73)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, non-invasive or possibly micro-invasive, high (DCIS only detected) or Positive; i.e. cancer detected, definitely micro-invasive, high (DCIS only detected).

top


KC62 ANNEX 1

Change to Central Return Form: Changed Description

Central Return Form Guidance
 

KC62: Adult Screening Programmes - Breast Screening

  1. KC62 Annex: Adult Screening Programmes - Breast Screening

top


KC62 B 1

Change to Central Return Form: Changed Description

Central Return Form Guidance
 

KC62: Adult Screening Programmes - Breast Screening

  1. Table B: Routine invitation to previous non-attenders

    This table reports the persons in a Screening Programme for Breast Screening whose SCREENING STATUS is routine recall and the last Screening Test Invitation resulted in ATTENDED OR DID NOT ATTEND of Patient arrived late and could not be seen or Appointment cancelled by the patient or Did not attend - no advance warning given.

    Part B1: Invitations and Outcomes
  2. Table B: Routine invitation to previous non-attenders
    Part B1: Invitations and Outcomes
    • This is a summary of the outcomes of screening and assessment of all women invited and/or screened.

      Age at first offered appointment (first column)
    • This is derived from the PERSON BIRTH DATE of the PERSON. Line 01 includes all women who were aged 44 or less at the time of the date of their first offered appointment for screening in the period covered by the return. Lines 02 to 09 include women in specified age groups. Line 10 includes all women who were aged 75 or over. Line 11 gives the total of all women in lines 03 to 08, giving a summary of the women in the NHS Breast Screening Programme target age range of 50 to 70 - the Screening Population. Line 12 gives the total of all women in lines 01 to 10 regardless of age.

    • Lines 13 - 24 in Part B2 Assessment and lines 25 - 36 in Part B3 Cancers diagnosed follow the pattern described above.

      Number of women invited (column 1)
    • Count of Screening Test Invitations where the first Screening Test Invitation has a test date offered (see ACTIVITY DATE) in the period covered by the return.

      Lost to follow-up after technically inadequate screening mammogram (column 2)
    • Count of women whose SCREENING TEST RESULT classification was Inadequate test, and for whom no REFERRAL REQUEST for breast assessment was made.

      Number screened (technically adequate) (column 3)
    • Count of women with a Screening Test Date in the period covered by the return whose SCREENING TEST RESULT classification was not Inadequate test.

      Outcome of initial screen : Not known (column 4)
    • Count of women with a valid Screening Test Date but where no breast cancer screening test outcome (see BREAST ASSESSMENT OR TEST OUTCOME) has been recorded.

      Outcome of initial screen: Routine recall (column 5)
    • Count of women with a breast cancer screening test outcome classification of Routine recall.

      Outcome of initial screen: Early recall (column 6)
    • Count of women with a breast cancer screening test outcome classification of Early recall but without a REFERRAL REQUEST for breast assessment.

      Outcome of initial screen: Referred for assessment (column 7)
    • Count of women with a REFERRAL REQUEST for breast assessment. This covers all the women reported in columns 8 to 12.

      Final outcome of assessment: Failed to attend for assessment (column 8)
    • Count of women with a REFERRAL REQUEST for breast assessment who failed to attend for all required assessment appointments and for whom there is no breast assessment final outcome (see BREAST ASSESSMENT OR TEST OUTCOME).

      Final outcome of assessment: Outcome of assessment not known (column 9)
    • Count of women with a breast assessment date (see ACTIVITY DATE) but where no breast assessment final outcome has been recorded.

      Final outcome of assessment: Routine recall (column 10)
    • Count of women with a breast assessment date and a breast assessment final outcome classification of Routine recall.

      Final outcome of assessment: Early recall (column 11)
    • Count of women with a breast assessment date and a breast assessment final outcome classification of Early recall.

      Final outcome of assessment: Cancer (column 12)
    • Count of women with a breast assessment date and a breast assessment final outcome classification of Cancer diagnosed. The total recorded in this column will equal the total recorded in columns 13, 18 and 24.

      Part B2: Assessment
    • This part breaks down the outcomes of assessment by the procedures involved for all women assessed as a result of screening.

      Cancer diagnosed without cytology or histology (column 13)
    • Count of women with a breast assessment date whose breast assessment final outcome classification was Cancer diagnosed, but who had no REFERRAL REQUEST for biopsy or a REFERRAL REQUEST for biopsy where the PATHOLOGY INVESTIGATION TYPE CODE classification was not Cytology and the BIOPSY REFERRAL OUTCOME classification was Inconclusive.

      Referred for cytology and/or core biopsy (column 14)
    • Count of women with a breast cancer screening test outcome classification of Referred for assessment and a subsequent REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE CODE classification of Cytology or Core biopsy.

      Not referred for open biopsy: No result recorded/inadequate result (column 15)
    • Count of women with a breast cancer screening test outcome classification of Referred for assessment and a subsequent REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE CODE classification of Cytology or Core biopsy but without any PATHOLOGY INVESTIGATION TYPE CODE classification of Histology (open biopsy). These women did not complete any or all procedures within 6 months of the date of the screen or had no breast assessment final outcome recorded.

      Not referred for open biopsy: Routine recall (column 16)
    • Count of women with a breast cancer screening test outcome classification of Referred for assessment, a subsequent REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE CODE classification of Cytology or Core biopsy but without any PATHOLOGY INVESTIGATION TYPE CODE classification of Histology (open biopsy). These women have a breast assessment final outcome classification of Routine recall.

      Not referred for open biopsy: Early recall (column 17)
    • Count of women with a breast cancer screening test outcome classification of Referred for assessment, a subsequent REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE CODE classification of Cytology or Core biopsy but without any PATHOLOGY INVESTIGATION TYPE CODE classification of Histology (open biopsy). These women have a breast assessment final outcome classification of Early recall.

      Not referred for open biopsy: Cancer (column 18)
    • Count of women with a breast cancer screening test outcome classification of Referred for assessment, a subsequent REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE CODE classification of Cytology or Core biopsy but without any PATHOLOGY INVESTIGATION TYPE CODE classification of Histology (open biopsy). These women have a breast assessment final outcome classification of Cancer diagnosed.

      Referred for open biopsy (column 19)
    • Count of women with a REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE CODE classification of Cytology or Core biopsy followed by a REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE CODE classification of Histology (open biopsy).

      Total referred for open biopsy (column 20)
    • Total count of women with a REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE CODE classification of Histology (open biopsy).

      Up to and including open biopsy: No result/inadequate result (column 21)
    • Count of women with a REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE CODE classification of Histology (open biopsy). These women have a BIOPSY REFERRAL OUTCOME classification of Inconclusive or Biopsy not done or result not yet known or did not attend for the biopsy within 6 months of the date of the Screening Test having no recorded date biopsy taken (see ACTIVITY DATE).

      Up to and including open biopsy: Result: Benign/normal: Routine recall (column 22)
    • Count of women with a REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE CODE classification of Histology (open biopsy). The BIOPSY REFERRAL OUTCOME classification is Benign or negative. The breast assessment final outcome classification for these women is Routine recall.

      Up to and including open biopsy: Result: Benign/normal: Early recall (column 23)
    • Count of women with a REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE CODE classification of Histology (open biopsy). The BIOPSY REFERRAL OUTCOME classification is Benign or negative. The breast assessment final outcome classification for these women is Early recall.

      Up to and including open biopsy: Cancer (column 24)
    • Count of women with a REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE CODE classification of Histology (open biopsy). The BIOPSY REFERRAL OUTCOME classification is Positive; i.e. cancer diagnosed. The breast assessment final outcome classification for these women is Cancer diagnosed.

top


KC62 B 2

Change to Central Return Form: Changed Description

Central Return Form Guidance
 

KC62: Adult Screening Programmes - Breast Screening

  1. Table B: Routine invitation to previous non-attenders
    • Table B: Routine invitation to previous non-attenders
      Part B3: Cancers Diagnosed
    • This part of the return describes the cancers formally diagnosed in women assessed as a result of screening. Only breast cancers should be reported, as defined in the Information and Training Manual for England and Wales.

      Age at first offered appointment (first column)
    • This is derived from the BIRTH DATE of the PERSON and the test date offered (see ACTIVITY DATE) of the first Screening Test Invitation within the period of the return.

      Total number of women with cancer (column 25)
    • This is derived from the PERSON BIRTH DATE of the PERSON and the test date offered (see ACTIVITY DATE) of the first Screening Test Invitation within the period of the return.

      Total number of women with cancer (column 25)
    • Count of all women in columns 18 and 24 of Part 2 Assessment i.e. those women with a proven diagnosis of breast cancer.

      Invasive status not known (column 26)
    • Count of women included in Part 3 with a BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected invasive status not known.

      Non-invasive or possibly micro-invasive (column 27)
    • Count of women included in Part 3 with a BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected non-invasive or possibly micro-invasive.

      Definitely micro-invasive (column 28)
    • Count of women included in Part 3 with a BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected definitely micro-invasive.

      Invasive size (columns 29 - 33)
    • These columns count all cancers classified as invasive, separated according to the pathological size of the cancer (INVASIVE LESION SIZE). The BIOPSY REFERRAL OUTCOME classification is Positive; i.e. cancer detected invasive size known.

      Invasive size (of cancer)<10mm (column 29)
      Invasive size (of cancer)>=10mm & <15mm (column 30)
      Invasive size (of cancer)>=15mm & <20mm (column 31)
      Invasive size (of cancer)>=20mm & <50mm (column 32)
      Invasive size (of cancer)>=50mm (column 33)
      Invasive size: Size not known (column 34)
    • These columns count all cancers classified as invasive, separated according to the pathological size of the cancer (INVASIVE LESION SIZE). The BIOPSY REFERRAL OUTCOME classification is Positive; i.e. cancer detected invasive size known.

      Invasive size (of cancer)<10mm (column 29)
      Invasive size (of cancer)>=10mm & <15mm (column 30)
      Invasive size (of cancer)>=15mm & <20mm (column 31)
      Invasive size (of cancer)>=20mm & <50mm (column 32)
      Invasive size (of cancer)>=50mm (column 33)

      Invasive size: Size not known (column 34)
    • This column counts invasive cancers where the BIOPSY REFERRAL OUTCOME classification is Positive; i.e. cancer detected invasive size not known.

      Total invasive (column 35)
    • This column counts the total number of cancers classified as invasive, that is with a BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected invasive size known or Positive; i.e. cancer detected invasive size not known.

top


KC62 B 3

Change to Central Return Form: Changed Description

Central Return Form Guidance
 

KC62: Adult Screening Programmes - Breast Screening

  1. Table B: Routine invitation to previous non-attenders
    • Table B: Routine invitation to previous non-attenders
      Part B4: Outcome measures
    • Part 4 presents a selection of outcome measures related to NHS Breast Screening Programme (NHSBSP) quality targets.

      Please note that where a column number is given within an outcome calculation, it relates to a specified column within the KC62 form for example:

      Number screened (technically adequate) (column 3) divided by Number of women invited (column 1) multiplied by 100 (for the appropriate age group).

      In this example (column 3) relates to Part 1 Invitations and Outcomes column 3.

      Age Groups of women (first column)
    • Outcome measures are assessed within three groups: the first being those within the previous target age range of 50-64, the second within the current target age range of 50-70 and the third, the total of those reported, regardless of age.

      Age Group (50-64) (line 37)
    • These are the outcome measures for women in the age group 50-64

      Age Group (50-70) (line 38)
    • These are the outcome measures for women in the age group 50-70

      Total all ages (line 39)
    • These are the outcome measures for women of all ages.

      Uptake rate (% of invited) (column 36)
    • This column gives the uptake rate (also known as the acceptance rate) for screening. It is defined as the percentage of women who receive a technically adequate and complete screen as a result of an invitation for routine screening, and is calculated as:

      Number screened (technically adequate) (column 3) divided by Number of women invited (column 1) multiplied by 100 (for the appropriate age group).

      Referral rate (% of screened) (column 37)
    • This column gives the rate of referrals to assessment from screening. It is defined as the percentage of women screened who are referred for any assessment procedure and is calculated as:

      Outcome of initial screen: Referred for assessment (column 7) divided by Number screened (technically adequate) (column 3) multiplied by 100 (for the appropriate age group).

      Non-invasive or micro-invasive cancers (per 1,000 screened) (column 38)
    • This column gives the cancers detected which are non-invasive, possibly micro-invasive, or definitely micro-invasive, per 1,000 screened calculated as:

      Non-invasive or possibly micro-invasive (column 27) plus Definitely micro-invasive (column 28) divided by Number screened (technically adequate) (column 3) multiplied by 1000 (for the appropriate age group).

      Benign biopsy rate (per 1,000 screened) (column 39)
    • This column gives the women screened who have an open biopsy with a result of benign or normal per 1,000 screened, calculated as:

      Up to and including open biopsy: Result: benign/normal (columns 22 + 23) divided by Number screened (technically adequate) (column 3) multiplied by 1000 (for the appropriate age group).

      Benign Therapeutic operation: Number (column 40)
    • This column gives the number of women screened who had a REFERRAL REQUEST for breast treatment and who had a BENIGN THERAPEUTIC OPERATION by the appropriate age group.

      Benign Therapeutic operation: Rate (per 1,000 screened) (column 41)
    • This column gives the women screened who have a BENIGN THERAPEUTIC OPERATION per 1,000 screened, calculated as:

      Number of BENIGN THERAPEUTIC OPERATIONS for the period (column 40) divided by Number screened (technically adequate) (column 3) multiplied by 1000 (for the appropriate age group).

      Invasive cancer detection rate (per 1,000 screened) (column 42)
    • This column gives the rate of invasive cancers detected per 1,000 women screened, calculated as:

      Total invasive (column 35) divided by Number screened (technically adequate) (column 3) multiplied by 1000 (for the appropriate age group).

      Detection rate of invasive cancers <10 mm (per 1,000 screened) (column 43)
    • This column gives the rate of invasive cancers smaller than 10mm detected per 1,000 women screened, calculated as:

      Invasive size < 10mm (column 29) divided by Number screened (technically adequate) (column 3) multiplied by 1000 (for the appropriate age group).

      Detection rate of invasive cancers <15 mm (per 1,000 screened) (column 44)
    • This column gives the rate of invasive cancers smaller than 15mm detected per 1,000 women screened, calculated as:

      Invasive size < 15mm (columns 29 + 30) divided by Number screened (technically adequate) (column 3) multiplied by 1000 (for the appropriate age group).

      Referral rate for cytology and/or core biopsy (% of screened) (column 45)
    • This column gives the percentage of women screened who are referred for fine needle aspiration cytology and/or core biopsy as part of the assessment process, calculated as:

      Referred for cytology and/or core biopsy (column 14) divided by Number screened (technically adequate) (column 3) multiplied by 100 (for the appropriate age group).

      Referral rate for open biopsy (% of screened) (column 46)
    • This column gives the percentage of women screened who are referred for an open biopsy, either directly from screening or following other assessment procedures, calculated as:

      Total open biopsy (column 20) divided by Number screened (technically adequate) (column 3) multiplied by 100 (for the appropriate age group).

      Pre-operative diagnosis rate (% of cancers diagnosed) (column 47)
    • This column gives the percentage of cancers diagnosed cytologically or histologically without surgery, calculated as:

      Not referred for open biopsy Cancer (column 18) divided by (Not referred for open biopsy Cancer (column 18) plus Open biopsy: Cancer (column 24)) multiplied by 100 (for the appropriate age group).

      Early recall rate following assessment (% of screened) (column 48)
    • This column gives the percentage of women screened who are recommended for early recall following any assessment procedure, calculated as:

      Early recall (column 11) divided by Number screened (technically adequate) (column 3) multiplied by 100 (for the appropriate age group).

      Number of invasive cancers observed (column 49)
    • This column gives the total number of detected cancers classified as invasive, calculated as:

      Total invasive (column 35) (for the appropriate age group).

      Number of invasive cancers expected (column 50)
    • This column is derived from the Number of invasive cancers observed (column 49) and a predefined incidence rate (calculated every three years for the appropriate age group).

      Please note KC62 is issued as an electronic spreadsheet and the predefined incident rate is contained within the spreadsheet for use within this calculation.

      Standardised Detection Ratio (SDR) (column 51)
    • This column is derived from column 49 and column 50.

      Please note KC62 is issued as an electronic spreadsheet and the formula to calculate this ratio is contained within the spreadsheet.

      Part B5: Data Completeness Indicators
    • Part B5 gives an indication of the completeness of data recorded on information systems in a variety of key areas.

      Please note that where a column number is given within an outcome calculation, it relates to a specified column within the KC62 form for example:

      Number screened (technically adequate) (column 3) divided by Number of women invited (column 1) multiplied by 100 (for the appropriate age group).

      In this example (column 3) relates to Part 1 Invitations and Outcomes column 3.

      Age Groups of women (first column) in Part B5.
    • Data Completeness Indicators are assessed within three groups: the first being those within the previous target age range of 50-64, the second within the current target age range of 50-70 and the third, the total of those reported, regardless of age.

      Age Group (50-64) (line 40)
    • These are the outcome measures for women in the previous target age group 50-64.

      Age Group (50-70) (line 41)
    • These are the outcome measures for women in the current target age group 50-70.

      Total all ages (line 42)
    • These are the outcome measures for all women reported, regardless of age.

      Assessment result not known (% of referred) (column 52)
    • This column gives the percentage of women assessed for whom the final outcome of assessment is not recorded, calculated as:

      Outcome of assessment not known (column 9) divided by Referred for assessment (column 7) minus Failed to attend for assessment (column 8) multiplied by 100 (for the appropriate age group)

      Cytology and/or core biopsy result not known (% of referred) (column 53)
    • This column gives the percentage of women referred for one or more cytology and/or core biopsy procedures, for whom a definitive result is not recorded and an open biopsy is not indicated. The column is calculated as:

      No result recorded/inadequate result (column 15) divided by Referred for cytology and/or core biopsy (column 14) multiplied by 100 (for the appropriate age group)

      Open-biopsy result not known (% of referred) (column 54)
    • This column gives the percentage of women referred for an open biopsy for whom a definitive result is not recorded, calculated as:

      No result /inadequate result (column 21) divided by Total open biopsy (column 20) multiplied by 100 (for the appropriate age group)

      Invasive status of cancer not known (% of all cancers diagnosed) (column 55)
    • This column gives the percentage of cancers diagnosed by cytology or histology in which the invasive status is not recorded. The column is calculated as:

      Invasive status not known (column 26) divided by Total number of women with cancer (column 25) multiplied by 100 (for the appropriate age group)

      Size not known (% of invasive cancers) (column 56)
    • This column gives the percentage of cancers diagnosed by cytology or histology which are recorded as invasive, but have no size recorded. The column is calculated as:

      Size not known (column 34) divided by total number of women with invasive cancer Total invasive (column 35) multiplied by 100 (for the appropriate age group)

      Lymph node status not known (% of invasive cancers) (column 57)
    • This column gives the percentage of cancers diagnosed by cytology or histology which are recorded as invasive, but the lymph node status is unknown. The column is calculated as:

      The number of women where no LYMPH NODE STATUS has been recorded and where the BIOPSY REFERRAL OUTCOME classification is Positive; i.e. cancer detected, invasive size known or Positive; i.e. cancer detected, invasive size not known divided by total number of women with invasive cancer: Total invasive (column 35) multiplied by 100 (for the appropriate age group)

      Grade not known (% of invasive cancers) (column 58)
    • This column gives the percentage of cancers diagnosed by cytology or histology, which are recorded as invasive, but the cancer grade is not known. The column is calculated as:

      The number of women where the BIOPSY REFERRAL OUTCOME is Positive; i.e. cancer detected, invasive size not known, grade not known or Positive; i.e. cancer detected, invasive size known, grade not known divided by total number of women with invasive cancer: Total invasive (column 35) multiplied by 100 (for the appropriate age group)

      Special type not known (% of invasive cancers) (column 59)
    • This column gives the percentage of cancers diagnosed by cytology or histology which are recorded as invasive, but the special type is not known. The column is calculated as:

      The number of women where no INVASIVE CANCER SPECIAL TYPE INDICATOR has been recorded and where the BIOPSY REFERRAL OUTCOME classification is Positive; i.e. cancer detected, invasive size known or Positive; i.e. cancer detected, invasive size not known divided by Total invasive (column 35) multiplied by 100 (for the appropriate age group)

      Grade not known (% of DCIS) (column 60)
    • This column gives the percentage of cancers diagnosed by cytology or histology, which are recorded as ductal carcinoma in-situ (DCIS), but the grade is not known. The column is calculated as:

      The number of women where the BIOPSY REFERRAL OUTCOME is Positive; i.e. cancer detected, non-invasive or possibly micro-invasive, grade not known (DCIS only detected) or Positive; i.e. cancer detected, definitely micro-invasive, grade not known (DCIS only detected) divided by total number of women with Non-invasive or possibly micro-invasive (column 27) plus Definitely micro-invasive (column 28) multiplied by 100 (for the appropriate age group)

      Part B6: Status of cancer
    • Part B6 gives status and grades of cancers detected.

      Age Groups of women (first column) in Part B6.
    • The status of cancers are assessed within three groups: the first being those within the previous target age range of 50-64, the second within the current target age range of 50-70 and the third, the total of those reported, regardless of age.

      Age Group (50-64) (line 43)
    • This is the outcome measure for women in the previous target age group 50-64

      Age Group (50-70) (line 44)
    • This is the outcome measure for women in the current target age group 50-70

      Total all ages (line 45)
    • This is the outcome measure for all women reported, regardless of age.

      Women with an invasive cancer detected: number with lymph nodes sampled (column 61)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known or Positive; i.e. cancer detected, invasive size not known with a Request for Pathology Investigation where a LYMPH NODE STATUS has been recorded.

      Women with an invasive cancer detected: number positive (column 62)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known or Positive; i.e. cancer detected, invasive size not known where at least one Request for Pathology Investigation with a LYMPH NODE STATUS of lymph node positive has been recorded.

      Note where more than one Request for Pathology Investigation with a LYMPH NODE STATUS has been recorded for a woman and any one of the LYMPH NODE STATUSES is lymph node positive, then the woman should be included in column 62, but should not be included in column 63.

      Women with an invasive cancer detected: number negative (column 63)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known or Positive; i.e. cancer detected, invasive size not known with a Request for Pathology Investigation with a LYMPH NODE STATUS of lymph node negative.

      Note where more than one Request for Pathology Investigation with a LYMPH NODE STATUS has been recorded for a woman, then every LYMPH NODE STATUS should be lymph node negative for inclusion in count for column 63. If any of the LYMPH NODE STATUSES is lymph node positive, then the woman should be included in column 62 and not included in column 63.

      Women with an invasive cancer detected: number with 4 or more nodes assessed (column 64)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known or Positive; i.e. cancer detected invasive size not known with four or more Request for Pathology Investigation where a LYMPH NODE STATUS has been recorded.

      Women with an invasive cancer detected: number with 4 or more nodes sampled: number positive (column 65)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known or Positive; i.e. cancer detected, invasive size not known with four or more Request for Pathology Investigation with a LYMPH NODE STATUS, any one of which is lymph node positive.

      Women with an invasive cancer detected: number with 4 or more nodes sampled: number negative (column 66)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known or Positive; i.e. cancer detected, invasive size not known with four or more Request for Pathology Investigation with a LYMPH NODE STATUS, any one of which is lymph node negative.

      Women with an invasive cancer detected: number grade 1 (column 67)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known ,Grade I or Positive; i.e. cancer detected, invasive size not known, Grade I.

      Women with an invasive cancer detected: number grade 2 (column 68)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known ,Grade II or Positive; i.e. cancer detected, invasive size not known, Grade II.

      Women with an invasive cancer detected: number grade 3 (column 69)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known, Grade III or Positive; i.e. cancer detected, invasive size not known, Grade III.

      Women with an invasive cancer detected: number special type (column 70)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known or Positive; i.e. cancer detected, invasive size not known with a Request for Pathology Investigation with a INVASIVE CANCER SPECIAL TYPE INDICATOR of special type.

      Women with an invasive cancer detected: number not special type (column 71)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known or Positive; i.e. cancer detected, invasive size not known with a Request for Pathology Investigation with a INVASIVE CANCER SPECIAL TYPE INDICATOR of not special type.

      Women with DCIS only detected: number low or intermediate grade (column 72)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, non-invasive or possibly micro-invasive low (DCIS only detected) or Positive; i.e. cancer detected, non-invasive or possibly micro-invasive, intermediate (DCIS only detected) or Positive; i.e. cancer detected, definitely micro-invasive, low (DCIS only detected) or Positive; i.e. cancer detected, definitely microinvasive, intermediate (DCIS only detected).

      Women with DCIS only detected: number high grade (column 73)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, non-invasive or possibly micro-invasive, high (DCIS only detected) or Positive; i.e. cancer detected, definitely micro-invasive, high (DCIS only detected).

top


KC62 C1 1

Change to Central Return Form: Changed Description

Central Return Form Guidance
 

KC62: Adult Screening Programmes - Breast Screening

  1. Table C1: Routine invitation to previous attenders (Last screen within 5 years)

    This table reports the person in a Screening Programme for Breast Screening whose SCREENING STATUS is routine recall and the last Screening Test was within 5 years.

    Part C1/1: Invitations and Outcomes
  2. Table C1: Routine invitation to previous attenders (Last screen within 5 years)
    Part C1/1: Invitations and Outcomes
    • This is a summary of the outcomes of screening and assessment of all women invited and/or screened.

      Age at first offered appointment (first column)
    • This is derived from the PERSON BIRTH DATE of the test date offered (see ACTIVITY DATE). Line 01 includes all women who were aged 44 or less at the time of the date of their first offered appointment for screening in the period covered by the return. Lines 02 to 09 include women in specified age groups. Line 10 includes all women who were aged 75 or over. Line 11 gives the total of all women in lines 03 to 08, giving a summary of the women in the NHS Breast Screening Programme target age range of 50 to 70 - the Screening Population. Line 12 gives the total of all women in lines 01 and 10 regardless of age.

    • Lines 13 - 24 in Part C1/2 Assessment and lines 25 - 36 in Part C1/2 Cancers diagnosed follow the pattern described above.

      Number of women invited (column 1)
    • Count of Screening Test Invitations where the first Screening Test Invitation has a test date offered in the period covered by the return.

      Lost to follow-up after technically inadequate screening mammogram (column 2)
    • Count of women whose SCREENING TEST RESULT classification was Inadequate test, and for whom no REFERRAL REQUEST for breast assessment was made.

      Number screened (technically adequate) (column 3)
    • Count of women with a Screening Test Date in the period covered by the return whose SCREENING TEST RESULT classification was not Inadequate test.

      Outcome of initial screen : Not known (column 4)
    • Count of women with a valid Screening Test Date but where no SCREENING TEST RESULT has been recorded.

      Outcome of initial screen: Routine recall (column 5)
    • Count of women with a breast cancer screening test outcome (see BREAST ASSESSMENT OR TEST OUTCOME) classification of Routine recall.

      Outcome of initial screen: Early recall (column 6)
    • Count of women with a breast cancer screening test outcome classification of Early recall but without a REFERRAL REQUEST for breast assessment.

      Outcome of initial screen: Referred for assessment (column 7)
    • Count of women with a REFERRAL REQUEST for breast assessment. This covers all the women reported in columns 8 to 12.

      Final outcome of assessment: Failed to attend for assessment (column 8)
    • Count of women with a REFERRAL REQUEST for breast assessment who failed to attend for all required assessment appointments and for whom there is no breast assessment final outcome (see BREAST ASSESSMENT OR TEST OUTCOME).

      Final outcome of assessment: Outcome of assessment not known (column 9)
    • Count of women with a breast assessment date (see ACTIVITY DATE) but where no breast assessment final outcome has been recorded

      Final outcome of assessment: Routine recall (column 10)
    • Count of women with a breast assessment date and a breast assessment final outcome classification of Routine recall.

      Final outcome of assessment: Early recall (column 11)
    • Count of women with a breast assessment date and a breast assessment final outcome classification of Early recall.

      Final outcome of assessment: Cancer (column 12)
    • Count of women with a breast assessment date and a breast assessment final outcome classification of Cancer diagnosed. The total recorded in this column will equal the total recorded in columns 13, 18 and 24.

      Part C1/2: Assessment
    • This part breaks down the outcomes of assessment by the procedures involved for all women assessed as a result of screening.

      Cancer diagnosed without cytology or histology (column 13)
    • Count of women with a breast assessment date whose breast assessment final outcome classification was Cancer diagnosed, but who had no REFERRAL REQUEST for biopsy or a REFERRAL REQUEST for biopsy where the PATHOLOGY INVESTIGATION TYPE CODE classification was not Cytology and the BIOPSY REFERRAL OUTCOME classification was Inconclusive.

      Referred for cytology and/or core biopsy (column 14)
    • Count of women with a breast cancer screening test outcome classification of Referred for assessment and a subsequent REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE CODE classification of Cytology or Core biopsy.

      Not referred for open biopsy: No result recorded/inadequate result (column 15)
    • Count of women with a breast cancer screening test outcome classification of Referred for assessment and a subsequent REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE CODE classification of Cytology or Core biopsy but without any PATHOLOGY INVESTIGATION TYPE CODE classification of Histology (open biopsy). These women did not complete any or all procedures within 6 months of the date of the screen or had no breast assessment final outcome recorded.

      Not referred for open biopsy: Routine recall (column 16)
    • Count of women with a breast cancer screening test outcome classification of Referred for assessment, a subsequent REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE CODE classification of Cytology or Core biopsy but without any PATHOLOGY INVESTIGATION TYPE CODE classification of Histology (open biopsy). These women have a breast assessment final outcome classification of Routine recall.

      Not referred for open biopsy: Early recall (column 17)
    • Count of women with a breast cancer screening test outcome classification of Referred for assessment, a subsequent REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE CODE classification of Cytology or Core biopsy but without any PATHOLOGY INVESTIGATION TYPE CODE classification of Histology (open biopsy). These women have a breast assessment final outcome classification of Early recall.

      Not referred for open biopsy: Cancer (column 18)
    • Count of women with a breast cancer screening test outcome classification of Referred for assessment, a subsequent REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE CODE classification of Cytology or Core biopsy but without any PATHOLOGY INVESTIGATION TYPE CODE classification of Histology (open biopsy). These women have a breast assessment final outcome classification of Cancer diagnosed.

      Referred for open biopsy (column 19)
    • Count of women with a REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE CODE classification of Cytology or Core biopsy followed by a REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE CODE classification of Histology (open biopsy).

      Total referred for open biopsy (column 20)
    • Total count of women with a REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE CODE classification of Histology (open biopsy).

      Up to and including open biopsy: No result/inadequate result (column 21)
    • Count of women with a REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE CODE classification of Histology (open biopsy). These women have a BIOPSY REFERRAL OUTCOME classification of Inconclusive or Biopsy not done or result not yet known or did not attend for the biopsy within 6 months of the date of the Screening Test having no recorded date biopsy taken (see ACTIVITY DATE).

      Up to and including open biopsy: Result: Benign/normal: Routine recall (column 22)
    • Count of women with a REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE CODE classification of Histology (open biopsy). The BIOPSY REFERRAL OUTCOME classification is Benign or negative. The breast assessment final outcome classification for these women is Routine recall.

      Up to and including open biopsy: Result: Benign/normal: Early recall (column 23)
    • Count of women with a REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE CODE classification of Histology (open biopsy). The BIOPSY REFERRAL OUTCOME classification is Benign or negative. The breast assessment final outcome classification for these women is Early recall.

      Up to and including open biopsy: Cancer (column 24)
    • Count of women with a REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE CODE classification of Histology (open biopsy). The BIOPSY REFERRAL OUTCOME classification is Positive; i.e. cancer diagnosed. The breast assessment final outcome classification for these women is Cancer diagnosed.

top


KC62 C1 2

Change to Central Return Form: Changed Description

Central Return Form Guidance
 

KC62: Adult Screening Programmes - Breast Screening

  1. Table C1: Routine invitation to previous attenders (Last screen within 5 years)
    • Table C1: Routine invitation to previous attenders (Last screen within 5 years)
      Part C1/3: Cancers Diagnosed
    • This part of the return describes the cancers formally diagnosed in women assessed as a result of screening. Only breast cancers should be reported, as defined in the Information and Training Manual for England and Wales.

      Age at first offered appointment (first column)
    • This is derived from the BIRTH DATE of the PERSON and the test date offered (see ACTIVITY DATE) of the first Screening Test Invitation within the period of the return.

      Total number of women with cancer (column 25)
    • This is derived from the PERSON BIRTH DATE of the PERSON and the test date offered (see ACTIVITY DATE) of the first Screening Test Invitation within the period of the return.

      Total number of women with cancer (column 25)
    • Count of all women in columns 18 and 24 of Part 2 Assessment i.e. those women with a proven diagnosis of breast cancer.

      Invasive status not known (column 26)
    • Count of women included in Part 3 with a BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected invasive status not known.

      Non-invasive or possibly micro-invasive (column 27)
    • Count of women included in Part 3 with a BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected non-invasive or possibly micro-invasive.

      Definitely micro-invasive (column 28)
    • Count of women included in Part 3 with a BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected definitely micro-invasive.

      Invasive size (columns 29 - 33)
    • These columns count all cancers classified as invasive, separated according to the pathological size of the cancer (INVASIVE LESION SIZE). The BIOPSY REFERRAL OUTCOME classification is Positive; i.e. cancer detected Invasive size known.

      Invasive size (of cancer)<10mm (column 29)
      Invasive size (of cancer)>=10mm & <15mm (column 30)
      Invasive size (of cancer)>=15mm & <20mm (column 31)
      Invasive size (of cancer)>=20mm & <50mm (column 32)
      Invasive size (of cancer)>=50mm (column 33)
      Invasive size: Size not known (column 34)
    • These columns count all cancers classified as invasive, separated according to the pathological size of the cancer (INVASIVE LESION SIZE). The BIOPSY REFERRAL OUTCOME classification is Positive; i.e. cancer detected Invasive size known.

      Invasive size (of cancer)<10mm (column 29)
      Invasive size (of cancer)>=10mm & <15mm (column 30)
      Invasive size (of cancer)>=15mm & <20mm (column 31)
      Invasive size (of cancer)>=20mm & <50mm (column 32)
      Invasive size (of cancer)>=50mm (column 33)

      Invasive size: Size not known (column 34)
    • This column counts invasive cancers where the BIOPSY REFERRAL OUTCOME classification is Positive; i.e. cancer detected invasive size not known.

      Total invasive (column 35)
    • This column counts the total number of cancers classified as invasive, that is with a BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected invasive size known or Positive; i.e. cancer detected invasive size not known

top


KC62 C1 3

Change to Central Return Form: Changed Description

Central Return Form Guidance
 

KC62: Adult Screening Programmes - Breast Screening

  1. Table C1: Routine invitation to previous attenders (Last screen within 5 years)
    • Table C1: Routine invitation to previous attenders (Last screen within 5 years)
      Part C1/4: Outcome measures
    • Part 4 presents a selection of outcome measures related to NHS Breast Screening Programme (NHSBSP) quality targets.

      Please note that where a column number is given within an outcome calculation, it relates to a specified column within the KC62 form for example:

      Number screened (technically adequate) (column 3) divided by Number of women invited (column 1) multiplied by 100 (for the appropriate age group).

      In this example (column 3) relates to Part 1 Invitations and Outcomes column 3.

      Age Groups of women (first column)
    • Outcome measures are assessed within three groups: the first being those within the previous target age range of 50-64, the second within the current target age range of 50-70 and the third, the total of those reported, regardless of age.

      Age Group (50-64) (line 37)
    • These are the outcome measures for women in the age group 50-64

      Age Group (50-70) (line 38)
    • These are the outcome measures for women in the age group 50-70

      Total all ages (line 39)
    • These are the outcome measures for women of all ages.

      Uptake rate (% of invited) (column 36)
    • This column gives the uptake rate (also known as the acceptance rate) for screening. It is defined as the percentage of women who receive a technically adequate and complete screen as a result of an invitation for routine screening, and is calculated as:

      Number screened (technically adequate) (column 3) divided by Number of women invited (column 1) multiplied by 100 (for the appropriate age group).

      Referral rate (% of screened) (column 37)
    • This column gives the rate of referrals to assessment from screening. It is defined as the percentage of women screened who are referred for any assessment procedure and is calculated as:

      Outcome of initial screen: Referred for assessment (column 7) divided by Number screened (technically adequate) (column 3) multiplied by 100 (for the appropriate age group).

      Non-invasive or micro-invasive cancers (per 1,000 screened) (column 38)
    • This column gives the cancers detected which are non-invasive, possibly micro-invasive, or definitely micro-invasive, per 1,000 screened calculated as:

      Non-invasive or possibly micro-invasive (column 27) plus Definitely micro-invasive (column 28) divided by Number screened (technically adequate) (column 3) multiplied by 1000 (for the appropriate age group).

      Benign biopsy rate (per 1,000 screened) (column 39)
    • This column gives the women screened who have an open biopsy with a result of benign or normal per 1,000 screened, calculated as:

      Up to and including open biopsy: Result: benign/normal (columns 22 + 23) divided by Number screened (technically adequate) (column 3) multiplied by 1000 (for the appropriate age group).

      Benign Therapeutic operation: Number (column 40)
    • This column gives the number of women screened who had a REFERRAL REQUEST for breast treatment and who had a BENIGN THERAPEUTIC OPERATION by the appropriate age group.

      Benign Therapeutic operation: Rate (per 1,000 screened) (column 41)
    • This column gives the women screened who have a BENIGN THERAPEUTIC OPERATION per 1,000 screened, calculated as:

      Number of BENIGN THERAPEUTIC OPERATIONS for the period (column 40) divided by Number screened (technically adequate) (column 3) multiplied by 1000 (for the appropriate age group).

      Invasive cancer detection rate (per 1,000 screened) (column 42)
    • This column gives the rate of invasive cancers detected per 1,000 women screened, calculated as:

      Total invasive (column 35) divided by Number screened (technically adequate) (column 3) multiplied by 1000 (for the appropriate age group).

      Detection rate of invasive cancers <10 mm (per 1,000 screened) (column 43)
    • This column gives the rate of invasive cancers smaller than 10mm detected per 1,000 women screened, calculated as:

      Invasive size < 10mm (column 29) divided by Number screened (technically adequate) (column 3) multiplied by 1000 (for the appropriate age group).

      Detection rate of invasive cancers <15 mm (per 1,000 screened) (column 44)
    • This column gives the rate of invasive cancers smaller than 15mm detected per 1,000 women screened, calculated as:

      Invasive size < 15mm (columns 29 + 30) divided by Number screened (technically adequate) (column 3) multiplied by 1000 (for the appropriate age group).

      Referral rate for cytology and/or core biopsy (% of screened) (column 45)
    • This column gives the percentage of women screened who are referred for fine needle aspiration cytology and/or core biopsy as part of the assessment process, calculated as:

      Referred for cytology and/or core biopsy (column 14) divided by Number screened (technically adequate) (column 3) multiplied by 100 (for the appropriate age group).

      Referral rate for open biopsy (% of screened) (column 46)
    • This column gives the percentage of women screened who are referred for an open biopsy, either directly from screening or following other assessment procedures, calculated as:

      Total open biopsy (column 20) divided by Number screened (technically adequate) (column 3) multiplied by 100 (for the appropriate age group).

      Pre-operative diagnosis rate (% of cancers diagnosed) (column 47)
    • This column gives the percentage of cancers diagnosed cytologically or histologically without surgery, calculated as:

      Not referred for open biopsy Cancer (column 18) divided by (Not referred for open biopsy Cancer (column 18) plus Open biopsy: Cancer (column 24)) multiplied by 100 (for the appropriate age group).

      Early recall rate following assessment (% of screened) (column 48)
    • This column gives the percentage of women screened who are recommended for early recall following any assessment procedure, calculated as:

      Early recall (column 11) divided by Number screened (technically adequate) (column 3) multiplied by 100 (for the appropriate age group).

      Number of invasive cancers observed (column 49)
    • This column gives the total number of detected cancers classified as invasive, calculated as:

      Total invasive (column 35) (for the appropriate age group).

      Number of invasive cancers expected (column 50)
    • This column is derived from the Number of invasive cancers observed (column 49) and a predefined incidence rate (calculated every three years for the appropriate age group).

      Please note KC62 is issued as an electronic spreadsheet and the predefined incident rate is contained within the spreadsheet for use within this calculation.

      Standardised Detection Ratio (SDR) (column 51)
    • This column is derived from column 49 and column 50.

      Please note KC62 is issued as an electronic spreadsheet and the formula to calculate this ratio is contained within the spreadsheet.

      Part C1/5: Data Completeness Indicators
    • Part C1/5 gives an indication of the completeness of data recorded on information systems in a variety of key areas.

      Please note that where a column number is given within an outcome calculation, it relates to a specified column within the KC62 form for example:

      Number screened (technically adequate) (column 3) divided by Number of women invited (column 1) multiplied by 100 (for the appropriate age group).

      In this example (column 3) relates to Part 1 Invitations and Outcomes column 3.

      Age Groups of women (first column) in Part C1/5.
    • Data Completeness Indicators are assessed within three groups: the first being those within the previous target age range of 50-64, the second within the current target age range of 50-70 and the third, the total of those reported, regardless of age.

      Age Group (50-64) (line 40)
    • These are the outcome measures for women in the previous target age group 50-64.

      Age Group (50-70) (line 41)
    • These are the outcome measures for women in the current target age group 50-70.

      Total all ages (line 42)
    • These are the outcome measures for all women reported, regardless of age.

      Assessment result not known (% of referred) (column 52)
    • This column gives the percentage of women assessed for whom the final outcome of assessment is not recorded, calculated as:

      Outcome of assessment not known (column 9) divided by Referred for assessment (column 7) minus Failed to attend for assessment (column 8) multiplied by 100 (for the appropriate age group)

      Cytology and/or core biopsy result not known (% of referred) (column 53)
    • This column gives the percentage of women referred for one or more cytology and/or core biopsy procedures, for whom a definitive result is not recorded and an open biopsy is not indicated. The column is calculated as:

      No result recorded/inadequate result (column 15) divided by Referred for cytology and/or core biopsy (column 14) multiplied by 100 (for the appropriate age group)

      Open-biopsy result not known (% of referred) (column 54)
    • This column gives the percentage of women referred for an open biopsy for whom a definitive result is not recorded, calculated as:

      No result /inadequate result (column 21) divided by Total open biopsy (column 20) multiplied by 100 (for the appropriate age group)

      Invasive status of cancer not known (% of all cancers diagnosed) (column 55)
    • This column gives the percentage of cancers diagnosed by cytology or histology in which the invasive status is not recorded. The column is calculated as:

      Invasive status not known (column 26) divided by Total number of women with cancer (column 25) multiplied by 100 (for the appropriate age group)

      Size not known (% of invasive cancers) (column 56)
    • This column gives the percentage of cancers diagnosed by cytology or histology which are recorded as invasive, but have no size recorded. The column is calculated as:

      Size not known (column 34) divided by total number of women with invasive cancer Total invasive (column 35) multiplied by 100 (for the appropriate age group)

      Lymph node status not known (% of invasive cancers) (column 57)
    • This column gives the percentage of cancers diagnosed by cytology or histology which are recorded as invasive, but the lymph node status is unknown. The column is calculated as:

      The number of women where no LYMPH NODE STATUS has been recorded and where the BIOPSY REFERRAL OUTCOME classification is Positive; i.e. cancer detected, invasive size known or Positive; i.e. cancer detected, invasive size not known divided by total number of women with invasive cancer: Total invasive (column 35) multiplied by 100 (for the appropriate age group)

      Grade not known (% of invasive cancers) (column 58)
    • This column gives the percentage of cancers diagnosed by cytology or histology, which are recorded as invasive, but the cancer grade is not known. The column is calculated as:

      The number of women where the BIOPSY REFERRAL OUTCOME is Positive; i.e. cancer detected, invasive size not known, grade not known or Positive; i.e. cancer detected, invasive size known, grade not known divided by total number of women with invasive cancer: Total invasive (column 35) multiplied by 100 (for the appropriate age group)

      Special type not known (% of invasive cancers) (column 59)
    • This column gives the percentage of cancers diagnosed by cytology or histology which are recorded as invasive, but the special type is not known. The column is calculated as:

      The number of women where no INVASIVE CANCER SPECIAL TYPE INDICATOR has been recorded and where the BIOPSY REFERRAL OUTCOME classification is Positive; i.e. cancer detected, invasive size known or Positive; i.e. cancer detected, invasive size not known divided by Total invasive (column 35) multiplied by 100 (for the appropriate age group)

      Grade not known (% of DCIS) (column 60)
    • This column gives the percentage of cancers diagnosed by cytology or histology, which are recorded as ductal carcinoma in-situ (DCIS), but the grade is not known. The column is calculated as:

      The number of women where the BIOPSY REFERRAL OUTCOME is Positive; i.e. cancer detected, non-invasive or possibly micro-invasive, grade not known (DCIS only detected) or Positive; i.e. cancer detected, definitely micro-invasive, grade not known (DCIS only detected) divided by total number of women with Non-invasive or possibly micro-invasive (column 27) plus Definitely microinvasive (column 28) multiplied by 100 (for the appropriate age group)

      Part C1/6: Status of cancer
    • Part C1/6 gives status and grades of cancers detected.

      Age Groups of women (first column) in Part C1/6.
    • The status of cancers are assessed within three groups: the first being those within the previous target age range of 50-64, the second within the current target age range of 50-70 and the third, the total of those reported, regardless of age.

      Age Group (50-64) (line 43)
    • This is the outcome measure for women in the previous target age group 50-64

      Age Group (50-70) (line 44)
    • This is the outcome measure for women in the current target age group 50-70

      Total all ages (line 45)
    • This is the outcome measure for all women reported, regardless of age.

      Women with an invasive cancer detected: number with lymph nodes sampled (column 61)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known or Positive; i.e. cancer detected, invasive size not known with a Request for Pathology Investigation where a LYMPH NODE STATUS has been recorded.

      Women with an invasive cancer detected: number positive (column 62)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known or Positive; i.e. cancer detected, invasive size not known where at least one Request for Pathology Investigation with a LYMPH NODE STATUS of lymph node positive has been recorded.

      Note where more than one Request for Pathology Investigation with a LYMPH NODE STATUS has been recorded for a woman and any one of the LYMPH NODE STATUSES is lymph node positive, then the woman should be included in column 62, but should not be included in column 63.

      Women with an invasive cancer detected: number negative (column 63)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known or Positive; i.e. cancer detected, invasive size not known with a Request for Pathology Investigation with a LYMPH NODE STATUS of lymph node negative.

      Note where more than one Request for Pathology Investigation with a LYMPH NODE STATUS has been recorded for a woman, then every LYMPH NODE STATUS should be lymph node negative for inclusion in count for column 63. If any of the LYMPH NODE STATUSES is lymph node positive, then the woman should be included in column 62 and not included in column 63.

      Women with an invasive cancer detected: number with 4 or more nodes assessed (column 64)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known or Positive; i.e. cancer detected invasive size not known with four or more Request for Pathology Investigation where a LYMPH NODE STATUS has been recorded.

      Women with an invasive cancer detected: number with 4 or more nodes sampled: number positive (column 65)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known or Positive; i.e. cancer detected, invasive size not known with four or more Request for Pathology Investigation with a LYMPH NODE STATUS, any one of which is lymph node positive.

      Women with an invasive cancer detected: number with 4 or more nodes sampled: number negative (column 66)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known or Positive; i.e. cancer detected, invasive size not known with four or more Request for Pathology Investigation with a LYMPH NODE STATUS, any one of which is lymph node negative.

      Women with an invasive cancer detected: number grade 1 (column 67)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known ,Grade I or Positive; i.e. cancer detected, invasive size not known, Grade I.

      Women with an invasive cancer detected: number grade 2 (column 68)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known ,Grade II or Positive; i.e. cancer detected, invasive size not known, Grade II.

      Women with an invasive cancer detected: number grade 3 (column 69)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known, Grade III or Positive; i.e. cancer detected, invasive size not known, Grade III.

      Women with an invasive cancer detected: number special type (column 70)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known or Positive; i.e. cancer detected, invasive size not known with a Request for Pathology Investigation with a INVASIVE CANCER SPECIAL TYPE INDICATOR of special type.

      Women with an invasive cancer detected: number not special type (column 71)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known or Positive; i.e. cancer detected, invasive size not known with a Request for Pathology Investigation with a INVASIVE CANCER SPECIAL TYPE INDICATOR of not special type.

      Women with DCIS only detected: number low or intermediate grade (column 72)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, non-invasive or possibly micro-invasive low (DCIS only detected) or Positive; i.e. cancer detected, non-invasive or possibly micro-invasive, intermediate (DCIS only detected) or Positive; i.e. cancer detected, definitely micro-invasive, low (DCIS only detected) or Positive; i.e. cancer detected, definitely microinvasive, intermediate (DCIS only detected).

      Women with DCIS only detected: number high grade (column 73)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, non-invasive or possibly micro-invasive, high (DCIS only detected) or Positive; i.e. cancer detected, definitely micro-invasive, high (DCIS only detected).

top


KC62 C2 1

Change to Central Return Form: Changed Description

Central Return Form Guidance
 

KC62: Adult Screening Programmes - Breast Screening

  1. Table C2: Routine invitation to previous attenders (Last screen more than 5 years)

    This table reports the person in a Screening Programme for Breast Screening whose SCREENING STATUS is routine recall and the last Screening Test was more than 5 years.

    Part C2/1: Invitations and Outcomes
  2. Table C2: Routine invitation to previous attenders (Last screen more than 5 years)
    Part C2/1: Invitations and Outcomes
    • This is a summary of the outcomes of screening and assessment of all women invited and/or screened.

      Age at first offered appointment (first column)
    • This is derived from the BIRTH DATE of the PERSON. Line 01 includes all women who were aged 44 or less at the time of the date of their first offered appointment for screening in the period covered by the return. Lines 02 to 09 include women in specified age groups. Line 10 includes all women who were aged 75 or over. Line 11 gives the total of all women in lines 03 to 08, giving a summary of the women in the NHS Breast Screening Programme target age range of 50 to 70 - the Screening Population. Line 12 gives the total of all women in lines 01 to 10 regardless of age.

    • This is derived from the PERSON BIRTH DATE of the PERSON. Line 01 includes all women who were aged 44 or less at the time of the date of their first offered appointment for screening in the period covered by the return. Lines 02 to 09 include women in specified age groups. Line 10 includes all women who were aged 75 or over. Line 11 gives the total of all women in lines 03 to 08, giving a summary of the women in the NHS Breast Screening Programme target age range of 50 to 70 - the Screening Population. Line 12 gives the total of all women in lines 01 to 10 regardless of age.

    • Lines 13 - 24 in Part C2/2 Assessment and lines 25 - 36 in Part C2/2 Cancers diagnosed follow the pattern described above.

      Number of women invited (column 1)
    • Count of Screening Test Invitations where the first Screening Test Invitation has a test date offered (see ACTIVITY DATE) in the period covered by the return.

      Lost to follow-up after technically inadequate screening mammogram (column 2)
    • Count of women whose SCREENING TEST RESULT classification was Inadequate test, and for whom no REFERRAL REQUEST for breast assessment was made.

      Number screened (technically adequate) (column 3)
    • Count of women with a Screening Test Date in the period covered by the return whose SCREENING TEST RESULT classification was not Inadequate test.

      Outcome of initial screen : Not known (column 4)
    • Count of women with a valid Screening Test Date but where no breast cancer screening test outcome (see BREAST ASSESSMENT OR TEST OUTCOME) has been recorded.

      Outcome of initial screen: Routine recall (column 5)
    • Count of women with a breast cancer screening test outcome classification of Routine recall.

      Outcome of initial screen: Early recall (column 6)
    • Count of women with a breast cancer screening test outcome classification of Early recall but without a REFERRAL REQUEST for breast assessment.

      Outcome of initial screen: Referred for assessment (column 7)
    • Count of women with a REFERRAL REQUEST for breast assessment. This covers all the women reported in columns 8 to 12.

      Final outcome of assessment: Failed to attend for assessment (column 8)
    • Count of women with a REFERRAL REQUEST for breast assessment who failed to attend for all required assessment appointments and for whom there is no breast assessment final outcome (see BREAST ASSESSMENT OR TEST OUTCOME).

      Final outcome of assessment: Outcome of assessment not known (column 9)
    • Count of women with a breast assessment date (see ACTIVITY DATE) but where no breast assessment final outcome has been recorded.

      Final outcome of assessment: Routine recall (column 10)
    • Count of women with a breast assessment date and a breast assessment final outcome classification of Routine recall.

      Final outcome of assessment: Early recall (column 11)
    • Count of women with a breast assessment date and a breast assessment final outcome classification of Early recall.

      Final outcome of assessment: Cancer (column 12)
    • Count of women with a breast assessment date and a breast assessment final outcome classification of Cancer diagnosed. The total recorded in this column will equal the total recorded in columns 13, 18 and 24.

      Part C2/2: Assessment
    • This part breaks down the outcomes of assessment by the procedures involved for all women assessed as a result of screening.

      Cancer diagnosed without cytology or histology (column 13)
    • Count of women with a breast assessment date whose breast assessment final outcome classification was Cancer diagnosed, but who had no REFERRAL REQUEST for biopsy or a REFERRAL REQUEST for biopsy where the PATHOLOGY INVESTIGATION TYPE CODE classification was not Cytology and the BIOPSY REFERRAL OUTCOME classification was Inconclusive.

      Referred for cytology and/or core biopsy (column 14)
    • Count of women with a breast cancer screening test outcome classification of Referred for assessment and a subsequent REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE CODE classification of Cytology or Core biopsy.

      Not referred for open biopsy: No result recorded/inadequate result (column 15)
    • Count of women with a breast cancer screening test outcome classification of Referred for assessment and a subsequent REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE CODE classification of Cytology or Core biopsy but without any PATHOLOGY INVESTIGATION TYPE CODE classification of Histology (open biopsy). These women did not complete any or all procedures within 6 months of the date of the screen or had no breast assessment final outcome recorded.

      Not referred for open biopsy: Routine recall (column 16)
    • Count of women with a breast cancer screening test outcome classification of Referred for assessment, a subsequent REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE CODE classification of Cytology or Core biopsy but without any PATHOLOGY INVESTIGATION TYPE CODE classification of Histology (open biopsy). These women have a breast assessment final outcome classification of Routine recall.

      Not referred for open biopsy: Early recall (column 17)
    • Count of women with a breast cancer screening test outcome classification of Referred for assessment, a subsequent REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE CODE classification of Cytology or Core biopsy but without any PATHOLOGY INVESTIGATION TYPE CODE classification of Histology (open biopsy). These women have a breast assessment final outcome classification of Early recall.

      Not referred for open biopsy: Cancer (column 18)
    • Count of women with a breast cancer screening test outcome classification of Referred for assessment, a subsequent REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE CODE classification of Cytology or Core biopsy but without any PATHOLOGY INVESTIGATION TYPE CODE classification of Histology (open biopsy). These women have a breast assessment final outcome classification of Cancer diagnosed.

      Referred for open biopsy (column 19)
    • Count of women with a REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE CODE classification of Cytology or Core biopsy followed by a REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE CODE classification of Histology (open biopsy).

      Total referred for open biopsy (column 20)
    • Total count of women with a REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE CODE classification of Histology (open biopsy).

      Up to and including open biopsy: No result/inadequate result (column 21)
    • Count of women with a REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE CODE classification of Histology (open biopsy). These women have a BIOPSY REFERRAL OUTCOME classification of Inconclusive or Biopsy not done or result not yet known or did not attend for the biopsy within 6 months of the date of the Screening Test having no recorded date biopsy taken (see ACTIVITY DATE).

      Up to and including open biopsy: Result: Benign/normal: Routine recall (column 22)
    • Count of women with a REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE CODE classification of Histology (open biopsy). The BIOPSY REFERRAL OUTCOME classification is Benign or negative. The breast assessment final outcome classification for these women is Routine recall.

      Up to and including open biopsy: Result: Benign/normal: Early recall (column 23)
    • Count of women with a REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE CODE classification of Histology (open biopsy). The BIOPSY REFERRAL OUTCOME classification is Benign or negative. The breast assessment final outcome classification for these women is Early recall.

      Up to and including open biopsy: Cancer (column 24)
    • Count of women with a REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE CODE classification of Histology (open biopsy). The BIOPSY REFERRAL OUTCOME classification is Positive; i.e. cancer diagnosed. The breast assessment final outcome classification for these women is Cancer diagnosed.

top


KC62 C2 2

Change to Central Return Form: Changed Description

Central Return Form Guidance
 

KC62: Adult Screening Programmes - Breast Screening

  1. Table C2: Routine invitation to previous attenders (Last screen more than 5 years)
    • Table C2: Routine invitation to previous attenders (Last screen more than 5 years)
      Part C2/3: Cancers Diagnosed
    • This part of the return describes the cancers formally diagnosed in women assessed as a result of screening. Only breast cancers should be reported, as defined in the Information and Training Manual for England and Wales.

      Age at first offered appointment (first column)
    • This is derived from the BIRTH DATE of the PERSON and the test date offered (see ACTIVITY DATE) of the first Screening Test Invitation within the period of the return.

      Total number of women with cancer (column 25)
    • This is derived from the PERSON BIRTH DATE of the PERSON and the test date offered (see ACTIVITY DATE) of the first Screening Test Invitation within the period of the return.

      Total number of women with cancer (column 25)
    • Count of all women in columns 18 and 24 of Part 2 Assessment i.e. those women with a proven diagnosis of breast cancer.

      Invasive status not known (column 26)
    • Count of women included in Part 3 with a BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer diagnosed invasive status not known.

      Non-invasive or possibly micro-invasive (column 27)
    • Count of women included in Part 3 with a BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer diagnosed non-invasive or possibly micro-invasive.

      Definitely micro-invasive (column 28)
    • Count of women included in Part 3 with a BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer diagnosed definitely micro-invasive.

      Invasive size (columns 29 - 33)
    • These columns count all cancers classified as invasive, separated according to the pathological size of the cancer (INVASIVE LESION SIZE). The BIOPSY REFERRAL OUTCOME classification is Positive; i.e. cancer diagnosed invasive size known.

      Invasive size (of cancer)<10mm (column 29)
      Invasive size (of cancer)>=10mm & <15mm (column 30)
      Invasive size (of cancer)>=15mm & <20mm (column 31)
      Invasive size (of cancer)>=20mm & <50mm (column 32)
      Invasive size (of cancer)>=50mm (column 33)
      Invasive size: Size not known (column 34)
    • These columns count all cancers classified as invasive, separated according to the pathological size of the cancer (INVASIVE LESION SIZE). The BIOPSY REFERRAL OUTCOME classification is Positive; i.e. cancer diagnosed invasive size known.

      Invasive size (of cancer)<10mm (column 29)
      Invasive size (of cancer)>=10mm & <15mm (column 30)
      Invasive size (of cancer)>=15mm & <20mm (column 31)
      Invasive size (of cancer)>=20mm & <50mm (column 32)
      Invasive size (of cancer)>=50mm (column 33)

      Invasive size: Size not known (column 34)
    • This column counts invasive cancers where the BIOPSY REFERRAL OUTCOME classification is Positive; i.e. cancer diagnosed invasive size not known.

      Total invasive (column 35)
    • This column counts the total number of cancers classified as invasive, that is with a BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected invasive size known or Positive; i.e. cancer detected invasive size not known

top


KC62 C2 3

Change to Central Return Form: Changed Description

Central Return Form Guidance
 

KC62: Adult Screening Programmes - Breast Screening

  1. Table C2: Routine invitation to previous attenders (Last screen more than 5 years)
    • Table C2: Routine invitation to previous attenders (Last screen more than 5 years)
      Part C2/4: Outcome measures
    • Part 4 presents a selection of outcome measures related to NHS Breast Screening Programme (NHSBSP) quality targets.

      Please note that where a column number is given within an outcome calculation, it relates to a specified column within the KC62 form for example:

      Number screened (technically adequate) (column 3) divided by Number of women invited (column 1) multiplied by 100 (for the appropriate age group).

      In this example (column 3) relates to Part 1 Invitations and Outcomes column 3.

      Age Groups of women (first column)
    • Outcome measures are assessed within three groups: the first being those within the previous target age range of 50-64, the second within the current target age range of 50-70 and the third, the total of those reported, regardless of age.

      Age Group (50-64) (line 37)
    • These are the outcome measures for women in the age group 50-64

      Age Group (50-70) (line 38)
    • These are the outcome measures for women in the age group 50-70

      Total all ages (line 39)
    • These are the outcome measures for women of all ages.

      Uptake rate (% of invited) (column 36)
    • This column gives the uptake rate (also known as the acceptance rate) for screening. It is defined as the percentage of women who receive a technically adequate and complete screen as a result of an invitation for routine screening, and is calculated as:

      Number screened (technically adequate) (column 3) divided by Number of women invited (column 1) multiplied by 100 (for the appropriate age group).

      Referral rate (% of screened) (column 37)
    • This column gives the rate of referrals to assessment from screening. It is defined as the percentage of women screened who are referred for any assessment procedure and is calculated as:

      Outcome of initial screen: Referred for assessment (column 7) divided by Number screened (technically adequate) (column 3) multiplied by 100 (for the appropriate age group).

      Non-invasive or micro-invasive cancers (per 1,000 screened) (column 38)
    • This column gives the cancers detected which are non-invasive, possibly micro-invasive, or definitely micro-invasive, per 1,000 screened calculated as:

      Non-invasive or possibly micro-invasive (column 27) plus Definitely micro-invasive (column 28) divided by Number screened (technically adequate) (column 3) multiplied by 1000 (for the appropriate age group).

      Benign biopsy rate (per 1,000 screened) (column 39)
    • This column gives the women screened who have an open biopsy with a result of benign or normal per 1,000 screened, calculated as:

      Up to and including open biopsy: Result: benign/normal (columns 22 + 23) divided by Number screened (technically adequate) (column 3) multiplied by 1000 (for the appropriate age group).

      Benign Therapeutic operation: Number (column 40)
    • This column gives the number of women screened who had a REFERRAL REQUEST for breast treatment and who had a BENIGN THERAPEUTIC OPERATION by the appropriate age group.

      Benign Therapeutic operation: Rate (per 1,000 screened) (column 41)
    • This column gives the women screened who have a BENIGN THERAPEUTIC OPERATION per 1,000 screened, calculated as:

      Number of BENIGN THERAPEUTIC OPERATIONS for the period (column 40) divided by Number screened (technically adequate) (column 3) multiplied by 1000 (for the appropriate age group).

      Invasive cancer detection rate (per 1,000 screened) (column 42)
    • This column gives the rate of invasive cancers detected per 1,000 women screened, calculated as:

      Total invasive (column 35) divided by Number screened (technically adequate) (column 3) multiplied by 1000 (for the appropriate age group).

      Detection rate of invasive cancers <10 mm (per 1,000 screened) (column 43)
    • This column gives the rate of invasive cancers smaller than 10mm detected per 1,000 women screened, calculated as:

      Invasive size < 10mm (column 29) divided by Number screened (technically adequate) (column 3) multiplied by 1000 (for the appropriate age group).

      Detection rate of invasive cancers <15 mm (per 1,000 screened) (column 44)
    • This column gives the rate of invasive cancers smaller than 15mm detected per 1,000 women screened, calculated as:

      Invasive size < 15mm (columns 29 + 30) divided by Number screened (technically adequate) (column 3) multiplied by 1000 (for the appropriate age group).

      Referral rate for cytology and/or core biopsy (% of screened) (column 45)
    • This column gives the percentage of women screened who are referred for fine needle aspiration cytology and/or core biopsy as part of the assessment process, calculated as:

      Referred for cytology and/or core biopsy (column 14) divided by Number screened (technically adequate) (column 3) multiplied by 100 (for the appropriate age group).

      Referral rate for open biopsy (% of screened) (column 46)
    • This column gives the percentage of women screened who are referred for an open biopsy, either directly from screening or following other assessment procedures, calculated as:

      Total open biopsy (column 20) divided by Number screened (technically adequate) (column 3) multiplied by 100 (for the appropriate age group).

      Pre-operative diagnosis rate (% of cancers diagnosed) (column 47)
    • This column gives the percentage of cancers diagnosed cytologically or histologically without surgery, calculated as:

      Not referred for open biopsy Cancer (column 18) divided by (Not referred for open biopsy Cancer (column 18) plus Open biopsy: Cancer (column 24)) multiplied by 100 (for the appropriate age group).

      Early recall rate following assessment (% of screened) (column 48)
    • This column gives the percentage of women screened who are recommended for early recall following any assessment procedure, calculated as:

      Early recall (column 11) divided by Number screened (technically adequate) (column 3) multiplied by 100 (for the appropriate age group).

      Number of invasive cancers observed (column 49)
    • This column gives the total number of detected cancers classified as invasive, calculated as:

      Total invasive (column 35) (for the appropriate age group).

      Number of invasive cancers expected (column 50)
    • This column is derived from the Number of invasive cancers observed (column 49) and a predefined incidence rate (calculated every three years for the appropriate age group).

      Please note KC62 is issued as an electronic spreadsheet and the predefined incident rate is contained within the spreadsheet for use within this calculation.

      Standardised Detection Ratio (SDR) (column 51)
    • This column is derived from column 49 and column 50.

      Please note KC62 is issued as an electronic spreadsheet and the formula to calculate this ratio is contained within the spreadsheet.

      Part C2/5: Data Completeness Indicators
    • Part C2/5 gives an indication of the completeness of data recorded on information systems in a variety of key areas.

      Please note that where a column number is given within an outcome calculation, it relates to a specified column within the KC62 form for example:

      Number screened (technically adequate) (column 3) divided by Number of women invited (column 1) multiplied by 100 (for the appropriate age group).

      In this example (column 3) relates to Part 1 Invitations and Outcomes column 3.

      Age Groups of women (first column) in Part C2/5.
    • Data Completeness Indicators are assessed within three groups: the first being those within the previous target age range of 50-64, the second within the current target age range of 50-70 and the third, the total of those reported, regardless of age.

      Age Group (50-64) (line 40)
    • These are the outcome measures for women in the previous target age group 50-64.

      Age Group (50-70) (line 41)
    • These are the outcome measures for women in the current target age group 50-70.

      Total all ages (line 42)
    • These are the outcome measures for all women reported, regardless of age.

      Assessment result not known (% of referred) (column 52)
    • This column gives the percentage of women assessed for whom the final outcome of assessment is not recorded, calculated as:

      Outcome of assessment not known (column 9) divided by Referred for assessment (column 7) minus Failed to attend for assessment (column 8) multiplied by 100 (for the appropriate age group)

      Cytology and/or core biopsy result not known (% of referred) (column 53)
    • This column gives the percentage of women referred for one or more cytology and/or core biopsy procedures, for whom a definitive result is not recorded and an open biopsy is not indicated. The column is calculated as:

      No result recorded/inadequate result (column 15) divided by Referred for cytology and/or core biopsy (column 14) multiplied by 100 (for the appropriate age group)

      Open-biopsy result not known (% of referred) (column 54)
    • This column gives the percentage of women referred for an open biopsy for whom a definitive result is not recorded, calculated as:

      No result /inadequate result (column 21) divided by Total open biopsy (column 20) multiplied by 100 (for the appropriate age group)

      Invasive status of cancer not known (% of all cancers diagnosed) (column 55)
    • This column gives the percentage of cancers diagnosed by cytology or histology in which the invasive status is not recorded. The column is calculated as:

      Invasive status not known (column 26) divided by Total number of women with cancer (column 25) multiplied by 100 (for the appropriate age group)

      Size not known (% of invasive cancers) (column 56)
    • This column gives the percentage of cancers diagnosed by cytology or histology which are recorded as invasive, but have no size recorded. The column is calculated as:

      Size not known (column 34) divided by total number of women with invasive cancer Total invasive (column 35) multiplied by 100 (for the appropriate age group)

      Lymph node status not known (% of invasive cancers) (column 57)
    • This column gives the percentage of cancers diagnosed by cytology or histology which are recorded as invasive, but the lymph node status is unknown. The column is calculated as:

      The number of women where no LYMPH NODE STATUS has been recorded and where the BIOPSY REFERRAL OUTCOME classification is Positive; i.e. cancer detected, invasive size known or Positive; i.e. cancer detected, invasive size not known divided by total number of women with invasive cancer: Total invasive (column 35) multiplied by 100 (for the appropriate age group)

      Grade not known (% of invasive cancers) (column 58)
    • This column gives the percentage of cancers diagnosed by cytology or histology, which are recorded as invasive, but the cancer grade is not known. The column is calculated as:

      The number of women where the BIOPSY REFERRAL OUTCOME is Positive; i.e. cancer detected, invasive size not known, grade not known or Positive; i.e. cancer detected, invasive size known, grade not known divided by total number of women with invasive cancer: Total invasive (column 35) multiplied by 100 (for the appropriate age group)

      Special type not known (% of invasive cancers) (column 59)
    • This column gives the percentage of cancers diagnosed by cytology or histology which are recorded as invasive, but the special type is not known. The column is calculated as:

      The number of women where no INVASIVE CANCER SPECIAL TYPE INDICATOR has been recorded and where the BIOPSY REFERRAL OUTCOME classification is Positive; i.e. cancer detected, invasive size known or Positive; i.e. cancer detected, invasive size not known divided by Total invasive (column 35) multiplied by 100 (for the appropriate age group)

      Grade not known (% of DCIS) (column 60)
    • This column gives the percentage of cancers diagnosed by cytology or histology, which are recorded as ductal carcinoma in-situ (DCIS), but the grade is not known. The column is calculated as:

      The number of women where the BIOPSY REFERRAL OUTCOME is Positive; i.e. cancer detected, non-invasive or possibly micro-invasive, grade not known (DCIS only detected) or Positive; i.e. cancer detected, definitely micro-invasive, grade not known (DCIS only detected) divided by total number of women with Non-invasive or possibly micro-invasive (column 27) plus Definitely micro-invasive (column 28) multiplied by 100 (for the appropriate age group)

      Part C2/6: Status of cancer
    • Part C2/6 gives status and grades of cancers detected.

      Age Groups of women (first column) in Part C2/6.
    • The status of cancers are assessed within three groups: the first being those within the previous target age range of 50-64, the second within the current target age range of 50-70 and the third, the total of those reported, regardless of age.

      Age Group (50-64) (line 43)
    • This is the outcome measure for women in the previous target age group 50-64

      Age Group (50-70) (line 44)
    • This is the outcome measure for women in the current target age group 50-70

      Total all ages (line 45)
    • This is the outcome measure for all women reported, regardless of age.

      Women with an invasive cancer detected: number with lymph nodes sampled (column 61)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known or Positive; i.e. cancer detected, invasive size not known with a Request for Pathology Investigation where a LYMPH NODE STATUS has been recorded.

      Women with an invasive cancer detected: number positive (column 62)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known or Positive; i.e. cancer detected, invasive size not known where at least one Request for Pathology Investigation with a LYMPH NODE STATUS of lymph node positive has been recorded.

      Note where more than one Request for Pathology Investigation with a LYMPH NODE STATUS has been recorded for a woman and any one of the LYMPH NODE STATUSES is lymph node positive, then the woman should be included in column 62, but should not be included in column 63.

      Women with an invasive cancer detected: number negative (column 63)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known or Positive; i.e. cancer detected, invasive size not known with a Request for Pathology Investigation with a LYMPH NODE STATUS of lymph node negative.

      Note where more than one Request for Pathology Investigation with a LYMPH NODE STATUS has been recorded for a woman, then every LYMPH NODE STATUS should be lymph node negative for inclusion in count for column 63. If any of the LYMPH NODE STATUSES is lymph node positive, then the woman should be included in column 62 and not included in column 63.

      Women with an invasive cancer detected: number with 4 or more nodes assessed (column 64)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known or Positive; i.e. cancer detected invasive size not known with four or more Request for Pathology Investigation where a LYMPH NODE STATUS has been recorded.

      Women with an invasive cancer detected: number with 4 or more nodes sampled: number positive (column 65)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known or Positive; i.e. cancer detected, invasive size not known with four or more Request for Pathology Investigation with a LYMPH NODE STATUS, any one of which is lymph node positive.

      Women with an invasive cancer detected: number with 4 or more nodes sampled: number negative (column 66)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known or Positive; i.e. cancer detected, invasive size not known with four or more Request for Pathology Investigation with a LYMPH NODE STATUS, any one of which is lymph node negative.

      Women with an invasive cancer detected: number grade 1 (column 67)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known ,Grade I or Positive; i.e. cancer detected, invasive size not known, Grade I.

      Women with an invasive cancer detected: number grade 2 (column 68)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known ,Grade II or Positive; i.e. cancer detected, invasive size not known, Grade II.

      Women with an invasive cancer detected: number grade 3 (column 69)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known, Grade III or Positive; i.e. cancer detected, invasive size not known, Grade III.

      Women with an invasive cancer detected: number special type (column 70)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known or Positive; i.e. cancer detected, invasive size not known with a Request for Pathology Investigation with a INVASIVE CANCER SPECIAL TYPE INDICATOR of special type.

      Women with an invasive cancer detected: number not special type (column 71)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known or Positive; i.e. cancer detected, invasive size not known with a Request for Pathology Investigation with a INVASIVE CANCER SPECIAL TYPE INDICATOR of not special type.

      Women with DCIS only detected: number low or intermediate grade (column 72)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, non-invasive or possibly micro-invasive low (DCIS only detected) or Positive; i.e. cancer detected, non-invasive or possibly micro-invasive, intermediate (DCIS only detected) or Positive; i.e. cancer detected, definitely micro-invasive, low (DCIS only detected) or Positive; i.e. cancer detected, definitely microinvasive, intermediate (DCIS only detected).

      Women with DCIS only detected: number high grade (column 73)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, non-invasive or possibly micro-invasive, high (DCIS only detected) or Positive; i.e. cancer detected, definitely micro-invasive, high (DCIS only detected).

top


KC62 D 1

Change to Central Return Form: Changed Description

Central Return Form Guidance
 

KC62: Adult Screening Programmes - Breast Screening

  1. Table D: Early Recalls

    This table reports the PERSON IN A SCREENING PROGRAMME for Breast Screening whose SCREENING TEST RESULT is Non-routine/early recall advised.

    Part D1: Invitations and Outcomes
    • Table D: Early Recalls
    • This table reports the PERSON IN A SCREENING PROGRAMME for Breast Screening whose SCREENING TEST RESULT is Non-routine/early recall advised.

      Part D1: Invitations and Outcomes
    • This is a summary of the outcomes of screening and assessment of all women invited and/or screened.

      Age at first offered appointment (first column)
    • This is derived from the BIRTH DATE of the PERSON. Line 01 includes all women who were aged 44 or less at the time of the date of their first offered appointment for screening in the period covered by the return. Lines 02 to 09 include women in specified age groups. Line 10 includes all women who were aged 75 or over. Line 11 gives the total of all women in lines 03 to 08, giving a summary of the women in the NHS Breast Screening Programme target age range of 50 to 70 - the Screening Population Line 12 gives the total of all women in lines 01 to 10 regardless of age.

    • This is derived from the PERSON BIRTH DATE of the PERSON. Line 01 includes all women who were aged 44 or less at the time of the date of their first offered appointment for screening in the period covered by the return. Lines 02 to 09 include women in specified age groups. Line 10 includes all women who were aged 75 or over. Line 11 gives the total of all women in lines 03 to 08, giving a summary of the women in the NHS Breast Screening Programme target age range of 50 to 70 - the Screening Population Line 12 gives the total of all women in lines 01 to 10 regardless of age.

    • Lines 13 - 24 in Part D2 Assessment and lines 25 - 36 in Part D2 Cancers diagnosed follow the pattern described above.

      Number of women invited (column 1)
    • Count of Screening Test Invitation where the first TEST DATE OFFERED in the period covered by the return.

      Lost to follow-up after technically inadequate screening mammogram (column 2)
    • Count of women whose SCREENING TEST RESULT classification was Inadequate test, and for whom no REFERRAL FOR BREAST ASSESSMENT was made.

      Number screened (technically adequate) (column 3)
    • Count of women with a SCREENING TEST DATE in the period covered by the return whose SCREENING TEST RESULT classification was not Inadequate test.

      Outcome of initial screen : Not known (column 4)
    • Count of women with a valid SCREENING TEST DATE but where no SCREENING TEST RESULT has been recorded.

      Outcome of initial screen: Routine recall (column 5)
    • Count of women with a BREAST CANCER SCREENING TEST OUTCOME classification of Routine recall.

      Outcome of initial screen: Early recall (column 6)
    • Count of women with a BREAST CANCER SCREENING TEST OUTCOME classification of Early recall but without a REFERRAL FOR BREAST ASSESSMENT.

      Outcome of initial screen: Referred for assessment (column 7)
    • Count of women with a REFERRAL FOR BREAST ASSESSMENT. This covers all the women reported in columns 8 to 12.

      Final outcome of assessment: Failed to attend for assessment (column 8)
    • Count of women with a REFERRAL FOR BREAST ASSESSMENT who failed to attend for all required assessment appointments and for whom there is no BREAST ASSESSMENT FINAL OUTCOME.

      Final outcome of assessment: Outcome of assessment not known (column 9)
    • Count of women with a BREAST ASSESSMENT DATE but where no BREAST ASSESSMENT FINAL OUTCOME has been recorded.

      Final outcome of assessment: Routine recall (column 10)
    • Count of women with a BREAST ASSESSMENT DATE and a BREAST ASSESSMENT FINAL OUTCOME classification of Routine recall.

      Final outcome of assessment: Early recall (column 11)
    • Count of women with a BREAST ASSESSMENT DATE and a BREAST ASSESSMENT FINAL OUTCOME classification of Early recall.

      Final outcome of assessment: Cancer (column 12)
    • Count of women with a BREAST ASSESSMENT DATE and a BREAST ASSESSMENT FINAL OUTCOME classification of Cancer diagnosed. The total recorded in this column will equal the total recorded in columns 13, 18 and 24.

      Part D2: Assessment
    • This part breaks down the outcomes of assessment by the procedures involved for all women assessed as a result of screening.

      Cancer diagnosed without cytology or histology (column 13)
    • Count of women with a BREAST ASSESSMENT DATE whose BREAST ASSESSMENT FINAL OUTCOME classification was Cancer diagnosed, but who had no BIOPSY REFERRAL OUTCOME or a REFERRAL FOR BIOPSY where the PATHOLOGY INVESTIGATION TYPE CODE classification was not Cytology and the BIOPSY REFERRAL OUTCOME classification was Inconclusive.

      Referred for cytology and/or core biopsy (column 14)
    • Count of women with a BREAST CANCER SCREENING TEST OUTCOME classification of Referred for assessment and a subsequent REFERRAL FOR BIOPSY with a PATHOLOGY INVESTIGATION TYPE CODE classification of Cytology or Core biopsy.

      Not referred for open biopsy: No result recorded/inadequate result (column 15)
    • Count of women with a BREAST CANCER SCREENING TEST OUTCOME classification of Referred for assessment and a subsequent REFERRAL FOR BIOPSY with a PATHOLOGY INVESTIGATION TYPE CODE classification of Cytology or Core biopsy but without any PATHOLOGY INVESTIGATION TYPE CODE classification of Histology (open biopsy). These women did not complete any or all procedures within 6 months of the date of the screen or had no BREAST ASSESSMENT FINAL OUTCOME recorded.

      Not referred for open biopsy: Routine recall (column 16)
    • Count of women with a BREAST CANCER SCREENING TEST OUTCOME classification of Referred for assessment, a subsequent REFERRAL FOR BIOPSY with a PATHOLOGY INVESTIGATION TYPE CODE classification of Cytology or Core biopsy but without any PATHOLOGY INVESTIGATION TYPE CODE classification of Histology (open biopsy). These women have a BREAST ASSESSMENT FINAL OUTCOME classification of Routine recall.

      Not referred for open biopsy: Early recall (column 17)
    • Count of women with a BREAST CANCER SCREENING TEST OUTCOME classification of Referred for assessment, a subsequent REFERRAL FOR BIOPSY with a PATHOLOGY INVESTIGATION TYPE CODE classification of Cytology or Core biopsy but without any PATHOLOGY INVESTIGATION TYPE CODE classification of Histology (open biopsy). These women have a BREAST ASSESSMENT FINAL OUTCOME classification of Early recall.

      Not referred for open biopsy: Cancer (column 18)
    • Count of women with a BREAST CANCER SCREENING TEST OUTCOME classification of Referred for assessment, a subsequent REFERRAL FOR BIOPSY with a PATHOLOGY INVESTIGATION TYPE CODE classification of Cytology or Core biopsy but without any PATHOLOGY INVESTIGATION TYPE CODE classification of Histology (open biopsy). These women have a BREAST ASSESSMENT FINAL OUTCOME classification of Cancer diagnosed.

      Referred for open biopsy (column 19)
    • Count of women with a REFERRAL FOR BIOPSY with a PATHOLOGY INVESTIGATION TYPE CODE classification of Cytology or Core biopsy followed by a REFERRAL FOR BIOPSY with a PATHOLOGY INVESTIGATION TYPE CODE classification of Histology (open biopsy).

      Total referred for open biopsy (column 20)
    • Total count of women with a REFERRAL FOR BIOPSY with a PATHOLOGY INVESTIGATION TYPE CODE classification of Histology (open biopsy).

      Up to and including open biopsy: No result/inadequate result (column 21)
    • Count of women with a REFERRAL FOR BIOPSY with a PATHOLOGY INVESTIGATION TYPE CODE classification of Histology (open biopsy). These women have a BIOPSY REFERRAL OUTCOME classification of Inconclusive or Biopsy not done or result not yet known or did not attend for the biopsy within 6 months of the date of the Screening Test having no recorded DATE BIOPSY TAKEN.

      Up to and including open biopsy: Result: Benign/normal: Routine recall (column 22)
    • Count of women with a REFERRAL FOR BIOPSY with a PATHOLOGY INVESTIGATION TYPE CODE classification of Histology (open biopsy). The BIOPSY REFERRAL OUTCOME classification is Benign or negative. The BREAST ASSESSMENT FINAL OUTCOME classification for these women is Routine recall.

      Up to and including open biopsy: Result: Benign/normal: Early recall (column 23)
    • Count of women with a REFERRAL FOR BIOPSY with a PATHOLOGY INVESTIGATION TYPE CODE classification of Histology (open biopsy). The BIOPSY REFERRAL OUTCOME classification is Benign or negative. The BREAST ASSESSMENT FINAL OUTCOME classification for these women is Early recall.

      Up to and including open biopsy: Cancer (column 24)
    • Count of women with a REFERRAL FOR BIOPSY with a PATHOLOGY INVESTIGATION TYPE CODE classification of Histology (open biopsy). The BIOPSY REFERRAL OUTCOME classification is Positive; i.e. cancer diagnosed. The BREAST ASSESSMENT FINAL OUTCOME classification for these women is Cancer diagnosed.

top


KC62 D 2

Change to Central Return Form: Changed Description

Central Return Form Guidance
 

KC62: Adult Screening Programmes - Breast Screening

  1. Table D3: Early Recalls
    • Table D3: Early Recalls
      Part D3: Cancers Diagnosed
    • This part of the return describes the cancers formally diagnosed in women assessed as a result of screening. Only breast cancers should be reported, as defined in the Information and Training Manual for England and Wales.

      Age at first offered appointment (first column)
    • This is derived from the BIRTH DATE of the PERSON and the test date offered (see ACTIVITY DATE) of the first Screening Test Invitation within the period of the return.

      Total number of women with cancer (column 25)
    • This is derived from the PERSON BIRTH DATE of the PERSON and the test date offered (see ACTIVITY DATE) of the first Screening Test Invitation within the period of the return.

      Total number of women with cancer (column 25)
    • Count of all women in columns 18 and 24 of Part 2 Assessment i.e. those women with a proven diagnosis of breast cancer.

      Invasive status not known (column 26)
    • Count of women included in Part 3 with a BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected invasive status not knwon.

      Non-invasive or possibly micro-invasive (column 27)
    • Count of women included in Part 3 with a BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected invasive status not known.

      Non-invasive or possibly micro-invasive (column 27)
    • Count of women included in Part 3 with a BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected non-invasive or possibly micro-invasive.

      Definitely micro-invasive (column 28)
    • Count of women included in Part 3 with a BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected definitely micro-invasive.

      Invasive size (columns 29 - 33)
    • These columns count all cancers classified as invasive, separated according to the pathological size of the cancer (INVASIVE LESION SIZE). The BIOPSY REFERRAL OUTCOME classification is Positive; i.e. cancer detected invasive size known.

      Invasive size (of cancer)<10mm (column 29)
      Invasive size (of cancer)>=10mm & <15mm (column 30)
      Invasive size (of cancer)>=15mm & <20mm (column 31)
      Invasive size (of cancer)>=20mm & <50mm (column 32)
      Invasive size (of cancer)>=50mm (column 33)
      Invasive size: Size not known (column 34)
    • These columns count all cancers classified as invasive, separated according to the pathological size of the cancer (INVASIVE LESION SIZE). The BIOPSY REFERRAL OUTCOME classification is Positive; i.e. cancer detected invasive size known.

      Invasive size (of cancer)<10mm (column 29)
      Invasive size (of cancer)>=10mm & <15mm (column 30)
      Invasive size (of cancer)>=15mm & <20mm (column 31)
      Invasive size (of cancer)>=20mm & <50mm (column 32)
      Invasive size (of cancer)>=50mm (column 33)

      Invasive size: Size not known (column 34)
    • This column counts invasive cancers where the BIOPSY REFERRAL OUTCOME classification is Positive; i.e. cancer detected invasive size not known.

      Total invasive (column 35)
    • This column counts the total number of cancers classified as invasive, that is with a BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected invasive size known or Positive; i.e. cancer detected invasive size not known

top


KC62 D 3

Change to Central Return Form: Changed Description

Central Return Form Guidance
 

KC62: Adult Screening Programmes - Breast Screening

  1. Table D: Early Recall
    • Table D: Early Recall
      Part D4: Outcome measures
    • Part 4 presents a selection of outcome measures related to NHS Breast Screening Programme (NHSBSP) quality targets.

      Please note that where a column number is given within an outcome calculation, it relates to a specified column within the KC62 form for example:

      Number screened (technically adequate) (column 3) divided by Number of women invited (column 1) multiplied by 100 (for the appropriate age group).

      In this example (column 3) relates to Part 1 Invitations and Outcomes column 3.

      Age Groups of women (first column)
    • Outcome measures are assessed within three groups: the first being those within the previous target age range of 50-64, the second within the current target age range of 50-70 and the third, the total of those reported, regardless of age.

      Age Group (50-64) (line 37)
    • These are the outcome measures for women in the age group 50-64

      Age Group (50-70) (line 38)
    • These are the outcome measures for women in the age group 50-70

      Total all ages (line 39)
    • These are the outcome measures for women of all ages.

      Uptake rate (% of invited) (column 36)
    • This column gives the uptake rate (also known as the acceptance rate) for screening. It is defined as the percentage of women who receive a technically adequate and complete screen as a result of an invitation for routine screening, and is calculated as:

      Number screened (technically adequate) (column 3) divided by Number of women invited (column 1) multiplied by 100 (for the appropriate age group).

      Referral rate (% of screened) (column 37)
    • This column gives the rate of referrals to assessment from screening. It is defined as the percentage of women screened who are referred for any assessment procedure and is calculated as:

      Outcome of initial screen: Referred for assessment (column 7) divided by Number screened (technically adequate) (column 3) multiplied by 100 (for the appropriate age group).

      Non-invasive or micro-invasive cancers (per 1,000 screened) (column 38)
    • This column gives the cancers detected which are non-invasive, possibly micro-invasive, or definitely micro-invasive, per 1,000 screened calculated as:

      Non-invasive or possibly micro-invasive (column 27) plus Definitely micro-invasive (column 28) divided by Number screened (technically adequate) (column 3) multiplied by 1000 (for the appropriate age group).

      Benign biopsy rate (per 1,000 screened) (column 39)
    • This column gives the women screened who have an open biopsy with a result of benign or normal per 1,000 screened, calculated as:

      Up to and including open biopsy: Result: benign/normal (columns 22 + 23) divided by Number screened (technically adequate) (column 3) multiplied by 1000 (for the appropriate age group).

      Benign Therapeutic operation: Number (column 40)
    • This column gives the number of women screened who had a REFERRAL REQUEST for breast treatment and who had a BENIGN THERAPEUTIC OPERATION by the appropriate age group.

      Benign Therapeutic operation: Rate (per 1,000 screened) (column 41)
    • This column gives the women screened who have a BENIGN THERAPEUTIC OPERATION per 1,000 screened, calculated as:

      Number of BENIGN THERAPEUTIC OPERATIONS for the period (column 40) divided by Number screened (technically adequate) (column 3) multiplied by 1000 (for the appropriate age group).

      Invasive cancer detection rate (per 1,000 screened) (column 42)
    • This column gives the rate of invasive cancers detected per 1,000 women screened, calculated as:

      Total invasive (column 35) divided by Number screened (technically adequate) (column 3) multiplied by 1000 (for the appropriate age group).

      Detection rate of invasive cancers <10 mm (per 1,000 screened) (column 43)
    • This column gives the rate of invasive cancers smaller than 10mm detected per 1,000 women screened, calculated as:

      Invasive size < 10mm (column 29) divided by Number screened (technically adequate) (column 3) multiplied by 1000 (for the appropriate age group).

      Detection rate of invasive cancers <15 mm (per 1,000 screened) (column 44)
    • This column gives the rate of invasive cancers smaller than 15mm detected per 1,000 women screened, calculated as:

      Invasive size < 15mm (columns 29 + 30) divided by Number screened (technically adequate) (column 3) multiplied by 1000 (for the appropriate age group).

      Referral rate for cytology and/or core biopsy (% of screened) (column 45)
    • This column gives the percentage of women screened who are referred for fine needle aspiration cytology and/or core biopsy as part of the assessment process, calculated as:

      Referred for cytology and/or core biopsy (column 14) divided by Number screened (technically adequate) (column 3) multiplied by 100 (for the appropriate age group).

      Referral rate for open biopsy (% of screened) (column 46)
    • This column gives the percentage of women screened who are referred for an open biopsy, either directly from screening or following other assessment procedures, calculated as:

      Total open biopsy (column 20) divided by Number screened (technically adequate) (column 3) multiplied by 100 (for the appropriate age group).

      Pre-operative diagnosis rate (% of cancers diagnosed) (column 47)
    • This column gives the percentage of cancers diagnosed cytologically or histologically without surgery, calculated as:

      Not referred for open biopsy Cancer (column 18) divided by (Not referred for open biopsy Cancer (column 18) plus Open biopsy: Cancer (column 24)) multiplied by 100 (for the appropriate age group).

      Early recall rate following assessment (% of screened) (column 48)
    • This column gives the percentage of women screened who are recommended for early recall following any assessment procedure, calculated as:

      Early recall (column 11) divided by Number screened (technically adequate) (column 3) multiplied by 100 (for the appropriate age group).

      Number of invasive cancers observed (column 49)
    • This column gives the total number of detected cancers classified as invasive, calculated as:

      Total invasive (column 35) (for the appropriate age group).

      Number of invasive cancers expected (column 50)
    • This column is derived from the Number of invasive cancers observed (column 49) and a predefined incidence rate (calculated every three years for the appropriate age group).

      Please note KC62 is issued as an electronic spreadsheet and the predefined incident rate is contained within the spreadsheet for use within this calculation.

      Standardised Detection Ratio (SDR) (column 51)
    • This column is derived from column 49 and column 50.

      Please note KC62 is issued as an electronic spreadsheet and the formula to calculate this ratio is contained within the spreadsheet.

      Part D5: Data Completeness Indicators
    • Part D5 gives an indication of the completeness of data recorded on information systems in a variety of key areas.

      Please note that where a column number is given within an outcome calculation, it relates to a specified column within the KC62 form for example:

      Number screened (technically adequate) (column 3) divided by Number of women invited (column 1) multiplied by 100 (for the appropriate age group).

      In this example (column 3) relates to Part 1 Invitations and Outcomes column 3.

      Age Groups of women (first column) in Part D5.
    • Data Completeness Indicators are assessed within three groups: the first being those within the previous target age range of 50-64, the second within the current target age range of 50-70 and the third, the total of those reported, regardless of age.

      Age Group (50-64) (line 40)
    • These are the outcome measures for women in the previous target age group 50-64.

      Age Group (50-70) (line 41)
    • These are the outcome measures for women in the current target age group 50-70.

      Total all ages (line 42)
    • These are the outcome measures for all women reported, regardless of age.

      Assessment result not known (% of referred) (column 52)
    • This column gives the percentage of women assessed for whom the final outcome of assessment is not recorded, calculated as:

      Outcome of assessment not known (column 9) divided by Referred for assessment (column 7) minus Failed to attend for assessment (column 8) multiplied by 100 (for the appropriate age group)

      Cytology and/or core biopsy result not known (% of referred) (column 53)
    • This column gives the percentage of women referred for one or more cytology and/or core biopsy procedures, for whom a definitive result is not recorded and an open biopsy is not indicated. The column is calculated as:

      No result recorded/inadequate result (column 15) divided by Referred for cytology and/or core biopsy (column 14) multiplied by 100 (for the appropriate age group)

      Open-biopsy result not known (% of referred) (column 54)
    • This column gives the percentage of women referred for an open biopsy for whom a definitive result is not recorded, calculated as:

      No result /inadequate result (column 21) divided by Total open biopsy (column 20) multiplied by 100 (for the appropriate age group)

      Invasive status of cancer not known (% of all cancers diagnosed) (column 55)
    • This column gives the percentage of cancers diagnosed by cytology or histology in which the invasive status is not recorded. The column is calculated as:

      Invasive status not known (column 26) divided by Total number of women with cancer (column 25) multiplied by 100 (for the appropriate age group)

      Size not known (% of invasive cancers) (column 56)
    • This column gives the percentage of cancers diagnosed by cytology or histology which are recorded as invasive, but have no size recorded. The column is calculated as:

      Size not known (column 34) divided by total number of women with invasive cancer Total invasive (column 35) multiplied by 100 (for the appropriate age group)

      Lymph node status not known (% of invasive cancers) (column 57)
    • This column gives the percentage of cancers diagnosed by cytology or histology which are recorded as invasive, but the lymph node status is unknown. The column is calculated as:

      The number of women where no LYMPH NODE STATUS has been recorded and where the BIOPSY REFERRAL OUTCOME classification is Positive; i.e. cancer detected, invasive size known or Positive; i.e. cancer detected, invasive size not known divided by total number of women with invasive cancer: Total invasive (column 35) multiplied by 100 (for the appropriate age group)

      Grade not known (% of invasive cancers) (column 58)
    • This column gives the percentage of cancers diagnosed by cytology or histology, which are recorded as invasive, but the cancer grade is not known. The column is calculated as:

      The number of women where the BIOPSY REFERRAL OUTCOME is Positive; i.e. cancer detected, invasive size not known, grade not known or Positive; i.e. cancer detected, invasive size known, grade not known divided by total number of women with invasive cancer: Total invasive (column 35) multiplied by 100 (for the appropriate age group)

      Special type not known (% of invasive cancers) (column 59)
    • This column gives the percentage of cancers diagnosed by cytology or histology which are recorded as invasive, but the special type is not known. The column is calculated as:

      The number of women where no INVASIVE CANCER SPECIAL TYPE INDICATOR has been recorded and where the BIOPSY REFERRAL OUTCOME classification is Positive; i.e. cancer detected, invasive size known or Positive; i.e. cancer detected, invasive size not known divided by Total invasive (column 35) multiplied by 100 (for the appropriate age group)

      Grade not known (% of DCIS) (column 60)
    • This column gives the percentage of cancers diagnosed by cytology or histology, which are recorded as ductal carcinoma in-situ (DCIS), but the grade is not known. The column is calculated as:

      The number of women where the BIOPSY REFERRAL OUTCOME is Positive; i.e. cancer detected, non-invasive or possibly micro-invasive, grade not known (DCIS only detected) or Positive; i.e. cancer detected, definitely micro-invasive, grade not known (DCIS only detected) divided by total number of women with Non-invasive or possibly micro-invasive (column 27) plus Definitely micro-invasive (column 28) multiplied by 100 (for the appropriate age group)

      Part D6: Status of cancer
    • Part D6 gives status and grades of cancers detected.

      Age Groups of women (first column) in Part D6.
    • The status of cancers are assessed within three groups: the first being those within the previous target age range of 50-64, the second within the current target age range of 50-70 and the third, the total of those reported, regardless of age.

      Age Group (50-64) (line 43)
    • This is the outcome measure for women in the previous target age group 50-64

      Age Group (50-70) (line 44)
    • This is the outcome measure for women in the current target age group 50-70

      Total all ages (line 45)
    • This is the outcome measure for all women reported, regardless of age.

      Women with an invasive cancer detected: number with lymph nodes sampled (column 61)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known or Positive; i.e. cancer detected, invasive size not known with a Request for Pathology Investigation where a LYMPH NODE STATUS has been recorded.

      Women with an invasive cancer detected: number positive (column 62)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known or Positive; i.e. cancer detected, invasive size not known where at least one Request for Pathology Investigation with a LYMPH NODE STATUS of lymph node positive has been recorded.

      Note where more than one Request for Pathology Investigation with a LYMPH NODE STATUS has been recorded for a woman and any one of the LYMPH NODE STATUSES is lymph node positive, then the woman should be included in column 62, but should not be included in column 63.

      Women with an invasive cancer detected: number negative (column 63)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known or Positive; i.e. cancer detected, invasive size not known with a Request for Pathology Investigation with a LYMPH NODE STATUS of lymph node negative.

      Note where more than one Request for Pathology Investigation with a LYMPH NODE STATUS has been recorded for a woman, then every LYMPH NODE STATUS should be lymph node negative for inclusion in count for column 63. If any of the LYMPH NODE STATUSES is lymph node positive, then the woman should be included in column 62 and not included in column 63.

      Women with an invasive cancer detected: number with 4 or more nodes assessed (column 64)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known or Positive; i.e. cancer detected invasive size not known with four or more Request for Pathology Investigation where a LYMPH NODE STATUS has been recorded.

      Women with an invasive cancer detected: number with 4 or more nodes sampled: number positive (column 65)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known or Positive; i.e. cancer detected, invasive size not known with four or more Request for Pathology Investigation with a LYMPH NODE STATUS, any one of which is lymph node positive.

      Women with an invasive cancer detected: number with 4 or more nodes sampled: number negative (column 66)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known or Positive; i.e. cancer detected, invasive size not known with four or more Request for Pathology Investigation with a LYMPH NODE STATUS, any one of which is lymph node negative.

      Women with an invasive cancer detected: number grade 1 (column 67)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known ,Grade I or Positive; i.e. cancer detected, invasive size not known, Grade I.

      Women with an invasive cancer detected: number grade 2 (column 68)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known ,Grade II or Positive; i.e. cancer detected, invasive size not known, Grade II.

      Women with an invasive cancer detected: number grade 3 (column 69)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known, Grade III or Positive; i.e. cancer detected, invasive size not known, Grade III.

      Women with an invasive cancer detected: number special type (column 70)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known or Positive; i.e. cancer detected, invasive size not known with a Request for Pathology Investigation with a INVASIVE CANCER SPECIAL TYPE INDICATOR of special type.

      Women with an invasive cancer detected: number not special type (column 71)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known or Positive; i.e. cancer detected, invasive size not known with a Request for Pathology Investigation with a INVASIVE CANCER SPECIAL TYPE INDICATOR of not special type.

      Women with DCIS only detected: number low or intermediate grade (column 72)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, non-invasive or possibly micro-invasive low (DCIS only detected) or Positive; i.e. cancer detected, non-invasive or possibly micro-invasive, intermediate (DCIS only detected) or Positive; i.e. cancer detected, definitely micro-invasive, low (DCIS only detected) or Positive; i.e. cancer detected, definitely microinvasive, intermediate (DCIS only detected).

      Women with DCIS only detected: number high grade (column 73)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, non-invasive or possibly micro-invasive, high (DCIS only detected) or Positive; i.e. cancer detected, definitely micro-invasive, high (DCIS only detected).

top


KC62 E 1

Change to Central Return Form: Changed Description

Central Return Form Guidance
 

KC62: Adult Screening Programmes - Breast Screening

  1. Table E: Self/GP referrals of women not screened previously

    This table reports women with a REFERRAL REQUEST for Screening Test with SCREENING REFERRAL SOURCE of Self-referral or GMP with no previous Screening Test. These women have been referred directly for a Screening Test rather than as an invitation as part of a Screening Programme.

    Part E1: Invitations and Outcomes
  2. Table E: Self/GP referrals of women not screened previously
    Part E1: Invitations and Outcomes
    • This is a summary of the outcomes of screening and assessment of all women invited and/or screened.

      Age at first offered appointment (first column)
    • This is derived from the BIRTH DATE of the PERSON. Line 01 includes all women who were aged 44 or less at the time of the date of their first offered appointment for screening in the period covered by the return. Lines 02 to 09 include women in specified age groups. Line 10 includes all women who were aged 75 or over. Line 11 gives the total of all women in lines 03 to 08, giving a summary of the women in the NHS Breast Screening Programme target age range of 50 to 70 - the Screening Population. Line 12 gives the total of all women in lines 01 to 10 regardless of age.

    • This is derived from the PERSON BIRTH DATE of the PERSON. Line 01 includes all women who were aged 44 or less at the time of the date of their first offered appointment for screening in the period covered by the return. Lines 02 to 09 include women in specified age groups. Line 10 includes all women who were aged 75 or over. Line 11 gives the total of all women in lines 03 to 08, giving a summary of the women in the NHS Breast Screening Programme target age range of 50 to 70 - the Screening Population. Line 12 gives the total of all women in lines 01 to 10 regardless of age.

    • Lines 13 - 24 in Part E2 Assessment and lines 25 - 36 in Part E2 Cancers diagnosed follow the pattern described above.

      Number of women invited (column 1)
    • Count of REFERRAL REQUESTS for Screening Test where the first test date offered (see ACTIVITY DATE) is in the period covered by the return.

      Lost to follow-up after technically inadequate screening mammogram (column 2)
    • Count of women whose SCREENING TEST RESULT classification was Inadequate test, and for whom no REFERRAL REQUEST for breast assessment was made.

      Number screened (technically adequate) (column 3)
    • Count of women with a Screening Test Date in the period covered by the return whose SCREENING TEST RESULT classification was not Inadequate test.

      Outcome of initial screen : Not known (column 4)
    • Count of women with a valid Screening Test Date but where no breast cancer screening test outcome (see BREAST ASSESSMENT OR TEST OUTCOME) has been recorded.

      Outcome of initial screen: Routine recall (column 5)
    • Count of women with a breast cancer screening test outcome classification of Routine recall.

      Outcome of initial screen: Early recall (column 6)
    • Count of women with a breast cancer screening test outcome classification of Early recall but without a REFERRAL REQUEST for breast assessment.

      Outcome of initial screen: Referred for assessment (column 7)
    • Count of women with a REFERRAL REQUEST for breast assessment. This covers all the women reported in columns 8 to 12.

      Final outcome of assessment: Failed to attend for assessment (column 8)
    • Count of women with a REFERRAL REQUEST for breast assessment who failed to attend for all required assessment appointments and for whom there is no breast assessment final outcome (see BREAST ASSESSMENT OR TEST OUTCOME).

      Final outcome of assessment: Outcome of assessment not known (column 9)
    • Count of women with a breast assessment date (see ACTIVITY DATE) but where no breast assessment final outcome has been recorded.

      Final outcome of assessment: Routine recall (column 10)
    • Count of women with a breast assessment date and a breast assessment final outcome classification of Routine recall.

      Final outcome of assessment: Early recall (column 11)
    • Count of women with a breast assessment date and a breast assessment final outcome classification of Early recall.

      Final outcome of assessment: Cancer (column 12)
    • Count of women with a breast assessment date and a breast assessment final outcome classification of Cancer diagnosed. The total recorded in this column will equal the total recorded in columns 13, 18 and 24.

      Part E2: Assessment
    • This part breaks down the outcomes of assessment by the procedures involved for all women assessed as a result of screening.

      Cancer diagnosed without cytology or histology (column 13)
    • Count of women with a breast assessment date whose breast assessment final outcome classification was Cancer diagnosed, but who had no REFERRAL REQUEST for biopsy or a REFERRAL REQUEST for biopsy where the PATHOLOGY INVESTIGATION TYPE CODE classification was not Cytology and the BIOPSY REFERRAL OUTCOME classification was inconclusive.

      Referred for cytology and/or core biopsy (column 14)
    • Count of women with a breast cancer screening test outcome classification of Referred for assessment and a subsequent REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE CODE classification of Cytology or Core biopsy.

      Not referred for open biopsy: No result recorded/inadequate result (column 15)
    • Count of women with a breast cancer screening test outcome classification of Referred for assessment and a subsequent REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE CODE classification of Cytology or Core biopsy but without any PATHOLOGY INVESTIGATION TYPE CODE classification of Histology (open biopsy). These women did not complete any or all procedures within 6 months of the date of the screen or had no breast assessment final outcome recorded.

      Not referred for open biopsy: Routine recall (column 16)
    • Count of women with a breast cancer screening test outcome classification of Referred for assessment, a subsequent REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE CODE classification of Cytology or Core biopsy but without any PATHOLOGY INVESTIGATION TYPE CODE classification of Histology (open biopsy). These women have a breast assessment final outcome classification of Routine recall.

      Not referred for open biopsy: Early recall (column 17)
    • Count of women with a breast cancer screening test outcome classification of Referred for assessment, a subsequent REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE CODE classification of Cytology or Core biopsy but without any PATHOLOGY INVESTIGATION TYPE CODE classification of Histology (open biopsy). These women have a breast assessment final outcome classification of Early recall.

      Not referred for open biopsy: Cancer (column 18)
    • Count of women with a breast cancer screening test outcome classification of Referred for assessment, a subsequent REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE CODE classification of Cytology or Core biopsy but without any PATHOLOGY INVESTIGATION TYPE CODE classification of Histology (open biopsy). These women have a breast assessment final outcome classification of Cancer diagnosed.

      Referred for open biopsy (column 19)
    • Count of women with a REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE CODE classification of Cytology or Core biopsy followed by a REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE CODE classification of Histology (open biopsy).

      Total referred for open biopsy (column 20)
    • Total count of women with a REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE CODE classification of Histology (open biopsy).

      Up to and including open biopsy: No result/inadequate result (column 21)
    • Count of women with a REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE CODE classification of Histology (open biopsy). These women have a BIOPSY REFERRAL OUTCOME classification of Inconclusive or Biopsy not done or result not yet known or did not attend for the biopsy within 6 months of the date of the Screening Test having no recorded date biopsy taken (see ACTIVITY DATE).

      Up to and including open biopsy: Result: Benign/normal: Routine recall (column 22)
    • Count of women with a REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE CODE classification of Histology (open biopsy). The BIOPSY REFERRAL OUTCOME classification is Benign or negative. The breast assessment final outcome classification for these women is Routine recall.

      Up to and including open biopsy: Result: Benign/normal: Early recall (column 23)
    • Count of women with a REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE CODE classification of Histology (open biopsy). The BIOPSY REFERRAL OUTCOME classification is Benign or negative. The breast assessment final outcome classification for these women is Early recall.

      Up to and including open biopsy: Cancer (column 24)
    • Count of women with a REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE CODE classification of Histology (open biopsy). The BIOPSY REFERRAL OUTCOME classification is Positive; i.e. cancer diagnosed. The breast assessment final outcome classification for these women is Cancer diagnosed.

top


KC62 E 2

Change to Central Return Form: Changed Description

Central Return Form Guidance
 

KC62: Adult Screening Programmes - Breast Screening

  1. Table E: Self/GP referrals of women not screened previously
    • Table E: Self/GP referrals of women not screened previously
      Part E3: Cancers Diagnosed
    • This part of the return describes the cancers formally diagnosed in women assessed as a result of screening. Only breast cancers should be reported, as defined in the Information and Training Manual for England and Wales.

      Age at first offered appointment (first column)
    • This is derived from the BIRTH DATE of the PERSON and the first test date offered (see ACTIVITY DATE) following a REFERRAL REQUEST for Screening Test.

      Total number of women with cancer (column 25)
    • This is derived from the PERSON BIRTH DATE of the PERSON and the first test date offered (see ACTIVITY DATE) following a REFERRAL REQUEST for Screening Test.

      Total number of women with cancer (column 25)
    • Count of all women in columns 18 and 24 of Part 2 Assessment i.e. those women with a proven diagnosis of breast cancer.

      Invasive status not known (column 26)
    • Count of women included in Part 3 with a BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected invasive status not known.

      Non-invasive or possibly micro-invasive (column 27)
    • Count of women included in Part 3 with a BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected non-invasive or possibly micro-invasive.

      Definitely micro-invasive (column 28)
    • Count of women included in Part 3 with a BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected definitely micro-invasive.

      Invasive size (columns 29 - 33)
    • These columns count all cancers classified as invasive, separated according to the pathological size of the cancer (INVASIVE LESION SIZE). The BIOPSY REFERRAL OUTCOME classification is Positive; i.e. cancer detected Invasive size known.

      Invasive size (of cancer)<10mm (column 29)
      Invasive size (of cancer)>=10mm & <15mm (column 30)
      Invasive size (of cancer)>=15mm & <20mm (column 31)
      Invasive size (of cancer)>=20mm & <50mm (column 32)
      Invasive size (of cancer)>=50mm (column 33)
      Invasive size: Size not known (column 34)
    • These columns count all cancers classified as invasive, separated according to the pathological size of the cancer (INVASIVE LESION SIZE). The BIOPSY REFERRAL OUTCOME classification is Positive; i.e. cancer detected Invasive size known.

      Invasive size (of cancer)<10mm (column 29)
      Invasive size (of cancer)>=10mm & <15mm (column 30)
      Invasive size (of cancer)>=15mm & <20mm (column 31)
      Invasive size (of cancer)>=20mm & <50mm (column 32)
      Invasive size (of cancer)>=50mm (column 33)

      Invasive size: Size not known (column 34)
    • This column counts invasive cancers where the BIOPSY REFERRAL OUTCOME classification is Positive; i.e. cancer detected Invasive size not known.

      Total invasive (column 35)
    • This column counts the total number of cancers classified as invasive, that is with a BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected invasive size known or Positive; i.e. cancer detected invasive size not known

top


KC62 E 3

Change to Central Return Form: Changed Description

Central Return Form Guidance
 

KC62: Adult Screening Programmes - Breast Screening

  1. Table E: Self/GP referrals of women not screened previously
    • Table E: Self/GP referrals of women not screened previously
      Part E4: Outcome measures
    • Part 4 presents a selection of outcome measures related to NHS Breast Screening Programme (NHSBSP) quality targets.

      Please note that where a column number is given within an outcome calculation, it relates to a specified column within the KC62 form for example:

      Number screened (technically adequate) (column 3) divided by Number of women invited (column 1) multiplied by 100 (for the appropriate age group).

      In this example (column 3) relates to Part 1 Invitations and Outcomes column 3.

      Age Groups of women (first column)
    • Outcome measures are assessed within three groups: the first being those within the previous target age range of 50-64, the second within the current target age range of 50-70 and the third, the total of those reported, regardless of age.

      Age Group (50-64) (line 37)
    • These are the outcome measures for women in the age group 50-64

      Age Group (50-70) (line 38)
    • These are the outcome measures for women in the age group 50-70

      Total all ages (line 39)
    • These are the outcome measures for women of all ages.

      Uptake rate (% of invited) (column 36)
    • This column gives the uptake rate (also known as the acceptance rate) for screening. It is defined as the percentage of women who receive a technically adequate and complete screen as a result of an invitation for routine screening, and is calculated as:

      Number screened (technically adequate) (column 3) divided by Number of women invited (column 1) multiplied by 100 (for the appropriate age group).

      Referral rate (% of screened) (column 37)
    • This column gives the rate of referrals to assessment from screening. It is defined as the percentage of women screened who are referred for any assessment procedure and is calculated as:

      Outcome of initial screen: Referred for assessment (column 7) divided by Number screened (technically adequate) (column 3) multiplied by 100 (for the appropriate age group).

      Non-invasive or micro-invasive cancers (per 1,000 screened) (column 38)
    • This column gives the cancers detected which are non-invasive, possibly micro-invasive, or definitely micro-invasive, per 1,000 screened calculated as:

      Non-invasive or possibly micro-invasive (column 27) plus Definitely micro-invasive (column 28) divided by Number screened (technically adequate) (column 3) multiplied by 1000 (for the appropriate age group).

      Benign biopsy rate (per 1,000 screened) (column 39)
    • This column gives the women screened who have an open biopsy with a result of benign or normal per 1,000 screened, calculated as:

      Up to and including open biopsy: Result: benign/normal (columns 22 + 23) divided by Number screened (technically adequate) (column 3) multiplied by 1000 (for the appropriate age group).

      Benign Therapeutic operation: Number (column 40)
    • This column gives the number of women screened who had a REFERRAL REQUEST for breast treatment and who had a BENIGN THERAPEUTIC OPERATION by the appropriate age group.

      Benign Therapeutic operation: Rate (per 1,000 screened) (column 41)
    • This column gives the women screened who have a BENIGN THERAPEUTIC OPERATION per 1,000 screened, calculated as:

      Number of BENIGN THERAPEUTIC OPERATIONS for the period (column 40) divided by Number screened (technically adequate) (column 3) multiplied by 1000 (for the appropriate age group).

      Invasive cancer detection rate (per 1,000 screened) (column 42)
    • This column gives the rate of invasive cancers detected per 1,000 women screened, calculated as:

      Total invasive (column 35) divided by Number screened (technically adequate) (column 3) multiplied by 1000 (for the appropriate age group).

      Detection rate of invasive cancers <10 mm (per 1,000 screened) (column 43)
    • This column gives the rate of invasive cancers smaller than 10mm detected per 1,000 women screened, calculated as:

      Invasive size < 10mm (column 29) divided by Number screened (technically adequate) (column 3) multiplied by 1000 (for the appropriate age group).

      Detection rate of invasive cancers <15 mm (per 1,000 screened) (column 44)
    • This column gives the rate of invasive cancers smaller than 15mm detected per 1,000 women screened, calculated as:

      Invasive size < 15mm (columns 29 + 30) divided by Number screened (technically adequate) (column 3) multiplied by 1000 (for the appropriate age group).

      Referral rate for cytology and/or core biopsy (% of screened) (column 45)
    • This column gives the percentage of women screened who are referred for fine needle aspiration cytology and/or core biopsy as part of the assessment process, calculated as:

      Referred for cytology and/or core biopsy (column 14) divided by Number screened (technically adequate) (column 3) multiplied by 100 (for the appropriate age group).

      Referral rate for open biopsy (% of screened) (column 46)
    • This column gives the percentage of women screened who are referred for an open biopsy, either directly from screening or following other assessment procedures, calculated as:

      Total open biopsy (column 20) divided by Number screened (technically adequate) (column 3) multiplied by 100 (for the appropriate age group).

      Pre-operative diagnosis rate (% of cancers diagnosed) (column 47)
    • This column gives the percentage of cancers diagnosed cytologically or histologically without surgery, calculated as:

      Not referred for open biopsy Cancer (column 18) divided by (Not referred for open biopsy Cancer (column 18) plus Open biopsy: Cancer (column 24)) multiplied by 100 (for the appropriate age group).

      Early recall rate following assessment (% of screened) (column 48)
    • This column gives the percentage of women screened who are recommended for early recall following any assessment procedure, calculated as:

      Early recall (column 11) divided by Number screened (technically adequate) (column 3) multiplied by 100 (for the appropriate age group).

      Number of invasive cancers observed (column 49)
    • This column gives the total number of detected cancers classified as invasive, calculated as:

      Total invasive (column 35) (for the appropriate age group).

      Number of invasive cancers expected (column 50)
    • This column is derived from the Number of invasive cancers observed (column 49) and a predefined incidence rate (calculated every three years for the appropriate age group). Please note KC62 is issued as an electronic spreadsheet and the predefined incident rate is contained within the spreadsheet for use within this calculation.

      Standardised Detection Ratio (SDR) (column 51)
    • This column is derived from column 49 and column 50.

      Please note KC62 is issued as an electronic spreadsheet and the formula to calculate this ratio is contained within the spreadsheet.

      Part E5: Data Completeness Indicators
    • Part E5 gives an indication of the completeness of data recorded on information systems in a variety of key areas.

      Please note that where a column number is given within an outcome calculation, it relates to a specified column within the KC62 form for example:

      Number screened (technically adequate) (column 3) divided by Number of women invited (column 1) multiplied by 100 (for the appropriate age group).

      In this example (column 3) relates to Part 1 Invitations and Outcomes column 3.

      Age Groups of women (first column) in Part E5.
    • Data Completeness Indicators are assessed within three groups: the first being those within the previous target age range of 50-64, the second within the current target age range of 50-70 and the third, the total of those reported, regardless of age.

      Age Group (50-64) (line 40)
    • These are the outcome measures for women in the previous target age group 50-64.

      Age Group (50-70) (line 41)
    • These are the outcome measures for women in the current target age group 50-70.

      Total all ages (line 42)
    • These are the outcome measures for all women reported, regardless of age.

      Assessment result not known (% of referred) (column 52)
    • This column gives the percentage of women assessed for whom the final outcome of assessment is not recorded, calculated as:

      Outcome of assessment not known (column 9) divided by Referred for assessment (column 7) minus Failed to attend for assessment (column 8) multiplied by 100 (for the appropriate age group)

      Cytology and/or core biopsy result not known (% of referred) (column 53)
    • This column gives the percentage of women referred for one or more cytology and/or core biopsy procedures, for whom a definitive result is not recorded and an open biopsy is not indicated. The column is calculated as:

      No result recorded/inadequate result (column 15) divided by Referred for cytology and/or core biopsy (column 14) multiplied by 100 (for the appropriate age group)

      Open-biopsy result not known (% of referred) (column 54)
    • This column gives the percentage of women referred for an open biopsy for whom a definitive result is not recorded, calculated as:

      No result /inadequate result (column 21) divided by Total open biopsy (column 20) multiplied by 100 (for the appropriate age group)

      Invasive status of cancer not known (% of all cancers diagnosed) (column 55)
    • This column gives the percentage of cancers diagnosed by cytology or histology in which the invasive status is not recorded. The column is calculated as:

      Invasive status not known (column 26) divided by Total number of women with cancer (column 25) multiplied by 100 (for the appropriate age group)

      Size not known (% of invasive cancers) (column 56)
    • This column gives the percentage of cancers diagnosed by cytology or histology which are recorded as invasive, but have no size recorded. The column is calculated as:

      Size not known (column 34) divided by total number of women with invasive cancer Total invasive (column 35) multiplied by 100 (for the appropriate age group)

      Lymph node status not known (% of invasive cancers) (column 57)
    • This column gives the percentage of cancers diagnosed by cytology or histology which are recorded as invasive, but the lymph node status is unknown. The column is calculated as:

      The number of women where no LYMPH NODE STATUS has been recorded and where the BIOPSY REFERRAL OUTCOME classification is Positive; i.e. cancer detected, invasive size known or Positive; i.e. cancer detected, invasive size not known divided by total number of women with invasive cancer: Total invasive (column 35) multiplied by 100 (for the appropriate age group)

      Grade not known (% of invasive cancers) (column 58)
    • This column gives the percentage of cancers diagnosed by cytology or histology, which are recorded as invasive, but the cancer grade is not known. The column is calculated as:

      The number of women where the BIOPSY REFERRAL OUTCOME is Positive; i.e. cancer detected, invasive size not known, grade not known or Positive; i.e. cancer detected, invasive size known, grade not known divided by total number of women with invasive cancer: Total invasive (column 35) multiplied by 100 (for the appropriate age group)

      Special type not known (% of invasive cancers) (column 59)
    • This column gives the percentage of cancers diagnosed by cytology or histology which are recorded as invasive, but the special type is not known. The column is calculated as:

      The number of women where no INVASIVE CANCER SPECIAL TYPE INDICATOR has been recorded and where the BIOPSY REFERRAL OUTCOME classification is Positive; i.e. cancer detected, invasive size known or Positive; i.e. cancer detected, invasive size not known divided by Total invasive (column 35) multiplied by 100 (for the appropriate age group)

      Grade not known (% of DCIS) (column 60)
    • This column gives the percentage of cancers diagnosed by cytology or histology, which are recorded as ductal carcinoma in-situ (DCIS), but the grade is not known. The column is calculated as:

      The number of women where the BIOPSY REFERRAL OUTCOME is Positive; i.e. cancer detected, non-invasive or possibly micro-invasive, grade not known (DCIS only detected) or Positive; i.e. cancer detected, definitely micro-invasive, grade not known (DCIS only detected) divided by total number of women with Non-invasive or possibly micro-invasive (column 27) plus Definitely micro-invasive (column 28) multiplied by 100 (for the appropriate age group)

      Part E6: Status of cancer
    • Part E6 gives status and grades of cancers detected.

      Age Groups of women (first column) in Part E6.
    • The status of cancers are assessed within three groups: the first being those within the previous target age range of 50-64, the second within the current target age range of 50-70 and the third, the total of those reported, regardless of age.

      Age Group (50-64) (line 43)
    • This is the outcome measure for women in the previous target age group 50-64

      Age Group (50-70) (line 44)
    • This is the outcome measure for women in the current target age group 50-70

      Total all ages (line 45)
    • This is the outcome measure for all women reported, regardless of age.

      Women with an invasive cancer detected: number with lymph nodes sampled (column 61)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known or Positive; i.e. cancer detected, invasive size not known with a Request for Pathology Investigation where a LYMPH NODE STATUS has been recorded.

      Women with an invasive cancer detected: number positive (column 62)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known or Positive; i.e. cancer detected, invasive size not known where at least one Request for Pathology Investigation with a LYMPH NODE STATUS of lymph node positive has been recorded.

      Note where more than one Request for Pathology Investigation with a LYMPH NODE STATUS has been recorded for a woman and any one of the LYMPH NODE STATUSES is lymph node positive, then the woman should be included in column 62, but should not be included in column 63.

      Women with an invasive cancer detected: number negative (column 63)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known or Positive; i.e. cancer detected, invasive size not known with a Request for Pathology Investigation with a LYMPH NODE STATUS of lymph node negative.

      Note where more than one Request for Pathology Investigation with a LYMPH NODE STATUS has been recorded for a woman, then every LYMPH NODE STATUS should be lymph node negative for inclusion in count for column 63. If any of the LYMPH NODE STATUSES is lymph node positive, then the woman should be included in column 62 and not included in column 63.

      Women with an invasive cancer detected: number with 4 or more nodes assessed (column 64)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known or Positive; i.e. cancer detected invasive size not known with four or more Request for Pathology Investigation where a LYMPH NODE STATUS has been recorded.

      Women with an invasive cancer detected: number with 4 or more nodes sampled: number positive (column 65)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known or Positive; i.e. cancer detected, invasive size not known with four or more Request for Pathology Investigation with a LYMPH NODE STATUS, any one of which is lymph node positive.

      Women with an invasive cancer detected: number with 4 or more nodes sampled: number negative (column 66)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known or Positive; i.e. cancer detected, invasive size not known with four or more Request for Pathology Investigation with a LYMPH NODE STATUS, any one of which is lymph node negative.

      Women with an invasive cancer detected: number grade 1 (column 67)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known ,Grade I or Positive; i.e. cancer detected, invasive size not known, Grade I.

      Women with an invasive cancer detected: number grade 2 (column 68)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known ,Grade II or Positive; i.e. cancer detected, invasive size not known, Grade II.

      Women with an invasive cancer detected: number grade 3 (column 69)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known, Grade III or Positive; i.e. cancer detected, invasive size not known, Grade III.

      Women with an invasive cancer detected: number special type (column 70)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known or Positive; i.e. cancer detected, invasive size not known with a Request for Pathology Investigation with a INVASIVE CANCER SPECIAL TYPE INDICATOR of special type.

      Women with an invasive cancer detected: number not special type (column 71)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known or Positive; i.e. cancer detected, invasive size not known with a Request for Pathology Investigation with a INVASIVE CANCER SPECIAL TYPE INDICATOR of not special type.

      Women with DCIS only detected: number low or intermediate grade (column 72)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, non-invasive or possibly micro-invasive low (DCIS only detected) or Positive; i.e. cancer detected, non-invasive or possibly micro-invasive, intermediate (DCIS only detected) or Positive; i.e. cancer detected, definitely micro-invasive, low (DCIS only detected) or Positive; i.e. cancer detected, definitely microinvasive, intermediate (DCIS only detected).

      Women with DCIS only detected: number high grade (column 73)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, non-invasive or possibly micro-invasive, high (DCIS only detected) or Positive; i.e. cancer detected, definitely micro-invasive, high (DCIS only detected).

top


KC62 F1 1

Change to Central Return Form: Changed Description

Central Return Form Guidance
 

KC62: Adult Screening Programmes - Breast Screening

  1. Table F1: Self/GP referrals of women screened previously (Last screen within 5 years)

    This table reports women with a REFERRAL REQUEST for Screening Test with SCREENING REFERRAL SOURCE of Self-referral or GMP with a previous Screening Test within the last 5 years. These women have been referred directly for a Screening Test rather than as an invitation as part of a Screening Programme.

    Part F1/1: Invitations and Outcomes
  2. Table F1: Self/GP referrals of women screened previously (Last screen within 5 years)
    Part F1/1: Invitations and Outcomes


    • This is a summary of the outcomes of screening and assessment of all women invited and/or screened.

      Age at first offered appointment (first column)
    • This is derived from the BIRTH DATE of the PERSON. Line 01 includes all women who were aged 44 or less at the time of the date of their first offered appointment for screening in the period covered by the return. Lines 02 to 09 include women in specified age groups. Line 10 includes all women who were aged 75 or over. Line 11 gives the total of all women in lines 03 to 08, giving a summary of the women in the NHS Breast Screening Programme target age range of 50 to 70 - the Screening Population. Line 12 gives the total of all women in lines 01 to 10 regardless of age.

    • This is derived from the PERSON BIRTH DATE of the PERSON. Line 01 includes all women who were aged 44 or less at the time of the date of their first offered appointment for screening in the period covered by the return. Lines 02 to 09 include women in specified age groups. Line 10 includes all women who were aged 75 or over. Line 11 gives the total of all women in lines 03 to 08, giving a summary of the women in the NHS Breast Screening Programme target age range of 50 to 70 - the Screening Population. Line 12 gives the total of all women in lines 01 to 10 regardless of age.

    • Lines 13 - 24 in Part F1/2 Assessment and lines 25 - 36 in Part F1/2 Cancers diagnosed follow the pattern described above.

      Number of women invited (column 1)
    • Count of REFERRAL REQUESTS for Screening Test where the first test date offered (see ACTIVITY DATE) is in the period covered by the return.

      Lost to follow-up after technically inadequate screening mammogram (column 2)
    • Count of women whose SCREENING TEST RESULT classification was Inadequate test, and for whom no REFERRAL REQUEST for breast assessment was made.

      Number screened (technically adequate) (column 3)
    • Count of women with a Screening Test Date in the period covered by the return whose SCREENING TEST RESULT classification was not Inadequate test.

      Outcome of initial screen : Not known (column 4)
    • Count of women with a valid Screening Test Date but where no breast cancer screening test outcome (see BREAST ASSESSMENT OR TEST OUTCOME) has been recorded.

      Outcome of initial screen: Routine recall (column 5)
    • Count of women with a breast cancer screening test outcome classification of Routine recall.

      Outcome of initial screen: Early recall (column 6)
    • Count of women with a breast cancer screening test outcome classification of Early recall but without a REFERRAL REQUEST for breast assessment.

      Outcome of initial screen: Referred for assessment (column 7)
    • Count of women with a REFERRAL REQUEST for breast assessment. This covers all the women reported in columns 8 to 12.

      Final outcome of assessment: Failed to attend for assessment (column 8)
    • Count of women with a REFERRAL REQUEST for breast assessment who failed to attend for all required assessment appointments and for whom there is no breast assessment final outcome (see BREAST ASSESSMENT OR TEST OUTCOME).

      Final outcome of assessment: Outcome of assessment not known (column 9)
    • Count of women with a breast assessment date (see ACTIVITY DATE) but where no breast assessment final outcome has been recorded.

      Final outcome of assessment: Routine recall (column 10)
    • Count of women with a breast assessment date and a breast assessment final outcome classification of Routine recall.

      Final outcome of assessment: Early recall (column 11)
    • Count of women with a breast assessment date and a breast assessment final outcome classification of Early recall.

      Final outcome of assessment: Cancer (column 12)
    • Count of women with a breast assessment date and a breast assessment final outcome classification of Cancer diagnosed. The total recorded in this column will equal the total recorded in columns 13, 18 and 24.

      Part F1/2: Assessment
    • This part breaks down the outcomes of assessment by the procedures involved for all women assessed as a result of screening.

      Cancer diagnosed without cytology or histology (column 13)
    • Count of women with a breast assessment date whose breast assessment final outcome classification was Cancer diagnosed, but who had no REFERRAL REQUEST for biopsy or a REFERRAL REQUEST for biopsy where the PATHOLOGY INVESTIGATION TYPE CODE classification was not Cytology and the BIOPSY REFERRAL OUTCOME classification was Inconclusive.

      Referred for cytology and/or core biopsy (column 14)
    • Count of women with a breast cancer screening test outcome classification of Referred for assessment and a subsequent REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE CODE classification of Cytology or Core biopsy.

      Not referred for open biopsy: No result recorded/inadequate result (column 15)
    • Count of women with a breast cancer screening test outcome classification of Referred for assessment and a subsequent REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE CODE classification of Cytology or Core biopsy but without any PATHOLOGY INVESTIGATION TYPE CODE classification of Histology (open biopsy). These women did not complete any or all procedures within 6 months of the date of the screen or had no breast assessment final outcome recorded.

      Not referred for open biopsy: Routine recall (column 16)
    • Count of women with a breast cancer screening test outcome classification of Referred for assessment, a subsequent REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE CODE classification of Cytology or Core biopsy but without any PATHOLOGY INVESTIGATION TYPE CODE classification of Histology (open biopsy). These women have a breast assessment final outcome classification of Routine recall.

      Not referred for open biopsy: Early recall (column 17)
    • Count of women with a breast cancer screening test outcome classification of Referred for assessment, a subsequent REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE CODE classification of Cytology or Core biopsy but without any PATHOLOGY INVESTIGATION TYPE CODE classification of Histology (open biopsy). These women have a breast assessment final outcome classification of Early recall.

      Not referred for open biopsy: Cancer (column 18)
    • Count of women with a breast cancer screening test outcome classification of Referred for assessment, a subsequent REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE CODE classification of Cytology or Core biopsy but without any PATHOLOGY INVESTIGATION TYPE CODE classification of Histology (open biopsy). These women have a breast assessment final outcome classification of Cancer diagnosed.

      Referred for open biopsy (column 19)
    • Count of women with a referral for biopsy with a PATHOLOGY INVESTIGATION TYPE CODE classification of Cytology or Core biopsy followed by a REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE CODE classification of Histology (open biopsy).

      Total referred for open biopsy (column 20)
    • Total count of women with a REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE CODE classification of Histology (open biopsy).

      Up to and including open biopsy: No result/inadequate result (column 21)
    • Count of women with a REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE CODE classification of Histology (open biopsy). These women have a BIOPSY REFERRAL OUTCOME classification of Inconclusive or Biopsy not done or result not yet known or did not attend for the biopsy within 6 months of the date of the Screening Test having no recorded date biopsy taken (.

      Up to and including open biopsy: Result: Benign/normal: Routine recall (column 22)
    • Count of women with a REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE CODE classification of Histology (open biopsy). The BIOPSY REFERRAL OUTCOME classification is Benign or negative. The breast assessment final outcome classification for these women is Routine recall.

      Up to and including open biopsy: Result: Benign/normal: Early recall (column 23)
    • Count of women with a REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE CODE classification of Histology (open biopsy). The BIOPSY REFERRAL OUTCOME classification is Benign or negative. The breast assessment final outcome classification for these women is Early recall.

      Up to and including open biopsy: Cancer (column 24)
    • Count of women with a REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE CODE classification of Histology (open biopsy). The BIOPSY REFERRAL OUTCOME classification is Positive; i.e. cancer diagnosed. The breast assessment final outcome classification for these women is Cancer diagnosed.

top


KC62 F1 2

Change to Central Return Form: Changed Description

Central Return Form Guidance
 

KC62: Adult Screening Programmes - Breast Screening

  1. Table F1: Self/GP referrals of women screened previously (Last screen within 5 years)
    • Table F1: Self/GP referrals of women screened previously (Last screen within 5 years)
      Part F1/3: Cancers Diagnosed
    • This part of the return describes the cancers formally diagnosed in women assessed as a result of screening. Only breast cancers should be reported, as defined in the Information and Training Manual for England and Wales.

      Age at first offered appointment (first column)
    • This is derived from the BIRTH DATE of the PERSON and the first test offered (see ACTIVITY DATE) following a REFERRAL REQUEST for Screening Test.

      Total number of women with cancer (column 25)
    • This is derived from the PERSON BIRTH DATE of the PERSON and the first test offered (see ACTIVITY DATE) following a REFERRAL REQUEST for Screening Test.

      Total number of women with cancer (column 25)
    • Count of all women in columns 18 and 24 of Part 2 Assessment i.e. those women with a proven diagnosis of breast cancer.

      Invasive status not known (column 26)
    • Count of women included in Part 3 with a BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected invasive status not known.

      Non-invasive or possibly micro-invasive (column 27)
    • Count of women included in Part 3 with a BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected non-invasive or possibly micro-invasive.

      Definitely micro-invasive (column 28)
    • Count of women included in Part 3 with a BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected definitely micro-invasive.

      Invasive size (columns 29 - 33)
    • These columns count all cancers classified as invasive, separated according to the pathological size of the cancer (INVASIVE LESION SIZE). The BIOPSY REFERRAL OUTCOME classification is Positive; i.e. cancer detected invasive size known.

      Invasive size (of cancer)<10mm (column 29)
      Invasive size (of cancer)>=10mm & <15mm (column 30)
      Invasive size (of cancer)>=15mm & <20mm (column 31)
      Invasive size (of cancer)>=20mm & <50mm (column 32)
      Invasive size (of cancer)>=50mm (column 33)
      Invasive size: Size not known (column 34)
    • This column counts invasive cancers where the BIOPSY REFERRAL OUTCOME classification is Positive; i.e. cancer detected invasive size not known.

      Total invasive (column 35)
    • This column counts the total number of cancers classified as invasive, that is with a BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected invasive size known or Positive; i.e. cancer detected invasive size not known

top


KC62 F1 3

Change to Central Return Form: Changed Description

Central Return Form Guidance
 

KC62: Adult Screening Programmes - Breast Screening

  1. Table F1: Self/GP referrals of women screened previously (Last screen within 5 years)
    • Table F1: Self/GP referrals of women screened previously (Last screen within 5 years)
      Part F1/4: Outcome measures
    • Part 4 presents a selection of outcome measures related to NHS Breast Screening Programme (NHSBSP) quality targets.

      Please note that where a column number is given within an outcome calculation, it relates to a specified column within the KC62 form for example:

      Number screened (technically adequate) (column 3) divided by Number of women invited (column 1) multiplied by 100 (for the appropriate age group).


      In this example (column 3) relates to Part 1 Invitations and Outcomes column 3.

      Age Groups of women (first column)
    • Outcome measures are assessed within three groups: the first being those within the previous target age range of 50-64, the second within the current target age range of 50-70 and the third, the total of those reported, regardless of age.

      Age Group (50-64) (line 37)
    • These are the outcome measures for women in the age group 50-64

      Age Group (50-70) (line 38)
    • These are the outcome measures for women in the age group 50-70

      Total all ages (line 39)
    • These are the outcome measures for women of all ages.

      Uptake rate (% of invited) (column 36)
    • This column gives the uptake rate (also known as the acceptance rate) for screening. It is defined as the percentage of women who receive a technically adequate and complete screen as a result of an invitation for routine screening, and is calculated as:

      Number screened (technically adequate) (column 3) divided by Number of women invited (column 1) multiplied by 100 (for the appropriate age group).

      Referral rate (% of screened) (column 37)
    • This column gives the rate of referrals to assessment from screening. It is defined as the percentage of women screened who are referred for any assessment procedure and is calculated as:

      Outcome of initial screen: Referred for assessment (column 7) divided by Number screened (technically adequate) (column 3) multiplied by 100 (for the appropriate age group).

      Non-invasive or micro-invasive cancers (per 1,000 screened) (column 38)
    • This column gives the cancers detected which are non-invasive, possibly micro-invasive, or definitely micro-invasive, per 1,000 screened calculated as:

      Non-invasive or possibly micro-invasive (column 27) plus Definitely micro-invasive (column 28) divided by Number screened (technically adequate) (column 3) multiplied by 1000 (for the appropriate age group).

      Benign biopsy rate (per 1,000 screened) (column 39)
    • This column gives the women screened who have an open biopsy with a result of benign or normal per 1,000 screened, calculated as:

      Up to and including open biopsy: Result: benign/normal (columns 22 + 23) divided by Number screened (technically adequate) (column 3) multiplied by 1000 (for the appropriate age group).

      Benign Therapeutic operation: Number (column 40)
    • This column gives the number of women screened who had a REFERRAL REQUEST for breast treatment and who had a BENIGN THERAPEUTIC OPERATION by the appropriate age group.

      Benign Therapeutic operation: Rate (per 1,000 screened) (column 41)
    • This column gives the women screened who have a BENIGN THERAPEUTIC OPERATION per 1,000 screened, calculated as:

      Number of BENIGN THERAPEUTIC OPERATIONS for the period (column 40) divided by Number screened (technically adequate) (column 3) multiplied by 1000 (for the appropriate age group).

      Invasive cancer detection rate (per 1,000 screened) (column 42)
    • This column gives the rate of invasive cancers detected per 1,000 women screened, calculated as:

      Total invasive (column 35) divided by Number screened (technically adequate) (column 3) multiplied by 1000 (for the appropriate age group).

      Detection rate of invasive cancers <10 mm (per 1,000 screened) (column 43)
    • This column gives the rate of invasive cancers smaller than 10mm detected per 1,000 women screened, calculated as:

      Invasive size < 10mm (column 29) divided by Number screened (technically adequate) (column 3) multiplied by 1000 (for the appropriate age group).

      Detection rate of invasive cancers <15 mm (per 1,000 screened) (column 44)
    • This column gives the rate of invasive cancers smaller than 15mm detected per 1,000 women screened, calculated as:

      Invasive size < 15mm (columns 29 + 30) divided by Number screened (technically adequate) (column 3) multiplied by 1000 (for the appropriate age group).

      Referral rate for cytology and/or core biopsy (% of screened) (column 45)
    • This column gives the percentage of women screened who are referred for fine needle aspiration cytology and/or core biopsy as part of the assessment process, calculated as:

      Referred for cytology and/or core biopsy (column 14) divided by Number screened (technically adequate) (column 3) multiplied by 100 (for the appropriate age group).

      Referral rate for open biopsy (% of screened) (column 46)
    • This column gives the percentage of women screened who are referred for an open biopsy, either directly from screening or following other assessment procedures, calculated as:

      Total open biopsy (column 20) divided by Number screened (technically adequate) (column 3) multiplied by 100 (for the appropriate age group).

      Pre-operative diagnosis rate (% of cancers diagnosed) (column 47)
    • This column gives the percentage of cancers diagnosed cytologically or histologically without surgery, calculated as:

      Not referred for open biopsy Cancer (column 18) divided by (Not referred for open biopsy Cancer (column 18) plus Open biopsy: Cancer (column 24)) multiplied by 100 (for the appropriate age group).

      Early recall rate following assessment (% of screened) (column 48)
    • This column gives the percentage of women screened who are recommended for early recall following any assessment procedure, calculated as:

      Early recall (column 11) divided by Number screened (technically adequate) (column 3) multiplied by 100 (for the appropriate age group).

      Number of invasive cancers observed (column 49)
    • This column gives the total number of detected cancers classified as invasive, calculated as:

      Total invasive (column 35) (for the appropriate age group).

      Number of invasive cancers expected (column 50)
    • This column is derived from the Number of invasive cancers observed (column 49) and a predefined incidence rate (calculated every three years for the appropriate age group).

      Please note KC62 is issued as an electronic spreadsheet and the predefined incident rate is contained within the spreadsheet for use within this calculation.

      Standardised Detection Ratio (SDR) (column 51)
    • This column is derived from column 49 and column 50.

      Please note KC62 is issued as an electronic spreadsheet and the formula to calculate this ratio is contained within the spreadsheet.

      Part F1/5: Data Completeness Indicators
    • Part F1/5 gives an indication of the completeness of data recorded on information systems in a variety of key areas.

      Please note that where a column number is given within an outcome calculation, it relates to a specified column within the KC62 form for example:

      Number screened (technically adequate) (column 3) divided by Number of women invited (column 1) multiplied by 100 (for the appropriate age group).

      In this example (column 3) relates to Part 1 Invitations and Outcomes column 3.

      Age Groups of women (first column) in Part F1/5.
    • Data Completeness Indicators are assessed within three groups: the first being those within the previous target age range of 50-64, the second within the current target age range of 50-70 and the third, the total of those reported, regardless of age.

      Age Group (50-64) (line 40)
    • These are the outcome measures for women in the previous target age group 50-64.

      Age Group (50-70) (line 41)
    • These are the outcome measures for women in the current target age group 50-70.

      Total all ages (line 42)
    • These are the outcome measures for all women reported, regardless of age.

      Assessment result not known (% of referred) (column 52)
    • This column gives the percentage of women assessed for whom the final outcome of assessment is not recorded, calculated as:

      Outcome of assessment not known (column 9) divided by Referred for assessment (column 7) minus Failed to attend for assessment (column 8) multiplied by 100 (for the appropriate age group)

      Cytology and/or core biopsy result not known (% of referred) (column 53)
    • This column gives the percentage of women referred for one or more cytology and/or core biopsy procedures, for whom a definitive result is not recorded and an open biopsy is not indicated. The column is calculated as:

      No result recorded/inadequate result (column 15) divided by Referred for cytology and/or core biopsy (column 14) multiplied by 100 (for the appropriate age group)

      Open-biopsy result not known (% of referred) (column 54)
    • This column gives the percentage of women referred for an open biopsy for whom a definitive result is not recorded, calculated as:

      No result /inadequate result (column 21) divided by Total open biopsy (column 20) multiplied by 100 (for the appropriate age group)

      Invasive status of cancer not known (% of all cancers diagnosed) (column 55)
    • This column gives the percentage of cancers diagnosed by cytology or histology in which the invasive status is not recorded. The column is calculated as:

      Invasive status not known (column 26) divided by Total number of women with cancer (column 25) multiplied by 100 (for the appropriate age group)

      Size not known (% of invasive cancers) (column 56)
    • This column gives the percentage of cancers diagnosed by cytology or histology which are recorded as invasive, but have no size recorded. The column is calculated as:

      Size not known (column 34) divided by total number of women with invasive cancer Total invasive (column 35) multiplied by 100 (for the appropriate age group)

      Lymph node status not known (% of invasive cancers) (column 57)
    • This column gives the percentage of cancers diagnosed by cytology or histology which are recorded as invasive, but the lymph node status is unknown. The column is calculated as:

      The number of women where no LYMPH NODE STATUS has been recorded and where the BIOPSY REFERRAL OUTCOME classification is Positive; i.e. cancer detected, invasive size known or Positive; i.e. cancer detected, invasive size not known divided by total number of women with invasive cancer: Total invasive (column 35) multiplied by 100 (for the appropriate age group)

      Grade not known (% of invasive cancers) (column 58)
    • This column gives the percentage of cancers diagnosed by cytology or histology, which are recorded as invasive, but the cancer grade is not known. The column is calculated as:

      The number of women where the BIOPSY REFERRAL OUTCOME is Positive; i.e. cancer detected, invasive size not known, grade not known or Positive; i.e. cancer detected, invasive size known, grade not known divided by total number of women with invasive cancer: Total invasive (column 35) multiplied by 100 (for the appropriate age group)

      Special type not known (% of invasive cancers) (column 59)
    • This column gives the percentage of cancers diagnosed by cytology or histology which are recorded as invasive, but the special type is not known. The column is calculated as:

      The number of women where no INVASIVE CANCER SPECIAL TYPE INDICATOR has been recorded and where the BIOPSY REFERRAL OUTCOME classification is Positive; i.e. cancer detected, invasive size known or Positive; i.e. cancer detected, invasive size not known divided by Total invasive (column 35) multiplied by 100 (for the appropriate age group)

      Grade not known (% of DCIS) (column 60)
    • This column gives the percentage of cancers diagnosed by cytology or histology, which are recorded as ductal carcinoma in-situ (DCIS), but the grade is not known. The column is calculated as:

      The number of women where the BIOPSY REFERRAL OUTCOME is Positive; i.e. cancer detected, non-invasive or possibly micro-invasive, grade not known (DCIS only detected) or Positive; i.e. cancer detected, definitely micro-invasive, grade not known (DCIS only detected) divided by total number of women with Non-invasive or possibly micro-invasive (column 27) plus Definitely micro-invasive (column 28) multiplied by 100 (for the appropriate age group)

      Part F1/6: Status of cancer
    • Part F1/6 gives status and grades of cancers detected.

      Age Groups of women (first column) in Part F1/6.
    • The status of cancers are assessed within three groups: the first being those within the previous target age range of 50-64, the second within the current target age range of 50-70 and the third, the total of those reported, regardless of age.

      Age Group (50-64) (line 43)
    • This is the outcome measure for women in the previous target age group 50-64

      Age Group (50-70) (line 44)
    • This is the outcome measure for women in the current target age group 50-70

      Total all ages (line 45)
    • This is the outcome measure for all women reported, regardless of age.

      Women with an invasive cancer detected: number with lymph nodes sampled (column 61)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known or Positive; i.e. cancer detected, invasive size not known with a Request for Pathology Investigation where a LYMPH NODE STATUS has been recorded.

      Women with an invasive cancer detected: number positive (column 62)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known or Positive; i.e. cancer detected, invasive size not known where at least one Request for Pathology Investigation with a LYMPH NODE STATUS of lymph node positive has been recorded.

      Note where more than one Request for Pathology Investigation with a LYMPH NODE STATUS has been recorded for a woman and any one of the LYMPH NODE STATUSES is lymph node positive, then the woman should be included in column 62, but should not be included in column 63.

      Women with an invasive cancer detected: number negative (column 63)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known or Positive; i.e. cancer detected, invasive size not known with a Request for Pathology Investigation with a LYMPH NODE STATUS of lymph node negative.

      Note where more than one Request for Pathology Investigation with a LYMPH NODE STATUS has been recorded for a woman, then every LYMPH NODE STATUS should be lymph node negative for inclusion in count for column 63. If any of the LYMPH NODE STATUSES is lymph node positive, then the woman should be included in column 62 and not included in column 63.

      Women with an invasive cancer detected: number with 4 or more nodes assessed (column 64)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known or Positive; i.e. cancer detected invasive size not known with four or more Request for Pathology Investigation where a LYMPH NODE STATUS has been recorded.

      Women with an invasive cancer detected: number with 4 or more nodes sampled: number positive (column 65)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known or Positive; i.e. cancer detected, invasive size not known with four or more Request for Pathology Investigation with a LYMPH NODE STATUS, any one of which is lymph node positive.

      Women with an invasive cancer detected: number with 4 or more nodes sampled: number negative (column 66)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known or Positive; i.e. cancer detected, invasive size not known with four or more Request for Pathology Investigation with a LYMPH NODE STATUS, any one of which is lymph node negative.

      Women with an invasive cancer detected: number grade 1 (column 67)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known ,Grade I or Positive; i.e. cancer detected, invasive size not known, Grade I.

      Women with an invasive cancer detected: number grade 2 (column 68)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known ,Grade II or Positive; i.e. cancer detected, invasive size not known, Grade II.

      Women with an invasive cancer detected: number grade 3 (column 69)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known, Grade III or Positive; i.e. cancer detected, invasive size not known, Grade III.

      Women with an invasive cancer detected: number special type (column 70)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known or Positive; i.e. cancer detected, invasive size not known with a Request for Pathology Investigation with a INVASIVE CANCER SPECIAL TYPE INDICATOR of special type.

      Women with an invasive cancer detected: number not special type (column 71)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known or Positive; i.e. cancer detected, invasive size not known with a Request for Pathology Investigation with a INVASIVE CANCER SPECIAL TYPE INDICATOR of not special type.

      Women with DCIS only detected: number low or intermediate grade (column 72)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, non-invasive or possibly micro-invasive low (DCIS only detected) or Positive; i.e. cancer detected, non-invasive or possibly micro-invasive, intermediate (DCIS only detected) or Positive; i.e. cancer detected, definitely micro-invasive, low (DCIS only detected) or Positive; i.e. cancer detected, definitely microinvasive, intermediate (DCIS only detected).

      Women with DCIS only detected: number high grade (column 73)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, non-invasive or possibly micro-invasive, high (DCIS only detected) or Positive; i.e. cancer detected, definitely micro-invasive, high (DCIS only detected).

top


KC62 F2 1

Change to Central Return Form: Changed Description

Central Return Form Guidance
 

KC62: Adult Screening Programmes - Breast Screening

  1. Table F2: Self/GP referrals of women screened previously (Last screen more than 5 years)

    This table reports women with a REFERRAL REQUEST for Screening Test with SCREENING REFERRAL SOURCE of Self-referral or GMP with a previous Screening Test more than 5 years previously. These women have been referred directly for a Screening Test rather than as an invitation as part of a Screening Programme.

    Part F2/1: Invitations and Outcomes
  2. Table F2: Self/GP referrals of women screened previously (Last screen more than 5 years)
    Part F2/1: Invitations and Outcomes
    • This is a summary of the outcomes of screening and assessment of all women invited and/or screened.

      Age at first offered appointment (first column)
    • This is derived from the BIRTH DATE of the PERSON. Line 01 includes all women who were aged 44 or less at the time of the date of their first offered appointment for screening in the period covered by the return. Lines 02 to 09 include women in specified age groups. Line 10 includes all women who were aged 75 or over. Line 11 gives the total of all women in lines 03 to 08, giving a summary of the women in the NHS Breast Screening Programme target age range of 50 to 70 - the Screening Population. Line 12 gives the total of all women in lines 01 to 10 regardless of age.

    • This is derived from the PERSON BIRTH DATE of the PERSON. Line 01 includes all women who were aged 44 or less at the time of the date of their first offered appointment for screening in the period covered by the return. Lines 02 to 09 include women in specified age groups. Line 10 includes all women who were aged 75 or over. Line 11 gives the total of all women in lines 03 to 08, giving a summary of the women in the NHS Breast Screening Programme target age range of 50 to 70 - the Screening Population. Line 12 gives the total of all women in lines 01 to 10 regardless of age.

    • Lines 13 - 24 in Part F2/2 Assessment and lines 25 - 36 in Part F2/2 Cancers diagnosed follow the pattern described above.

      Number of women invited (column 1)
    • Count of REFERRAL REQUESTS for Screening Test where the first offered date (see ACTIVITY DATE) is in the period covered by the return.

      Lost to follow-up after technically inadequate screening mammogram (column 2)
    • Count of women whose SCREENING TEST RESULT classification was Inadequate test, and for whom no REFERRAL REQUEST for breast assessment was made.

      Number screened (technically adequate) (column 3)
    • Count of women with a Screening Test Date in the period covered by the return whose SCREENING TEST RESULT classification was not Inadequate test.

      Outcome of initial screen : Not known (column 4)
    • Count of women with a valid Screening Test Date but where no breast cancer screening test outcome (see BREAST ASSESSMENT OR TEST OUTCOME) has been recorded.

      Outcome of initial screen: Routine recall (column 5)
    • Count of women with a breast cancer screening test outcome classification of Routine recall.

      Outcome of initial screen: Early recall (column 6)
    • Count of women with a breast cancer screening test outcome classification of Early recall but without a REFERRAL REQUEST for breast assessment.

      Outcome of initial screen: Referred for assessment (column 7)
    • Count of women with a REFERRAL REQUEST for breast assessment. This covers all the women reported in columns 8 to 12.

      Final outcome of assessment: Failed to attend for assessment (column 8)
    • Count of women with a REFERRAL REQUEST for breast assessment who failed to attend for all required assessment appointments and for whom there is no breast assessment final outcome (see BREAST ASSESSMENT OR TEST OUTCOME).

      Final outcome of assessment: Outcome of assessment not known (column 9)
    • Count of women with a breast cancer screening test outcome but where no breast assessment final outcome has been recorded.

      Final outcome of assessment: Routine recall (column 10)
    • Count of women with a breast assessment date (see ACTIVITY DATE) and a breast assessment final outcome classification of Routine recall.

      Final outcome of assessment: Early recall (column 11)
    • Count of women with a breast assessment date and a breast assessment final outcome classification of Early recall.

      Final outcome of assessment: Cancer (column 12)
    • Count of women with a breast assessment date and a breast assessment final outcome classification of Cancer diagnosed. The total recorded in this column will equal the total recorded in columns 13, 18 and 24.

      Part F2/2: Assessment
    • This part breaks down the outcomes of assessment by the procedures involved for all women assessed as a result of screening.

      Cancer diagnosed without cytology or histology (column 13)
    • Count of women with a breast assessment date whose breast assessment final outcome classification was Cancer diagnosed, but who had no REFERRAL REQUEST for biopsy or a REFERRAL REQUEST for biopsy where the PATHOLOGY INVESTIGATION TYPE CODE classification was not Cytology and the BIOPSY REFERRAL OUTCOME classification was Inconclusive.

      Referred for cytology and/or core biopsy (column 14)
    • Count of women with a breast cancer screening test outcome classification of Referred for assessment and a subsequent REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE CODE classification of Cytology or Core biopsy.

      Not referred for open biopsy: No result recorded/inadequate result (column 15)
    • Count of women with a breast cancer screening test outcome classification of Referred for assessment and a subsequent REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE CODE classification of Cytology or Core biopsy but without any PATHOLOGY INVESTIGATION TYPE CODE classification of Histology (open biopsy). These women did not complete any or all procedures within 6 months of the DATE of the screen or had no result recorded.

      Not referred for open biopsy: Routine recall (column 16)
    • Count of women with a breast cancer screening test outcome classification of Referred for assessment, a subsequent REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE CODE classification of Cytology or Core biopsy but without any PATHOLOGY INVESTIGATION TYPE CODE classification of Histology (open biopsy). These women have a breast assessment final outcome classification of Routine recall.

      Not referred for open biopsy: Early recall (column 17)
    • Count of women with a breast cancer screening test outcome classification of Referred for assessment, a subsequent REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE CODE classification of Cytology or Core biopsy but without any PATHOLOGY INVESTIGATION TYPE CODE classification of Histology (open biopsy). These women have a breast assessment final outcome classification of Early recall.

      Not referred for open biopsy: Cancer (column 18)
    • Count of women with a breast cancer screening test outcome classification of Referred for assessment, a subsequent REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE CODE classification of Cytology or Core biopsy but without any PATHOLOGY INVESTIGATION TYPE CODE classification of Histology (open biopsy). These women have a breast assessment final outcome classification of Cancer diagnosed.

      Referred for open biopsy (column 19)
    • Count of women with a REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE CODE classification of Cytology or Core biopsy followed by a REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE CODE classification of Histology (open biopsy).

      Total referred for open biopsy (column 20)
    • Total count of women with a REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE classification of Histology (open biopsy).

      Up to and including open biopsy: No result/inadequate result (column 21)
    • Count of women with a REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE classification of Histology (open biopsy). These women have a BIOPSY REFERRAL OUTCOME classification of Inconclusive or Biopsy not done or result not yet known or did not attend for the biopsy within 6 months of the date of the Screening Test having no recorded date biopsy taken (see ACTIVITY DATE).

      Up to and including open biopsy: Result: Benign/normal: Routine recall (column 22)
    • Count of women with a REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE classification of Histology (open biopsy). The BIOPSY REFERRAL OUTCOME classification is Benign or negative. The breast assessment final outcome classification for these women is Routine recall.

      Up to and including open biopsy: Result: Benign/normal: Early recall (column 23)
    • Count of women with a REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE classification of Histology (open biopsy). The BIOPSY REFERRAL OUTCOME classification is Benign or negative. The breast assessment final outcome classification for these women is Early recall.

      Up to and including open biopsy: Cancer (column 24)
    • Count of women with a REFERRAL REQUEST for biopsy with a PATHOLOGY INVESTIGATION TYPE classification of Histology (open biopsy). The BIOPSY REFERRAL OUTCOME classification is Positive; i.e. cancer diagnosed. The breast assessment final outcome classification for these women is Cancer diagnosed.

top


KC62 F2 2

Change to Central Return Form: Changed Description

Central Return Form Guidance
 

KC62: Adult Screening Programmes - Breast Screening

  1. Table F2: Self/GP referrals of women screened previously (Last screen more than 5 years)
    • Table F2: Self/GP referrals of women screened previously (Last screen more than 5 years)
      Part F2/3: Cancers Diagnosed
    • This part of the return describes the cancers formally diagnosed in women assessed as a result of screening. Only breast cancers should be reported, as defined in the Information and Training Manual for England and Wales.

      Age at first offered appointment (first column)
    • This is derived from the BIRTH DATE of the PERSON and the first test date offered (see ACTIVITY DATE) following a REFERRAL REQUEST for Screening Test.

      Total number of women with cancer (column 25)
    • This is derived from the PERSON BIRTH DATE of the PERSON and the first test date offered (see ACTIVITY DATE) following a REFERRAL REQUEST for Screening Test.

      Total number of women with cancer (column 25)
    • Count of all women in columns 18 and 24 of Part 2 Assessment i.e. those women with a proven diagnosis of breast cancer.

      Invasive status not known (column 26)
    • Count of women included in Part 3 with a BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer diagnosed invasive status not known.

      Non-invasive or possibly micro-invasive (column 27)
    • Count of women included in Part 3 with a BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer diagnosed non-invasive or possibly micro-invasive.

      Definitely micro-invasive (column 28)
    • Count of women included in Part 3 with a BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer diagnosed definitely micro-invasive.

      Invasive size (columns 29 - 33)
    • These columns count all cancers classified as invasive, separated according to the pathological size of the cancer (INVASIVE LESION SIZE). The BIOPSY REFERRAL OUTCOME classification is Positive; i.e. cancer diagnosed invasive size known.

      Invasive size (of cancer)<10mm (column 29)
      Invasive size (of cancer)>=10mm & <15mm (column 30)
      Invasive size (of cancer)>=15mm & <20mm (column 31)
      Invasive size (of cancer)>=20mm & <50mm (column 32)
      Invasive size (of cancer)>=50mm (column 33)
      Invasive size: Size not known (column 34)
    • These columns count all cancers classified as invasive, separated according to the pathological size of the cancer (INVASIVE LESION SIZE). The BIOPSY REFERRAL OUTCOME classification is Positive; i.e. cancer diagnosed invasive size known.

      Invasive size (of cancer)<10mm (column 29)
      Invasive size (of cancer)>=10mm & <15mm (column 30)
      Invasive size (of cancer)>=15mm & <20mm (column 31)
      Invasive size (of cancer)>=20mm & <50mm (column 32)
      Invasive size (of cancer)>=50mm (column 33)

      Invasive size: Size not known (column 34)
    • This column counts invasive cancers where the BIOPSY REFERRAL OUTCOME classification is Positive; i.e. cancer diagnosed invasive size not known.

      Total invasive (column 35)
    • This column counts the total number of cancers classified as invasive, that is with a BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected invasive size known or Positive; i.e. cancer detected invasive size not known.

top


KC62 F2 3

Change to Central Return Form: Changed Description

Central Return Form Guidance
 

KC62: Adult Screening Programmes - Breast Screening

  1. Table F2: Self/GP referrals of women not screened previously
    • Table F2: Self/GP referrals of women not screened previously
      Part F2/4: Outcome measures
    • Part 4 presents a selection of outcome measures related to NHS Breast Screening Programme (NHSBSP) quality targets.

      Please note that where a column number is given within an outcome calculation, it relates to a specified column within the KC62 form for example:

      Number screened (technically adequate) (column 3) divided by Number of women invited (column 1) multiplied by 100 (for the appropriate age group).


      In this example (column 3) relates to Part 1 Invitations and Outcomes column 3.

      Age Groups of women (first column)
    • Outcome measures are assessed within three groups: the first being those within the previous target age range of 50-64, the second within the current target age range of 50-70 and the third, the total of those reported, regardless of age.

      Age Group (50-64) (line 37)
    • These are the outcome measures for women in the age group 50-64

      Age Group (50-70) (line 38)
    • These are the outcome measures for women in the age group 50-70

      Total all ages (line 39)
    • These are the outcome measures for women of all ages.

      Uptake rate (% of invited) (column 36)
    • This column gives the uptake rate (also known as the acceptance rate) for screening. It is defined as the percentage of women who receive a technically adequate and complete screen as a result of an invitation for routine screening, and is calculated as:

      Number screened (technically adequate) (column 3) divided by Number of women invited (column 1) multiplied by 100 (for the appropriate age group).

      Referral rate (% of screened) (column 37)
    • This column gives the rate of referrals to assessment from screening. It is defined as the percentage of women screened who are referred for any assessment procedure and is calculated as:

      Outcome of initial screen: Referred for assessment (column 7) divided by Number screened (technically adequate) (column 3) multiplied by 100 (for the appropriate age group).

      Non-invasive or micro-invasive cancers (per 1,000 screened) (column 38)
    • This column gives the cancers detected which are non-invasive, possibly micro-invasive, or definitely micro-invasive, per 1,000 screened calculated as:

      Non-invasive or possibly micro-invasive (column 27) plus Definitely micro-invasive (column 28) divided by Number screened (technically adequate) (column 3) multiplied by 1000 (for the appropriate age group).

      Benign biopsy rate (per 1,000 screened) (column 39)
    • This column gives the women screened who have an open biopsy with a result of benign or normal per 1,000 screened, calculated as:

      Up to and including open biopsy: Result: benign/normal (columns 22 + 23) divided by Number screened (technically adequate) (column 3) multiplied by 1000 (for the appropriate age group).

      Benign Therapeutic operation: Number (column 40)
    • This column gives the number of women screened who had a REFERRAL REQUEST for breast treatment and who had a BENIGN THERAPEUTIC OPERATION by the appropriate age group.

      Benign Therapeutic operation: Rate (per 1,000 screened) (column 41)
    • This column gives the women screened who have a BENIGN THERAPEUTIC OPERATION per 1,000 screened, calculated as:

      Number of BENIGN THERAPEUTIC OPERATIONS for the period (column 40) divided by Number screened (technically adequate) (column 3) multiplied by 1000 (for the appropriate age group).

      Invasive cancer detection rate (per 1,000 screened) (column 42)
    • This column gives the rate of invasive cancers detected per 1,000 women screened, calculated as:

      Total invasive (column 35) divided by Number screened (technically adequate) (column 3) multiplied by 1000 (for the appropriate age group).

      Detection rate of invasive cancers <10 mm (per 1,000 screened) (column 43)
    • This column gives the rate of invasive cancers smaller than 10mm detected per 1,000 women screened, calculated as:

      Invasive size < 10mm (column 29) divided by Number screened (technically adequate) (column 3) multiplied by 1000 (for the appropriate age group).

      Detection rate of invasive cancers <15 mm (per 1,000 screened) (column 44)
    • This column gives the rate of invasive cancers smaller than 15mm detected per 1,000 women screened, calculated as:

      Invasive size < 15mm (columns 29 + 30) divided by Number screened (technically adequate) (column 3) multiplied by 1000 (for the appropriate age group).

      Referral rate for cytology and/or core biopsy (% of screened) (column 45)
    • This column gives the percentage of women screened who are referred for fine needle aspiration cytology and/or core biopsy as part of the assessment process, calculated as:

      Referred for cytology and/or core biopsy (column 14) divided by Number screened (technically adequate) (column 3) multiplied by 100 (for the appropriate age group).

      Referral rate for open biopsy (% of screened) (column 46)
    • This column gives the percentage of women screened who are referred for an open biopsy, either directly from screening or following other assessment procedures, calculated as:

      Total open biopsy (column 20) divided by Number screened (technically adequate) (column 3) multiplied by 100 (for the appropriate age group).

      Pre-operative diagnosis rate (% of cancers diagnosed) (column 47)
    • This column gives the percentage of cancers diagnosed cytologically or histologically without surgery, calculated as:

      Not referred for open biopsy Cancer (column 18) divided by (Not referred for open biopsy Cancer (column 18) plus Open biopsy: Cancer (column 24)) multiplied by 100 (for the appropriate age group).

      Early recall rate following assessment (% of screened) (column 48)
    • This column gives the percentage of women screened who are recommended for early recall following any assessment procedure, calculated as:

      Early recall (column 11) divided by Number screened (technically adequate) (column 3) multiplied by 100 (for the appropriate age group).

      Number of invasive cancers observed (column 49)
    • This column gives the total number of detected cancers classified as invasive, calculated as:

      Total invasive (column 35) (for the appropriate age group).

      Number of invasive cancers expected (column 50)
    • This column is derived from the Number of invasive cancers observed (column 49) and a predefined incidence rate (calculated every three years for the appropriate age group).

      Please note KC62 is issued as an electronic spreadsheet and the predefined incident rate is contained within the spreadsheet for use within this calculation.

      Standardised Detection Ratio (SDR) (column 51)
    • This column is derived from column 49 and column 50.

      Please note KC62 is issued as an electronic spreadsheet and the formula to calculate this ratio is contained within the spreadsheet.

      Part F2/5: Data Completeness Indicators
    • Part F2/5 gives an indication of the completeness of data recorded on information systems in a variety of key areas.

      Please note that where a column number is given within an outcome calculation, it relates to a specified column within the KC62 form for example:

      Number screened (technically adequate) (column 3) divided by Number of women invited (column 1) multiplied by 100 (for the appropriate age group).

      In this example (column 3) relates to Part 1 Invitations and Outcomes column 3.

      Age Groups of women (first column) in Part F2/5.
    • Data Completeness Indicators are assessed within three groups: the first being those within the previous target age range of 50-64, the second within the current target age range of 50-70 and the third, the total of those reported, regardless of age.

      Age Group (50-64) (line 40)
    • These are the outcome measures for women in the previous target age group 50-64.

      Age Group (50-70) (line 41)
    • These are the outcome measures for women in the current target age group 50-70.

      Total all ages (line 42)
    • These are the outcome measures for all women reported, regardless of age.

      Assessment result not known (% of referred) (column 52)
    • This column gives the percentage of women assessed for whom the final outcome of assessment is not recorded, calculated as:

      Outcome of assessment not known (column 9) divided by Referred for assessment (column 7) minus Failed to attend for assessment (column 8) multiplied by 100 (for the appropriate age group)

      Cytology and/or core biopsy result not known (% of referred) (column 53)
    • This column gives the percentage of women referred for one or more cytology and/or core biopsy procedures, for whom a definitive result is not recorded and an open biopsy is not indicated. The column is calculated as:

      No result recorded/inadequate result (column 15) divided by Referred for cytology and/or core biopsy (column 14) multiplied by 100 (for the appropriate age group)

      Open-biopsy result not known (% of referred) (column 54)
    • This column gives the percentage of women referred for an open biopsy for whom a definitive result is not recorded, calculated as:

      No result /inadequate result (column 21) divided by Total open biopsy (column 20) multiplied by 100 (for the appropriate age group)

      Invasive status of cancer not known (% of all cancers diagnosed) (column 55)
    • This column gives the percentage of cancers diagnosed by cytology or histology in which the invasive status is not recorded. The column is calculated as:

      Invasive status not known (column 26) divided by Total number of women with cancer (column 25) multiplied by 100 (for the appropriate age group)

      Size not known (% of invasive cancers) (column 56)
    • This column gives the percentage of cancers diagnosed by cytology or histology which are recorded as invasive, but have no size recorded. The column is calculated as:

      Size not known (column 34) divided by total number of women with invasive cancer Total invasive (column 35) multiplied by 100 (for the appropriate age group)

      Lymph node status not known (% of invasive cancers) (column 57)
    • This column gives the percentage of cancers diagnosed by cytology or histology which are recorded as invasive, but the lymph node status is unknown. The column is calculated as:

      The number of women where no LYMPH NODE STATUS has been recorded and where the BIOPSY REFERRAL OUTCOME classification is Positive; i.e. cancer detected, invasive size known or Positive; i.e. cancer detected, invasive size not known divided by total number of women with invasive cancer: Total invasive (column 35) multiplied by 100 (for the appropriate age group)

      Grade not known (% of invasive cancers) (column 58)
    • This column gives the percentage of cancers diagnosed by cytology or histology, which are recorded as invasive, but the cancer grade is not known. The column is calculated as:

      The number of women where the BIOPSY REFERRAL OUTCOME is Positive; i.e. cancer detected, invasive size not known, grade not known or Positive; i.e. cancer detected, invasive size known, grade not known divided by total number of women with invasive cancer: Total invasive (column 35) multiplied by 100 (for the appropriate age group)

      Special type not known (% of invasive cancers) (column 59)
    • This column gives the percentage of cancers diagnosed by cytology or histology which are recorded as invasive, but the special type is not known. The column is calculated as:

      The number of women where no INVASIVE CANCER SPECIAL TYPE INDICATOR has been recorded and where the BIOPSY REFERRAL OUTCOME classification is Positive; i.e. cancer detected, invasive size known or Positive; i.e. cancer detected, invasive size not known divided by Total invasive (column 35) multiplied by 100 (for the appropriate age group)

      Grade not known (% of DCIS) (column 60)
    • This column gives the percentage of cancers diagnosed by cytology or histology, which are recorded as ductal carcinoma in-situ (DCIS), but the grade is not known. The column is calculated as:

      The number of women where the BIOPSY REFERRAL OUTCOME is Positive; i.e. cancer detected, non-invasive or possibly micro-invasive, grade not known (DCIS only detected) or Positive; i.e. cancer detected, definitely micro-invasive, grade not known (DCIS only detected) divided by total number of women with Non-invasive or possibly micro-invasive (column 27) plus Definitely micro-invasive (column 28) multiplied by 100 (for the appropriate age group)

      Part F2/6: Status of cancer
    • Part F2/6 gives status and grades of cancers detected.

      Age Groups of women (first column) in Part F2/6.
    • The status of cancers are assessed within three groups: the first being those within the previous target age range of 50-64, the second within the current target age range of 50-70 and the third, the total of those reported, regardless of age.

      Age Group (50-64) (line 43)
    • This is the outcome measure for women in the previous target age group 50-64

      Age Group (50-70) (line 44)
    • This is the outcome measure for women in the current target age group 50-70

      Total all ages (line 45)
    • This is the outcome measure for all women reported, regardless of age.

      Women with an invasive cancer detected: number with lymph nodes sampled (column 61)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known or Positive; i.e. cancer detected, invasive size not known with a Request for Pathology Investigation where a LYMPH NODE STATUS has been recorded.

      Women with an invasive cancer detected: number positive (column 62)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known or Positive; i.e. cancer detected, invasive size not known where at least one Request for Pathology Investigation with a LYMPH NODE STATUS of lymph node positive has been recorded.

      Note where more than one Request for Pathology Investigation with a LYMPH NODE STATUS has been recorded for a woman and any one of the LYMPH NODE STATUSES is lymph node positive, then the woman should be included in column 62, but should not be included in column 63.

      Women with an invasive cancer detected: number negative (column 63)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known or Positive; i.e. cancer detected, invasive size not known with a Request for Pathology Investigation with a LYMPH NODE STATUS of lymph node negative.

      Note where more than one Request for Pathology Investigation with a LYMPH NODE STATUS has been recorded for a woman, then every LYMPH NODE STATUS should be lymph node negative for inclusion in count for column 63. If any of the LYMPH NODE STATUSES is lymph node positive, then the woman should be included in column 62 and not included in column 63.

      Women with an invasive cancer detected: number with 4 or more nodes assessed (column 64)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known or Positive; i.e. cancer detected invasive size not known with four or more Request for Pathology Investigation where a LYMPH NODE STATUS has been recorded.

      Women with an invasive cancer detected: number with 4 or more nodes sampled: number positive (column 65)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known or Positive; i.e. cancer detected, invasive size not known with four or more Request for Pathology Investigation with a LYMPH NODE STATUS, any one of which is lymph node positive.

      Women with an invasive cancer detected: number with 4 or more nodes sampled: number negative (column 66)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known or Positive; i.e. cancer detected, invasive size not known with four or more Request for Pathology Investigation with a LYMPH NODE STATUS, any one of which is lymph node negative.

      Women with an invasive cancer detected: number grade 1 (column 67)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known ,Grade I or Positive; i.e. cancer detected, invasive size not known, Grade I.

      Women with an invasive cancer detected: number grade 2 (column 68)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known ,Grade II or Positive; i.e. cancer detected, invasive size not known, Grade II.

      Women with an invasive cancer detected: number grade 3 (column 69)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known, Grade III or Positive; i.e. cancer detected, invasive size not known, Grade III.

      Women with an invasive cancer detected: number special type (column 70)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known or Positive; i.e. cancer detected, invasive size not known with a Request for Pathology Investigation with a INVASIVE CANCER SPECIAL TYPE INDICATOR of special type.

      Women with an invasive cancer detected: number not special type (column 71)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, invasive size known or Positive; i.e. cancer detected, invasive size not known with a Request for Pathology Investigation with a INVASIVE CANCER SPECIAL TYPE INDICATOR of not special type.

      Women with DCIS only detected: number low or intermediate grade (column 72)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, non-invasive or possibly micro-invasive low (DCIS only detected) or Positive; i.e. cancer detected, non-invasive or possibly micro-invasive, intermediate (DCIS only detected) or Positive; i.e. cancer detected, definitely micro-invasive, low (DCIS only detected) or Positive; i.e. cancer detected, definitely microinvasive, intermediate (DCIS only detected).

      Women with DCIS only detected: number high grade (column 73)
    • Count of women with BIOPSY REFERRAL OUTCOME classification of Positive; i.e. cancer detected, non-invasive or possibly micro-invasive, high (DCIS only detected) or Positive; i.e. cancer detected, definitely micro-invasive, high (DCIS only detected).

top


KC62 T 1

Change to Central Return Form: Changed Description

Central Return Form Guidance
 

KC62: Adult Screening Programmes - Breast Screening

  1. Table T: All invitations and screenings: Sum of Tables A - F2

top


KC62 T 2

Change to Central Return Form: Changed Description

Central Return Form Guidance
 

KC62: Adult Screening Programmes - Breast Screening

  1. Table T: All invitations and screenings: Sum of Tables A - F2

top


KC62 T 3

Change to Central Return Form: Changed Description

Central Return Form Guidance
 

KC62: Adult Screening Programmes - Breast Screening

  1. Table T: All invitations and screenings: Sum of Tables A - F2

top


ABOUT US HELP

Change to Supporting Information: Changed Description


The NHS Data Model and Dictionary is maintained by the NHS Data Model and Dictionary Service.

NHS Data Model and Dictionary Service Products

The NHS Data Model and Dictionary Service produce other supporting products and services which complement the content of the NHS Data Model and Dictionary.

These can be found on the NHS Data Model and Dictionary Service website and can be accessed by clicking on the link to the 'NHS Data Model and Dictionary Service' on the front page of the dictionary.

The NHS Data Model and Dictionary Service website contains information, such as:


What would you like to do next?

  •  NHS Data Model and Dictionary Content

Access the NHS Data Model and Dictionary Main Menu.

  •   Help Pages

If you need help using the NHS Data Model and Dictionary, access the Help pages.

The NHS Data Model and Dictionary is maintained by the NHS Data Model and Dictionary Service.

NHS Data Model and Dictionary Service Products

The NHS Data Model and Dictionary Service produce other supporting products and services which complement the content of the NHS Data Model and Dictionary.

These can be found on the NHS Data Model and Dictionary Service website and can be accessed by clicking on the link to the 'NHS Data Model and Dictionary Service' on the front page of the dictionary.

The NHS Data Model and Dictionary Service website contains information, such as:


What would you like to do next?

  •  NHS Data Model and Dictionary Content

Access the NHS Data Model and Dictionary Main Menu.

  •   Help Pages

If you need help using the NHS Data Model and Dictionary, access the Help pages.

top


GLOSSARY OF TERMS

Change to Supporting Information: Changed Description


The Glossary lists commonly used terms in alphabetical order. These terms are not defined and therefore do not have a class or attribute. Each entry in the Glossary is shown with its related class and attribute where appropriate.

For example 'Booked Admission' is shown as relating to the class ELECTIVE ADMISSION LIST ENTRY. ELECTIVE ADMISSION LIST ENTRY has an attribute ELECTIVE ADMISSION TYPE and reference to the attribute definition will identify that 'Booked Admission' is one of the national code classifications of ELECTIVE ADMISSION TYPES.

ClassAttribute
Admission 
Hospital Provider Spell ACTIVITY DATE of the ACTIVITY DATE TYPE Start Date
Annual Census 
Hospital Provider Spell ACTIVITY DATE of the ACTIVITY DATE TYPE Start Date
OPERATIVE PROCEDURE  
Mental Health Act Legal Status MENTAL CATEGORY 
Hospital Provider Spell ACTIVITY DATE of the ACTIVITY DATE TYPE Discharge Date
PATIENT DIAGNOSIS  
Booked Admission 
ELECTIVE ADMISSION LIST ENTRY ELECTIVE ADMISSION TYPE 
Code of General Practitioner 
GENERAL MEDICAL PRACTITIONER GENERAL MEDICAL PRACTITIONER PPD CODE 
GENERAL DENTAL PRACTITIONER GENERAL DENTAL PRACTITIONER CODE 
Consultant Code 
CONSULTANT CONSULTANT CODE 
Consultant Name 
PERSON NAME  
Day Case Admission 
Hospital Provider Spell PATIENT CLASSIFICATION 
Diagnostic Services 
Pathology Department  
Radiology Department  
Isotope Procedure Department  
Physiological Measurement Department  
Discharge 
Hospital Provider Spell ACTIVITY DATE of the ACTIVITY DATE TYPE Discharge Date
Drop-In Clinic 
REFERRAL REQUEST OUT-PATIENT CLINIC REFERRING INDICATOR 
Emergency Admission 
Hospital Provider Spell ADMISSION METHOD 
Emergency Journey 
Emergency Transport Request  
General Practitioner Name 
PERSON NAME  
GMC or GDC Reference Number 
CARE PROFESSIONAL CARE PROFESSIONAL IDENTIFIER 
Local Patient Identifier 
PATIENT ORGANISATION LOCAL PATIENT IDENTIFIER 
Maternity Admission 
Hospital Provider Spell ADMISSION METHOD 
Neonate 
PATIENT  
Nurse Identifier 
CARE PROFESSIONAL CARE PROFESSIONAL IDENTIFIER 
Nurse Name 
PERSON NAME  
Ordinary Admission 
Hospital Provider Spell PATIENT CLASSIFICATION 
Organisation Postcode 
ADDRESS POSTCODE 
ADDRESS ASSOCIATION  
Organisation Address 
ADDRESS ASSOCIATION ADDRESS ASSOCIATION TYPE 
Patient Name 
PERSON NAME  
Patients Usual Address 
ADDRESS ASSOCIATION ADDRESS ASSOCIATION TYPE 
Planned Admission 
ELECTIVE ADMISSION LIST ENTRY ELECTIVE ADMISSION TYPE 
Postcode of Usual Address 
ADDRESS POSTCODE 
Regular Day Admission 
Hospital Provider Spell PATIENT CLASSIFICATION 
Sex 
PERSON GENDER PERSON GENDER CODE 
PERSON GENDER CURRENT  
PERSON GENDER AT REGISTRATION  
PERSON GENDER CODE CURRENT 
PERSON GENDER CODE AT REGISTRATION 
Special/Planned Journey 
Special Transport Request  
Planned Transport Request  
Telephone Number 
COMMUNICATION CONTACT INFORMATION COMMUNICATION CONTACT METHOD 
COMMUNICATION CONTACT STRING 
Two Man/One Man Crew 
TRANSPORT REQUIREMENT TRANSPORT NEED 
TCI (To Come In Date) 
OFFER OF ADMISSION OFFERED FOR ADMISSION DATE 
Urgent Journey 
Urgent Transport Request  
Waiting List Admission 
ELECTIVE ADMISSION LIST ENTRY ELECTIVE ADMISSION TYPE 
Ward Transfer 
Ward Stay ACTIVITY DATE of the ACTIVITY DATE TYPE End Date
WARD STAY TERMINATION REASON 

top


INDEX

Change to Supporting Information: Changed Description


NHS DATA MODEL AND DICTIONARY

Version 3

What's New: September 2012What's New: November 2012

Welcome to the NHS Data Model and Dictionary for England

If you would like to know more about us or need help using the NHS Data Model and Dictionary, see the Help pages

The NHS Data Model and Dictionary provides a reference point for assured information standards to support health care activities within the NHS in England. It has been developed for everyone who is actively involved in the collection of data and the management of information in the NHS.

The NHS Data Model and Dictionary is maintained and published by the NHS Data Model and Dictionary Service and all changes are assured by the Information Standards Board for Health and Social Care. Changes are published as Information Standards Notices (ISN) by the Information Standards Board for Health and Social Care and Data Dictionary Change Notices (DDCN) by the NHS Data Model and Dictionary Service.

 

Related Links
Frequently Asked Questions
Useful Links
Department of Health website
Health and Social Care Information Centre
Information Catalogue
Secondary Uses Service website

 
 

Related Links
Frequently Asked Questions
Department of Health website
Health and Social Care Information Centre
Information Catalogue
Secondary Uses Service website

 

top


SAME SEX ACCOMMODATION

Change to Supporting Information: Changed Description

Same Sex Accommodation is where male and female PATIENTS sleep in separate areas and have access to toilets and washing facilities used only by their own SEX.Same Sex Accommodation is where male and female PATIENTS sleep in separate areas and have access to toilets and washing facilities used only by their own sex.

Same Sex Accommodation can be provided in single-sex and mixed-sex WARDS.

In a same-sex WARD, the WARD is occupied by either men or women and has its own dedicated toilet and washing facilities.

In mixed-sex WARDS, Same Sex Accommodation can be provided either as:

  • single rooms with same-sex toilet and washing facilities and
  • Multi-Bed Bays or rooms occupied solely by either men or women with their own same-sex toilet and washing facilities.

Additionally, PATIENTS should not need to pass through mixed communal areas or sleeping areas, toilet or washing facilities used by the opposite gender in order to get to their own facilities.

 

top


SECURITY ISSUES AND PATIENT CONFIDENTIALITY

Change to Supporting Information: Changed Description


  • A. Removal of name and address where the NHS Number is present
  • From 1 April 1999, PATIENT NAME and PATIENT USUAL ADDRESS (not POSTCODE OF USUAL ADDRESS) must be removed from all Commissioning Data Sets where a valid NHS NUMBER is present. This applies to all nationally defined Commissioning Data Set data and any additional locally agreed flows from service providers to commissioning bodies.

  • A valid NHS NUMBER is one that has passed the check digit calculation on entry into the source system. If an NHS NUMBER is not valid (i.e. does not conform with the check digit algorithm) then PATIENT NAMES and PATIENT USUAL ADDRESSES should not be removed, as the reliability of the NHS NUMBER will not be known.

  • The NHS NUMBER STATUS INDICATOR CODE is a mandatory part of the Commissioning Data Set. PATIENT NAME and PATIENT USUAL ADDRESS should be removed when a valid NHS NUMBER is present, even if the NHS NUMBER STATUS INDICATOR CODE does not have a status of 01, Number present and verified.

    B. Marital Status
  • Following the recommendations of the Data Protection Registrar, Providers should not record MARITAL STATUS in any CDS TYPE, except in respect of the psychiatric specialities in the Admitted Patient Care CDS Types, where it will continue to be recorded.

    C. Sensitive data
  • The Human Fertilisation and Embryology Act 1990 as amended by the Human Fertilisation and Embryology (Disclosure of Information) Act 1992 imposes statutory restrictions on the disclosure of information about identifiable individuals in connection with certain infertility treatments. A list of the relevant codes is given in Table 1. In these cases the NHS NUMBER, LOCAL PATIENT IDENTIFIER, PATIENT NAMES, POSTCODE OF USUAL ADDRESS and PERSON BIRTH DATE should be omitted from the CDS Types.

  • From Commissioning Data Set Version 6-2, records where the patient-identifiable data has been withheld should be submitted using the PATIENT IDENTITY - WITHHELD IDENTITY STRUCTURE data group in CDS types where identification is carried.  This data group allows only the NHS NUMBER STATUS INDICATOR CODE (the actual value held on source systems should be used), ORGANISATION CODE (RESIDENCE RESPONSIBILITY) and WITHHELD IDENTITY REASON to flow.  The WITHHELD IDENTITY REASON allows Health Care Providers to inform their Commissioners why a record has been anonymised.  Note that the same rules apply to the additional PATIENT IDENTITY structures relating to Mother and Baby in the Delivery and Birth CDS types.

  • Other statutory restrictions on the disclosure of PATIENT information do not prohibit the disclosure to individuals involved with the treatment and prevention of certain specific diseases (HIV/AIDS and venereal diseases) in the population.

    TABLE 1: TREATMENTS PROVIDED UNDER THE LICENCE OF THE HUMAN FERTILISATION AND EMBRYOLOGY AUTHORITY

    DescriptionOPCS-4*ICD-10
    Standard In Vitro Fertilisation (IVF)Q13.-1 Introduction of gamete into uterine cavity, or
    Q38.3 Endoscopic intrafallopian transfer of gamete
    Z31.2 In vitro fertilization
    In Vitro Fertilisation (IVF) with donor spermQ13.- 1 Introduction of gamete into uterine cavity, or
    Q38.3 Endoscopic intrafallopian transfer of gamete
    Z31.2 In vitro fertilization
    In Vitro Fertilisation (IVF) with donor eggsQ13.-1 Introduction of gamete into uterine cavity, or
    Q38.3 Endoscopic intrafallopian transfer of gamete
    Z31.2 In vitro fertilization
    Donor insemination (DI)Q13.3 Intrauterine artificial insemination, or
    Q13.2 Intracervical artificial insemination
    Z31.1 Artificial insemination
    Gamete intrafallopian transfer (GIFT) with donor spermQ38.3 Endoscopic intrafallopian transfer of gameteZ31.3 Other assisted fertilization methods
    Gamete intrafallopian transfer (GIFT) with donor eggsQ38.3 Endoscopic intrafallopian transfer of gameteZ31.3Other assisted fertilization methods
    Intracytoplasmic sperm injection (ICSI)  
    Sub-zonal insemination (SUZI)  
    Zygote intrafallopian transfer (ZIFT)Q38.3 Endoscopic intrafallopian transfer of gameteZ31.2 In vitro fertilization
    Partial Zona Dissection (PZD)  
    Zona drilling  
    Hamster- egg penetration test  
    Assisted hatching  
    Pre-implantation Genetic Diagnosis (PGD)  
    Storage of sperm  
    Storage of embryos  
    Use and storage of testicular tissue  
    Transport/satellite In Vitro Fertilisation (IVF) / Intracytoplasmic sperm injection (ICSI)  
    Embryo donation Z31.8 Other procreative management
    Research  

    1.- means all fourth characters of this rubric should be included.
    * see OPCS Classification of Interventions and Procedures

  • All records containing patient identifiable information, other than those covered by the Human Fertilisation & Embryology Acts, as outlined in the Table above, should be treated as sensitive. ORGANISATIONS may continue to exchange records containing NHS NUMBER, POSTCODE OF USUAL ADDRESS and PERSON BIRTH DATE in these cases, but receiving organisations must ensure that only those staff with legitimate need have access to this information, e.g. public health departments, and strictly on a need to know basis. No-one should have unrestricted access unless fully justified in accordance with the principles of the Caldicott Committee Report.

  • Where PATIENT level data is required for other purposes within an organisation, it should be anonymised/aggregated prior to disclosure by someone with legitimate access. If this is not practicable, local protocols defining which CDS TYPES are particularly sensitive (including, but not necessarily restricted to HIV/AIDS and venereal disease) agreed by the organisation Caldicott Guardian, should be put in place and identifiers stripped from these records.

  • Your Caldicott Guardian will be able to advise you further on all issues relating to patient confidentiality.

  • Where appropriate, further information about confidentiality is contained within the notes for individual data items.

top


SUPPORTING INFORMATION MENU

Change to Supporting Information: Changed Description

top


WHAT'S NEW: NOVEMBER 2012  renamed from WHAT'S NEW: SEPTEMBER 2012

Change to Supporting Information: Changed Name, Description

Release: November 2012

Information Standards Notices and Data Dictionary Change Notices incorporated into the NHS Data Model and Dictionary:
  • CR1166, CR1167 and CR1306 (1 November 2012) - ISB 0092 Amd-16-2010 Commissioning Data Set Version 6-2, Commissioning Data Set XML Message Version 6-2 and Retirement of CDS 6-0
  • CR1305 (1 April 2013) - ISB 0092 Amd 06/2011 Allied Health Professions Referral to Treatment (AHP RTT) Update - CDS 6-2
  • CR1286 (1 November 2012) - ISB 0028 Amd 17/2012 Treatment Function Codes Update
  • CR1343 (Immediate) - DDCN 1343/2012 Change of name for NHS Commissioning Board Authority
  • CR1342 (Immediate) - DDCN 1342/2012 Overseas Visitors Update
  • CR1341 (Immediate) - DDCN 1341/2012 Discharge Default Code Descriptions
  • CR1323 (Immediate) - National Cancer Waiting Times Monitoring Data Set Update for "Delay Reason To Treatment For Cancer"

CR1323 is a corrigendum to CR1258 (1 July 2012) - ISB 0147 Amd 23/2011 Changes to the National Cancer Waiting Times Monitoring Data Set published in the June 2012 release

The following have been incorporated early to allow users to see the changes, but please note that the implementation date is 1 April 2013:

  • CR1231 and CR1288 (1 April 2013) - ISB 1570 Amd 164/2010 HIV and AIDS Reporting Data Set and HIV and AIDS Related Data Set Message

Release: September 2012

Information Standards Notices and Data Dictionary Change Notices incorporated into the NHS Data Model and Dictionary:
  • CR1103 (Immediate) - ISB 0066 Amd 43/2010 Renal Data Set - Data Item Addition, Changes and Deletions
  • CR1334 (Immediate) - DDCN 1334/2012 Psychology Definitions
  • CR1331 (Immediate) - DDCN 1331/2012 Activity Date Time Type
  • CR1329 (Immediate) - DDCN 1329/2012 Change of name for "Health and Social Care Information Centre"

Release: August 2012

Information Standards Notices and Data Dictionary Change Notices incorporated into the NHS Data Model and Dictionary:
  • CR1326 (Immediate) - DDCN 1326/2012 Health and Care Professions Council
  • CR1241 (Immediate) - DDCN 1241/2012 NHS dictionary of medicines and devices
  • CR1292 (Immediate) - ISB 1549 Amd 4/2011 and DDCN 1292/2012 Deprecation and withdrawal of version 3.2 of the Acute Myocardial Infarction Data Set and subsequent retiring of the Data Set from the NHS Data Model and Dictionary

Release: June 2012

Information Standards Notices and Data Dictionary Change Notices incorporated into the NHS Data Model and Dictionary:
  • CR1314 (Immediate) - DDCN 1314/2012 Reasonable Offer Update
  • CR1282 (29 June 2012) - ISB 0090 Amd 36/2011 Independent Sector Healthcare Provider (ISHP) Codes extended for ISHPs and Sites
  • CR1258 (1 July 2012) - ISB 0147 Amd 23/2011 Changes to the National Cancer Waiting Times Monitoring Data Set

Release: May 2012

Information Standards Notices and Data Dictionary Change Notices incorporated into the NHS Data Model and Dictionary:
  • CR1215 (1 June 2012) - ISB 1067 Amd 30/2011 National Workforce Data Set

    The following have been incorporated early to allow users to see the changes, but please note that the implementation date is 1 April 2013:

  • CR1028 (1 April 2013) - ISB 1069 Amd 14/2012 Children and Young People's Health Services Data Set
  • CR1029 (1 April 2013) - ISB 1072 Amd 12/2012 Child and Adolescent Mental Health Services (CAMHS) Data Set
  • CR1104 (1 April 2013) - ISB 1513 Amd 13/2012 Maternity Secondary Uses Data Set

Release: March 2012

Information Standards Notices and Data Dictionary Change Notices incorporated into the NHS Data Model and Dictionary:

Release: January 2012

Information Standards Notices and Data Dictionary Change Notices incorporated into the NHS Data Model and Dictionary:

Release: November 2011

Information Standards Notices and Data Dictionary Change Notices incorporated into the NHS Data Model and Dictionary:
  • CR1264 (Immediate) - ISB 1077 Amd 3/2012 Automatic Identification and Data Capture (AIDC) for Patient Identification Data Set
  • CR1274 (Immediate) - DDCN 1274/2011 CDS Prime Recipient Identity Update

    The following have been incorporated early to allow users to see the changes, but please note that the implementation date is 1 April 2012:

  • CR1265 (1 April 2012) - ISB 1520 Amd 29/2011 Changes to the Improving Access to Psychological Therapies Data Set

Release: October 2011

Information Standards Notices and Data Dictionary Change Notices incorporated into the NHS Data Model and Dictionary:
  • CR1271 (Immediate) - DDCN 1271/2011 Commissioning Data Set Addressing Grid Update
  • CR1268 (Immediate) - DDCN 1268/2011 Sexual Orientation Code
  • The following has been incorporated early to allow users to see the changes, but please note that the implementation date is 1 April 2012:

  • CR1158 and CR1260 (1 April 2012) - ISB 1533 Amd 63/2010 Systemic Anti-Cancer Therapy Data Set and Systemic Anti-Cancer Therapy Data Set Message Schema

    The following have been incorporated early to allow users to see the changes, but please note that the implementation date is 1 July 2012:

  • CR1270 (1 July 2012) - ISB 1080 Amd 25/2011 Amendments to NHS Health Check Data Set
  • CR1250 (1 July 2012) - ISB 1080 Amd 25/2011 NHS Health Checks Data Set Message Schema Version 2.0.0

Release: August 2011

Information Standards Notices and Data Dictionary Change Notices incorporated into the NHS Data Model and Dictionary:
  • CR1232 (Immediate) - ISB 0034 Amd 26/2006 Systematized Nomenclature of Medicine Clinical Terms (SNOMED CT) - NHS Data Model and Dictionary Overview
  • CR1222 (1 April 2012) - ISB 0021 Amd 86/2010 Introduction of the International Classification of Diseases Tenth Revision 4th Edition
  • CR1190 (1 September 2011) - ISB 1538 Amd 131/2010 Chlamydia Testing Activity Data Set
  • CR1188 (Immediate) - Amd 85/2010 Genitourinary Medicine Clinic Activity Data Set (GUMCAD) Extension to include Enhanced Sexual Health Services (ESHS)

The following data set is initially being introduced for local use only. A future Information Standards Notice will be published to notify providers and system suppliers of the requirement to flow the data set nationally:

Release: July 2011

Information Standards Notices and Data Dictionary Change Notices incorporated into the NHS Data Model and Dictionary:
  • CR1249 (Immediate) - DDCN 1249/2011 General Pharmaceutical Council Registration Changes

The following has been incorporated early to allow users to see the changes, but please note that the implementation date is 1 July 2012:

Release: June 2011

Information Standards Notices and Data Dictionary Change Notices incorporated into the NHS Data Model and Dictionary:
  • CR1256 (Immediate) - DDCN 1256/2011 School Definitions
  • CR1117 (26 August 2011) - ISB 0090 Amd 94/2010 Organisation Data Service Identification Codes for Local Authorities in England and Wales
  • CR1251 (Immediate) - DDCN 1251/2011 Change to the Format/Length of Weekly Hours Worked
  • CR1243 (Immediate) - DDCN 1243/2011 National Interim Clinical Imaging Procedure (NICIP) Code Set

Release: April 2011

Information Standards Notices and Data Dictionary Change Notices incorporated into the NHS Data Model and Dictionary:
  • CR1154 (1 April 2011) - ISB 0011 Amd 87/2010 Mental Health Minimum Data Set Version 4.0
  • CR1234 (Immediate) - DDCN 1234/2011 Technology Reference Data Update Distribution Service (TRUD)
  • CR1168 (Immediate) - ISB 0097 Amd 140/2010 Genitourinary Medicine Access Monthly Monitoring Data Set Amendments - Removal of Human Immunodeficiency Virus data

The following has been incorporated early to allow users to see the changes, but please note that the implementation date is 1 April 2012:

Release: March 2011

Information Standards Notices and Data Dictionary Change Notices incorporated into the NHS Data Model and Dictionary:

Release: January 2011

Information Standards Notices and Data Dictionary Change Notices incorporated into the NHS Data Model and Dictionary:
  • CR1116 (1 April 2010) - ISB 0003 Amd 79/2010 Immunisation Programmes Activity Data Set (KC50)
  • CR1112 (1 April 2010) - ISB 1511 Amd 26/2010 NHS Continuing Healthcare and NHS Funded Nursing Care
  • CR1068 (Immediate) - ISB 0133 Amd 161/2010 Change To Central Return: Human Papillomavirus (HPV) Immunisation Programme - Vaccine Monitoring Minimum Data Set
  • CR1211 (Immediate) - DDCN 1211/2010 Commissioning Data Set Addressing Grid / Organisation Code (Code of Commissioner) Update

Release: December 2010

Information Standards Notices and Data Dictionary Change Notices incorporated into the NHS Data Model and Dictionary:

Release: November 2010

Information Standards Notices and Data Dictionary Change Notices incorporated into the NHS Data Model and Dictionary:

  • CR1119 (Immediate) - DDCN 1119/2010 Organisation Codes Update 
  • CR1192 (Immediate) - DDCN 1192/2010 Change of name for "Health Solution Wales"
  • CR1199 (Immediate) - DDCN 1199/2010 General Pharmaceutical Council and Royal Pharmaceutical Society of Great Britain Update
  • CR1189 (Immediate) - DDCN 1189/2010 National Institute for Health and Clinical Excellence
  • CR1187 (Immediate) - DDCN 1187/2010 Introduction of the Department for Education

Release: September 2010

Information Standards Notices and Data Dictionary Change Notices incorporated into the NHS Data Model and Dictionary:

  • CR1128 (Immediate) - DDCN 1128/2010 Changes to reporting procedures for Overseas Visitors from the European Economic Area and Switzerland
  • CR1173 (Immediate) - DDCN 1173/2010 Care Quality Commission Update
  • CR1143 (Immediate) - DDCN 1143/2010 General Pharmaceutical Council
  • CR1061 (1 October 2010) - ISB 0092/2010 CDS Type 20: Out-patient: Retirement of Default Codes for Out-patient Procedures
  • CR1133 (Immediate) - ISB 00289/2010 National Specialty List

Release: August 2010

  • The August 2010 Release introduces the NHS Data Model and Dictionary Help Pages.

Release: July 2010

Information Standards Notices and Data Set Change Notices incorporated into the NHS Data Model and Dictionary:

Release: May 2010

Data Set Change Notices incorporated into the NHS Data Model and Dictionary:

Release: March 2010

Data Set Change Notices incorporated into the NHS Data Model and Dictionary:

  • CR1123 (1 April 2010) - DSCN 18/2010 Information Standards Notice (ISN)
  • CR1139 (Immediate) - DSCN 16/2010 Person Weight
  • CR1130 (Immediate) - DSCN 15/2010 Change of name for "The NHS Information Centre for health and social care"
  • CR1013 (April 2010) - DSCN 14/2010 Sexual and Reproductive Health Activity Dataset (SRHAD)
  • CR1125 (Immediate) - DSCN 13/2010 NHS Data Model and Dictionary Maintenance Update - Policy Definitions
  • CR1122 (Immediate) - DSCN 11/2010 Changes to Family Planning References

Release: January 2010

Data Set Change Notices incorporated into the NHS Data Model and Dictionary:

  • CR1115 (Immediate) - DSCN 10/2010 Data Standards: Updating of e-Government Interoperability Framework and Government Data Standards Catalogue References

Release: December 2009

Data Set Change Notices incorporated into the NHS Data Model and Dictionary:

  • CR1100 (Immediate) - DSCN 25/2009 NHS Prescription Services Update
  • CR1045 (1 December 2009) - DSCN 17/2009 Referral to Treatment Clock Stop Administrative Event
  • CR1003 (1 December 2009) - DSCN 16/2009 Commissioning Data Sets: Mandation of 18 Week Referral To Treatment Data Items

Release: November 2009

Data Set Change Notices incorporated into the NHS Data Model and Dictionary:

  • CR1113 (Immediate) - DSCN 24/2009 Information Standards Board for Health and Social Care Update
  • CR1087 (Immediate) - DSCN 23/2009 Health Professions Council Update
  • CR1081 (Immediate) - DSCN 22/2009 Data Standards: NHS Data Model and Dictionary Maintenance Update
  • CR1019 (27 November 2009) - DSCN 21/2009 Data Standards: Organisation Data Service (ODS) - Optical Sites and Optical Headquarters
  • CR1034 (27 November 2009) - DSCN 20/2009 Data Standards: Organisation Data Service (ODS) - Care Homes in England and Wales and their Headquarters

Release: September 2009

Data Set Change Notices incorporated into the NHS Data Model and Dictionary:

  • CR1065 (1 October 2009) - DSCN 15/2009 Data Standards: Organisation Data Service, Local Health Boards

Release: June 2009

Data Set Change Notices incorporated into the NHS Data Model and Dictionary:

  • CR1014 (1 June 2009) - DSCN 13/2009 Religious and Other Belief System Affiliation
  • CR1074 (Immediate) - DSCN 12/2009 Data Standards: Care Quality Commission
  • CR1056 (Immediate) - DSCN 11/2009 Data Standards: NHS Data Model and Dictionary Maintenance Update
  • CR1072 (1 December 2009) - DSCN 10/2009 Data Standards: National Radiotherapy Data Set
  • CR1073 (Immediate) - DSCN 09/2009 Central Returns: Diagnostic Waiting Times and Activity Data Set
  • CR1066 (Immediate) - DSCN 08/2009 Data Standards: NHS Prescription Services and NHS Dental Services
  • CR1047 (1 April 2011) - DSCN 07/2009 Data Standards: Diabetic Retinopathy Screening Dataset v3.6 
  • CR1059 (Immediate) - DSCN 06/2009 Data Standard: National Workforce Data Set v2.1
  • CR914 (April 2008 (Retrospective)) - DSCN 05/2009 NHS Stop Smoking Services Quarterly Monitoring Return
  • CR899 (Immediate) - DSCN 02/2009 NHS Data Model and Dictionary Maintenance Update

Release: March 2009

Data Set Change Notices incorporated into the NHS Data Model and Dictionary:

  • CR1001 (1 April 2009) - DSCN 03/2009 Introduction of Commissioning Data Set Schema Version 6-1 (2008-04-01) and update to Commissioning Data Set Schema Version 6-0 (2008-01-14)
  • CR976 (31 March 2009) - DSCN 26/2008 Subject: KP90 - Admissions, Changes in Status and Detentions under the Mental Health Act
  • CR1017 (1 April 2009) - DSCN 25/2008 Critical Care Minimum Data Set
  • CR1002 (1 April 2009) - DSCN 24/2008 Data Standards: Introduction of Commissioning Dataset Version 6.1
  • CR1016 (Immediate) - DSCN 23/2008 4 Byte Version of the Read Codes - Withdrawal

Release: December 2008

Data Set Change Notices incorporated into the NHS Data Model and Dictionary:

  • CR1022 (1 January 2009) - DSCN 29/2008 Data Standards: 18 Weeks Referral to Treatment (RTT) Time, Performance Sharing
  • CR901 (Immediate) - DSCN 28/2008 Removal of references to EDIFACT and the NHS Wide Clearing Service (NWCS) 
  • CR843 (1 April 2009) - DSCN 22/2008 Data Standards: National Radiotherapy Data Set
  • CR1011 (1 January 2009) - DSCN 20/2008 Data Standards: National Cancer Waiting Times Minimum Data Set 

Release: November 2008

Data Set Change Notices incorporated into the NHS Data Model and Dictionary:

  • CR1026 (3 November 2008) - DSCN 21/2008 Information Standard: Mental Health Act 2007 Mental Category

Release: August 2008

Data Set Change Notices incorporated into the NHS Data Model and Dictionary:

  • CR1018 (Immediate) - DSCN 19/2008 Data Standards: Change of Name for National Administrative Code Services (NACS) to Organisation Data Service (ODS)
  • CR956 (1 September 2008) - DSCN 18/2008 Central Return: Human Papillomavirus (HPV) Immunisation Programme, Vaccine Monitoring Minimum Dataset
  • CR861 (Immediate) - DSCN 16/2008 Central Return:  Hospital and Community Services Complaints and General Practice (including Dental) Complaints - KO41(a) and KO 41(b)
  • CR964 (Immediate) - DSCN 14/2008 Central Return: 18 Weeks ‘Adjusted’ Referral to Treatment (RTT) Dataset
  • CR965 (Immediate) - DSCN 13/2008 Data Standards: Organisation Data Service (ODS) - Change to the Default Codes Set to Support Changes to GMS Contract
  • CR879 (Immediate) - DSCN 12/2008 Data Standards: Quarterly Monitoring: Cancelled Operations Data Set (QMCO)

Release: May 2008

Data Set Change Notices incorporated into the NHS Data Model and Dictionary:

  • CR502 (Immediate) - DSCN 10/2008 Data Standards: National Workforce Data Definitions (v2.0)
  • CR910 (1 April 2008) - DSCN 08/2008 Data Standards: National Direct Access Audiology Patient Tracking List (PTL) and Waiting Times (WT) data sets
  • CR900 (Immediate) - DSCN 07/2008 Data Standards: Inter-Provider Transfer Administrative Minimum Data Set
  • CR934 (1 April 2008) - DSCN 06/2008 Data Standards: Mental Health Minimum Data Set (version 3.0)
  • CR935 (Immediate) - DSCN 05/2008 Data Standards: 18 Weeks Rules Suite
  • CR925 (1 September 2008) - DSCN 04/2008 Genitourinary Medicine Clinic Activity Data Set Change to an Information Standard
  • CR942 (1 June 2008) - DSCN 03/2008 General Practice and General Medical Practitioner (GMP) - changes resulting from the introduction of the General Medical Services (GMS) Contract

Release: February 2008

Data Set Change Notices incorporated into the NHS Data Model and Dictionary:

  • CR812 (Immediate) - DSCN 01/2008 Central Return: Diagnostics Waiting Times Census Data Set
  • CR881 (31 December 2007) - DSCN 42/2007 Central Return: Referral To Treatment Summary Patient Tracking List
  • CR904 (Immediate) - DSCN 41/2007 Data Standards: Admission Intended Procedure Update
  • CR824 (1 February 2008) - DSCN 39/2007 Data Standards: 48 Hour Genitourinary Medicine Access Monthly Monitoring (GUMAMM)

Release: November 2007

Data Set Change Notices incorporated into the NHS Data Model and Dictionary:

  • CR919 (Immediate) - DSCN 38/2007 Data Standards: Mental Health Minimum Data Set Schema
  • CR814 (1 April 2008) - DSCN 37/2007 Data Standards: Introduction of Mental Health Minimum Data Set version 2.1
  • CR930 (31 December 2007) - DSCN 35/2007 Data Standards: A correction to the version 6 Commissioning Data Set schema
  • CR834 (Immediate) - DSCN 34/2007 Data Standards: Referral Request Received Date
  • CR875 (Immediate) - DSCN 33/2007 Data Standards: National Administrative Codes Service: Introduction of codes for the new Pan SHAs
  • CR880 (Immediate) - DSCN 29/2007 Data Standards: Amendments to Doctor Index Number (DIN) Description

Release: August 2007

Data Set Change Notices incorporated into the NHS Data Model and Dictionary:

  • CR845 (Immediate) - DSCN 28/2007 Data Standards: Treatment Function Code (Referral to Treatment Period)
  • CR831 (1 October 2007) - DSCN 27/2007 Data Standards: Update to Commissioning Data Set XML Schema v5
  • CR825 (1 October 2007) - DSCN 16/2007 Data Standards: Source of Referral for Outpatients (18 Weeks)

Release: June 2007

Data Set Change Notices incorporated into the NHS Data Model and Dictionary:

  • CR799 (31 December 2007) - DSCN 18/2007 Data Standards: Introduction of Commissioning Data Set Version 6
  • CR833 (Immediate) - DSCN 17/2007 Data Standards: Introduction of Commissioning Data Set validation table
  • CR801 (Immediate) - DSCN 15/2007 Data Standards: Cover of Vaccination Evaluated Rapidly (COVER) Return

Release: May 2007

Data Set Change Notices incorporated into the NHS Data Model and Dictionary:

  • CR800 (31 December 2007) - DSCN 14/2007 Commissioning Data Set Schema Version 6-0
  • CR856 (1 October 2007) - DSCN 13/2007 Data Standards: Discharge Ready Date
  • CR869 (Immediate) - DSCN 12/2007 Data Standards: Update to Clinical Coding Introduction
  • CR827 (1 October 2007) - DSCN 09/2007 Data Standards: Earliest Reasonable Offer Date
  • CR817 (1 October 2007) - DSCN 08/2007 Data Standards: Introduction of Age into Commissioning Data Sets
  • CR849 (May 2007) - DSCN 07/2007 National Administrative Codes Service: Introduction of new identification codes for Dental Consultants
  • CR822 (Immediate) - DSCN 06/2007 Data Standards: Update to Organisation Codes
  • CR850 (Immediate) - DSCN 05/2007 National Administrative Codes Service: Amendments to Default Codes
  • CR786 (1 April 2007) - DSCN 04/2007 Quarterly Monitoring Accident and Emergency Services (QMAE) Central Return

Release: February 2007

Data Set Change Notices incorporated into the NHS Data Model and Dictionary:

  • CR811 (Immediate) - DSCN 03/2007 Diagnostic Waiting Times and Activity
  • CR826 (1 October 2007) - DSCN 02/2007 Extension of Treatment Function to Support the Measurement of 18 Week Referral to Treatment Periods
  • CR813 (1 April 2007) - DSCN 01/2007 Paediatric Critical Care Minimum Data Set
  • CR768 (1 January 2007) - DSCN 18/2006 Changes to the NHS Data Dictionary to support the measurement of 18 week referral to treatment periods
  • CR798 (6 November 2006) - DSCN 19/2006 Commissioning Data Set (CDS) Version 5 XML Message Schema
  • CR776 (1 October 2006) - DSCN 05/2006 Data Standards: Accident and Emergency Enhancements to Investigation and Treatment Codes

Release: September 2006

Data Set Change Notices incorporated into the NHS Data Model and Dictionary:

  • CR795 (31 October 2006) - DSCN 22/2006 Organisation Codes / Organisation Site Codes
  • CR792 (1 April 2007) - DSCN 15/2006 Neonatal Critical Care
  • CR719 (1 April 2006) - DSCN 09/2006 Measuring and Recording of Waiting Times
  • CR791 (1 April 2007) - DSCN 13/2006 Priority Type
  • CR774 (1 September 2006) - DSCN 12/2006 Person Marital Status

Release: May 2006

Data Set Change Notices incorporated into the NHS Data Model and Dictionary:

  • CR764 (1 April 2006) - DSCN 08/2006 Diagnostics waiting times and activity
  • Correction to menu structure to include Critical Care Minimum Data Set

Release: April 2006

Data Set Change Notices incorporated into the NHS Data Model and Dictionary:

  • CR608 (1 October 2006) - DSCN 07/2006 Introduction of Commissioning Data Set Version 5 and its associated XML schema into the NHS Data Dictionary.
  • CR756 (1 September 2005) - DSCN 19/2005 PbR Commissioning for Out of Area Treatments (OATs) and Charge-Exempt Overseas Visitors
  • CR724 (1 April 2006) - DSCN 13/2005 Critical Care Minimum Data Set
  • CR754 (1 April 2006) - DSCN 17/2005 Treatment Function and Main Specialty Code Revisions
  • CR763 (1 April 2006) - DSCN 20/2005 New Treatment Functions for therapy services and anticoagulant service
  • CR767 (Immediate) - DSCN 02/2006 Referral Request Received Date
  • CR690 (1 September 2005) - DSCN 16/2005 Marital Status

Release: August 2005

Data Set Change Notices incorporated into the NHS Data Model and Dictionary:

  • CR555 (1 April 2005) - DSCN 11/2005 Data Standards: COVER - Hepatitis B immunisation for babies
  • CR715 (Immediate) - DSCN 10/2005 Data Standards: Treatment Function Codes - correction and clarification of names and descriptions
  • CR706 (1 April 2005) - DSCN 09/2005 Data Standards: Cancer Registration Data Set
  • CR691 (1 July 2005) - DSCN 06/2005 Data Standards: NSCAG Commissioner Code

For all Information Standards Notices and Data Set Change Notices, see the Information Standards Board for Health and Social Care Website

top


ACTIVITY DATE AND TIME TYPE

Change to Attribute: Changed Description

The type of DATE AND TIME that that defines the usage with regard to the ACTIVITY.The type of DATE AND TIME that defines the usage with regard to the ACTIVITY.

An ACTIVITY may have many DATES AND TIMES associated with it but may only have one DATE AND TIME of a particular type.

National Codes:

300Maternal Critical Incident Date and Time
301Procedure Date and Time
302Baby First Feed Date and Time
303Date and Time of Decision to Deliver
304Discharge Date and Time (Mother Post Delivery Hospital Provider Spell)
305Oxytocin Administered Date and Time
306Rupture of Membranes Date and Time
307Transfer Start Date and Time (Neonatal Unit)
308Urgent Care Service Accessed Date and Time

Note: This list is not in alphabetical order.

 

top


ATTENDED OR DID NOT ATTEND

Change to Attribute: Changed Description

This indicates whether an APPOINTMENT for a CARE CONTACT took place.An indication of whether an APPOINTMENT for a CARE CONTACT took place.

If the APPOINTMENT did not take place it also indicates if advance warning was given.

When an APPOINTMENT is cancelled the APPOINTMENT CANCELLED DATE should also be recorded.

National Codes:

5Attended on time or, if late, before the relevant CARE PROFESSIONAL was ready to see the PATIENT 
6Arrived late, after the relevant CARE PROFESSIONAL was ready to see the PATIENT, but was seen
7PATIENT arrived late and could not be seen
2APPOINTMENT cancelled by, or on behalf of, the PATIENT 
3Did not attend - no advance warning given
4APPOINTMENT cancelled or postponed by the Health Care Provider 
0Not applicable - APPOINTMENT occurs in the future *

Note: The classification has been listed in logical sequence rather than alphanumeric order.

* Note that code 0 - 'Not applicable - APPOINTMENT occurs in the future' is NOT valid for use in the following data sets:

Use in the Future Outpatient Commissioning Data Set:

  • For referral records with no APPOINTMENT yet made, or for future APPOINTMENTS, code 0 - Not applicable - APPOINTMENT occurs in the future should be used.
  • Where the future attendance has been cancelled, use the appropriate value from the National Codes.
 

top


CURRENCY TYPE

Change to Attribute: Changed Description

The type of CURRENCY used in a financial amount.

National Codes:

GBPPound Sterling
USDUS Dollar
EUREuro

Refer to BSEN 4217 for actual lists of codes and names Note: ISO standard no longer contains obsolete euro-zone currencies (plus 'Milk Tokens' for the Department for Work and Pensions (DWP)).

References:
The e-GIF version approved for use in NHS England is:
Government Data Standards Catalogue: (GDSC), Version 2.0, Agreed 1 January 2002.
Further information can be found on the Cabinet Office website.

 

top


LIVE OR STILL BIRTH

Change to Attribute: Changed Description

An indicator of whether the birth was a live or still birth. A still birth is a birth after a gestation of 24 weeks (168 days) where the baby shows no identifiable signs of life at delivery.An indication of whether the birth was a live or still birth.

A still birth is a birth after a gestation of 24 weeks (168 days) where the baby shows no identifiable signs of life at delivery.

National Codes:

1Live
2Still birth ante-partum
3Still birth intra-partum
4Still birth indeterminate
 

top


MEASUREMENT VALUE TYPE CODE

Change to Attribute: Changed Description

The type of measurement used for the MEASURED PERSON OBSERVATION being recorded.

The unit of measurement is based on the MEASURED PERSON OBSERVATION TYPE CODE for that MEASURED PERSON OBSERVATION.

National Codes:

01Millimoles per litre (mmol/L)
02Micromoles per litre (µmol/L)
03Microgrammes per litre (ug/L)
04Microgrammes per mililitre (ug/mmol)
05Microgramme albumin per hour (ug/ml/hr)
06Microgramme albumin per minute (ug/min)
07Microgramme albumin per 24 hours (ug/24hr)
03Micrograms per litre (ug/L)
04Micrograms per millimole (ug/mmol)
05Microgram albumin per hour (ug/ml/hr)
06Microgram albumin per minute (ug/min)
07Microgram albumin per 24 hours (ug/24hr)
08Number
09Percentage (%)
10Kilograms (kg)
11Metres (m)
13Square Metres (m2)
14Millilitres per Minute (ml/min)
15Millimetre of mercury (mmHg)
16Litres (l)
17Beats per minute (bpm)
18Centimetres (cm)
19Milligrams (mg)
20Millilitres (ml)
21Minutes
22Celsius
 

top


ORGANISATION CODE

Change to Attribute: Changed Description

An ORGANISATION CODE is a code which identifies an ORGANISATION uniquely.

For NHS ORGANISATIONS it is a code that is managed by either the:

to identify most ORGANISATIONS that exchange information within the NHS or return information to the Centre. Examples of ORGANISATIONS that can be identified this way are Primary Care Trusts and Strategic Health Authorities.

Notes:

ORGANISATION CODING FRAMES

  • All NHS ORGANISATIONS are coded using coding frames, as shown in the tables below:

Character
Position

 

1

 

2

 

3

 

4

 

5

 

6

 

7

 

8

 

Format

 

a/n

 

a/n

 

a/n

 

a/n

 

a/n

 

a/n

 

a/n

 

a/n

 

A Frame

 

Organisation
Type Identifier

 

Organisation Identifier

 
   

B Frame

 

Organisation Type Identifier

 

Organisation Identifier

 
   

C Frame

 

Organisation Type Identifier

 

Organisation Identifier

 

D Frame

 

Organisation Type Identifier

 

Organisation Identifier

 
     

E Frame

 

Organisation Identifier

 
       

F Frame

 

Organisation Type Identifier

 

Organisation Identifier

 
    

G Frame

 

Organisation Type Identifier

 

Practice Identifier

 
  

H Frame

 

Organisation Type Identifier

 

Organisation Identifier

 
     

I Frame

 

Organisation Type Identifier

 

Organisation Identifier

 
   

J Frame

 

Organisation Type Identifier

 

Organisation Identifier

 
   

K Frame

 

Organisation Identifier

 
     

 L Frame

 

Organisation Type Identifier

 

Organisation Identifier

 

Organisation Type Identifier

 
   

M Frame

 

Organisation and Organisation Type Identifier

 
     

NHS Organisations:

A Frame:

Example
Independent Provider (IP) e.g. 8HA03

  • 8 = Organisation Type Identifier
  • Remainder of code identifies organisation

Also:

Cancer Registrye.g. Y0401
Primary Care Group/Local Health Group (now all closed)e.g. 4AA24

B Frame:

Example
Local Service Provider e.g. LSP01

  • LSP = Organisation Type Identifier
  • 01 = Organisation Identifier

Also:

Application Service Providere.g. YGM01
Education (Deanery)e.g. YDF01
NHS Support Agenciese.g. YDD01
Workforce Development Confederation (All closed June 2006) e.g. LWF03

C Frame:

Example
School e.g. EE134290

  • EE = Organisation Type Identifier
  • Remainder of code identifies organisation

D Frame:

Example
Strategic Health Authority e.g. Q30

  • Q = Organisation Type Identifier
  • 30 = Organisation Identifier

Also:

Care Trust e.g. TAK
Local Health Board (Wales) e.g. 7A1
NHS Trust e.g. RH8
Primary Care Trust e.g. 5CT
Welsh Local Health Board (All closed 30 September 2009) e.g. 6C4

E Frame:

Example
Government Office Region (GOR) e.g. K

  • K = Organisation Identifier
Note: ORGANISATION TYPE of Government Office Region (GOR) is identified by a one character code; no other one character code exists.

F Frame:

Example
Pharmacy HQ e.g. P001

  • P = Organisation Type Identifier
  • 001 = Organisation Identifier

Also:

Care Home Headquarterse.g.CA0A
Local Authority
Please Note: The Local Authority codes are not available for general use
but must only be used to facilitate Spine Smartcard and Endpoint Registration
.
e.g.V001
Optical Headquarters e.g.T1A1

G Frame:

Example
GP Practice e.g. Y00001

  • Y = Organisation Type Identifier
  • 00001 = Practice Identifier

Also:

General Dental Practicee.g.V20052

H Frame:

Example
Cancer Network e.g. N01

  • N0 (where the 2nd character is numeric and not alpha) = Organisation Type Identifier
  • 1 = Organisation Identifier

Also:

Booking Management System (BMS) Call Centre Establishmente.g. YF1
Government Departmente.g. XDA
Independent Sector Healthcare Provider (ISHP) (where the 2nd character is alpha)e.g. NV7
IT Cluster (ITC) (All closed in England on 31 March 2007) e.g. Y41
National Application Service Provider (NASP) (NPfIT)e.g. YEA
Other Statutory Authority (OSA)e.g. X16
Pan SHAe.g. Y51

I Frame:

Example
Special Health Authority (SpHA) e.g. T1150

  • T1 = Organisation Type Identifier
  • 150 = Organisation Identifier

J Frame:

Example
Transplant Consortium e.g. Y01T1

  • Y01T = Organisation Type Identifier
  • 1 = Organisation Identifier

K Frame:

Example
NHS Wales Informatics Service e.g. W00

  • W00 = Organisation Identifier

L Frame:

Example
Local Commissioning Group (Northern Ireland) e.g. ZC010

  • Characters 1-3 (ZC0) AND character 5 (0) = Organisation Type Identifier
  • Character 4 identifies organisation

Note: this is a 5 character method of displaying Local Commissioning Group (Northern Ireland) identifiers.
Characters 3 and 5 are ‘fillers’. If a 3 character code is required (as used by the Office for National Statistics in the NHS Postcode Directory) zeros can be omitted, e.g. ZC1.
The 3 character method of displaying the Local Commissioning Group (Northern Ireland) identifiers fit under the H Frame.
Guidance on the use of Northern Ireland codes can be found in Data Set Change Notice 19/2009.


M Frame:

Example
Clinical Commissioning Group (CCGFrom April 2013 e.g. 12A

  • 12A = Organisation and Organisation Type Identifier

The structure and format of ORGANISATION CODES maintained by the Organisation Data Service, NHS Prescription Services, NHS Dental Services and other agencies are detailed in the tables below.

ORGANISATION CODES TABLES

Table 1: CODING FORMATS FOR ORGANISATIONS IN ENGLAND AND WALES

ORGANISATION CODES for England and Wales are published by the Organisation Data Service and can be found:

Organisation Type

Frame Type

Character Position

Code allocated by:

Notes/Comments

 

See Coding Frames Table

 

1

 

2

 

3

 

4

 

5

 

6

 

7

 

8

 
  

Application Service Provider

 

B

 

Y

 

G

 

M

 

A-9

 

A-9

 
   

ODS 

 

e.g. YGM01

 

Booking Management System (BMS) Call Centre Establishment

 

H

 

Y

 

F

 

A-9

 
     

ODS

 

e.g. YF1

 

Cancer Network

 

H

 

N

 

0-9

 

A-9

 
     

ODS

 

e.g. N01

 

Cancer Registry

 

A

 

Y

 

A-9

 

A-9

 

A-9

 

A-9

 
   

ODS

 

e.g. Y0401

 

Care Home Headquarters

 

F

 

A, C or D

 

A-9

 

A-9

 

A-9

 
    

ODS

 

e.g. CA0A

 

Care Trust (CT)

 

D

 

T

 

A-Y

 

A-Y

 
     

ODS

 

e.g. TAK

 

Clinical Commissioning Group (CCG)
From April 2013

 

M

 

0-9

 

0-9

 

A-Y

 
     

ODS

 

From April 2013

e.g. 12A

 

Directorate of Health and Social Care (DHSC)

 

N/A

All Closed

Y

 

2

 

0-9

 
     

ODS

 

DHSCs in England all closed in June 2003

e.g. Y21

 

Directorate of Health and Social Care (DHSC)

 

N/A

All Closed

Y

 

2

 

0-9

 
     

ODS

 

DHSCs in England all closed in June 2003

e.g. Y21

 

Education (Deanery)

 

B

 

Y

 

D

 

F

 

A-9

 

A-9

 
   

ODS

 

e.g. YDF01

 

Executive Agency

 

N/A

See Note 1 

X

 

0-9

 

0-9

 
     

ODS

 

e.g. X09

 

Executive Agency Programme

 

N/A

See Note 1 

X

 

0-9

 

0-9

 

0-9

 

0-9

 

0-9

 
  

ODS

 

First three characters denote Executive Agency

e.g. X09001

 

General Dental Practice - England and Wales

 

G

 

V

 

0-9

 

0-9

 

0-9

 

0-9

 

0-9

 
  

NHS Dental Services

 

e.g. V20052

 

Government Department

 

H

 

X

 

A-Y

 

A-Y

 
     

ODS

 

e.g. XDA

 

Government Office Region (GOR)

 

E

 

A-Y

 
       

ONS

 

e.g. K

Government Office Regions (GORs) closed 31 March 2011 - from 1 April 2011 referred to as Regions

 

GP Practice - England and Wales

 

G

 

A-H,
J-N,
P,
W &
Y

 

0-9

 

0-9

 

0-9

 

0-9

 

0-9

 
  

NHS Prescription Services

 

Char 1 = W for Welsh GP Practice.
All other values represent English GP Practices

From 2003, ALL newly allocated Practice Codes begin with a Y"

e.g. Y00001

 

Independent Provider (IP

 

A

 

8

 

A-Y

 

A-9

 

0-9

 

0-9

 
   

ODS - England
NHS Wales Informatics Service - Wales

 

Character 2: W - Wales.

All other values represent England.

e.g. 8HA03

 

Independent Sector Healthcare Provider (ISHP)

 

H

 

A, B, D, G, I, K, L, M , N, O, S, U, V, W

 

A-Y

 

A-Y, 0-9

 
     

ODS

 

e.g. NV7

Note: The A-Y range includes all letters except Z

 

IT Cluster (ITC)

 

H

 

Y

 

4

 

0-9

 
     

ODS

 

e.g. Y41

All IT Clusters in England closed on 31 March 2007

 

Independent Sector Healthcare Provider (ISHP)

 

H

 

A, B, D, G, I, K, L, M , N, O, S, U, V, W

 

A-Y

 

A-Y, 0-9

 
     

ODS

 

e.g. NV7

IT Cluster (ITC)

 

H

 

Y

 

4

 

0-9

 
     

ODS

 

e.g. Y41

All IT Clusters in England closed on 31 March 2007

 

Local Authority (LA)

 

F

 

V

 

A-9

 

A-9

 

A-9

 
    

ODS

 

e.g. V001

 

Local Commissioning Group (Northern Ireland)

 

L

 

Z

 

C

 

0

 

0-9

 

0

 
   

Department for Health, Social Services and Public Safety (DHSSPS), Northern Ireland

 

e.g.ZC010

Note that characters 3 and 5 are ‘fillers’ to create a 5 character code. If a 3 character code is required (as used by the Office for National Statistics in the NHS Postcode Directory), zeros can be omitted and fits under the H frame: e.g. ZC1.
Guidance on the use of Northern Ireland codes can be found in Data Set Change Notice 19/2009. 

 

Local Health Board (Wales)

 

B

 

7

 

A-9

 

A-9

 
     

ODS 

 

e.g. 7A1 

 

Local Service Provider (LSP)

 

B

 

L

 

S

 

P

 

0-9

 

0-9

 
   

ODS

 

e.g. LSP01

 

National Application Service Provider (NASP) (NPfIT)

 

H

 

Y

 

E

 

A-9

 
     

ODS

 

e.g. YEA

 

NHS Support Agencies (Shared Services and Health Informatics Services)

 

B

 

Y

 

D

 

D

 

A-9

 

A-9

 
   

ODS

 

e.g. YDD01

 

NHS Trust

 

D

 

R

 

A-9

 

A-9

 
     

ODS

 

e.g. RH8

 

NHS Wales Informatics Service (NWIS)

 

K

 

W

 

0

 

0

 
     

ODS

 

Only one organisation of this type exists for Wales

e.g. W00

 

Optical Headquarters

 

 

 

0-9

 

A-9

 

A-9

 
    

ODS 

 

e.g. T1A1 

 

Other Statutory Authority (OSA)

 

H

 

X

 

0-9

 

0-9

 
     

ODS

 

e.g. X16

 

Pan SHA

 

H

See Note 2 

Y

 

5

 

0-9

 
     

ODS

 

e.g. Y51

 

Pharmacy HQ

 

F

 

P

 

A-9

 

A-9

 

A-9

 
    

ODS

 

e.g. P001

 

Primary Care Group/ Local Health Group

 

A

 

4

 

A-Y

 

A-Y

 

0-9

 

0-9

 
   

ODS

 

Primary Care Groups in England and Local Health Groups in Wales
2nd char = W for Welsh LHGs.

PCGs all closed by March 2002

e.g. 4AA24

 

Primary Care Group/ Local Health Group

 

A

 

4

 

A-Y

 

A-Y

 

0-9

 

0-9

 
   

ODS

 

Primary Care Groups in England and Local Health Groups in Wales
2nd char = W for Welsh LHGs.

PCGs all closed by March 2002

e.g. 4AA24

 

Primary Care Trust (PCT)

 

D

 

5

 

A-9

 

A-9

 
     

ODS

 

e.g. 5CT

 

School

 

C

 

E

 

E

 

A-9

 

A-9

 

A-9

 

A-9

 

A-9

 

A-9

 

Department for Education and ODS

 

e.g. EE134290

 

Special Health Authority (SpHA)

 

I

 

T

 

1

 

0-9

 

0-9

 

0

 
   

ODS

 

e.g. T1150

 

Strategic Health Authority (SHA)

 

D

 

Q

 

A-9

 

A-9

 
     

ODS

 

Strategic Health Authorities in England

e.g. Q30

 

Transplant Consortium

 

J

 

Y, S, W or Z

 

0-9

 

0-9

 

T

 

0-9

 
   

ODS

 

English Transplant Consortiums are all Closed.

England = Y, Scotland = S, Wales = W and N.Ireland = Z

e.g. Y01T1

 

Welsh Local Health Board (WLHB)

 

D

 

6

 

A-Y

 

0-9

 
     

ODS

 

e.g. 6C4

All Welsh Local Health Boards closed on 30 September 2009.

Local Health Boards introduced from 1 October 2009.

 

Workforce Development Confederation

 

B

 

L

 

W

 

F

 

A-9

 

A-9

 
   

ODS

 

e.g. LWF03

All closed June 2006

 

Transplant Consortium

 

J

 

Y, S, W or Z

 

0-9

 

0-9

 

T

 

0-9

 
   

ODS

 

English Transplant Consortiums are all Closed

England = Y, Scotland = S, Wales = W and N.Ireland = Z

e.g. Y01T1

 

Welsh Local Health Board (WLHB)

 

D

 

6

 

A-Y

 

0-9

 
     

ODS

 

e.g. 6C4

All Welsh Local Health Boards closed on 30 September 2009

Local Health Boards introduced from 1 October 2009

 

Workforce Development Confederation

 

B

 

L

 

W

 

F

 

A-9

 

A-9

 
   

ODS

 

e.g. LWF03

All closed June 2006

 

Note 1: Codes for Executive Agency, Executive Agency Programme, Executive Agency Site and Executive Agency Programme Department do not easily fit into the coding frames as shown above and are therefore not included. This is due to their unusual structure in that there are more hierarchical 'tiers' than with other organisations.

Executive Agency and Executive Agency Programme are both considered Organisation level entities, although each Programme does have a relationship to an Executive Agency. Executive Agency codes are three characters long. Executive Agency Programme codes are six, and their first three characters are the same as the Executive Agency they are associated to.

Department codes of eight characters long can then be allocated underneath a Programme code (sharing the first six characters). Executive Agency Site codes of five characters long can be allocated under an Executive Agency code (and share the first three characters).

Note 2: The Pan SHAs are made up of confederations of SHAs and as such, are Health Areas, not organisations. However, it has been recognised that these health areas do require codes in order that NHS systems continue to function.


Note: A-9 indicates that characters A-Z and 0-9 are valid: except B, I, O, S, U and Z (to avoid ambiguity). This applies to all ORGANISATION CODES in the Coding Format Table above except Independent Sector Healthcare Providers (ISHP).

Table 2: CODING FORMATS FOR ORGANISATIONS IN SCOTLAND

Scottish ORGANISATION CODES are supplied by the Information Standards Directorate from NHS Scotland and published by the Organisation Data Service:

Organisation Type

Character Position

Code allocated by:

Notes/Comments

 123456  
GP Practice - ScotlandS0-90-90-90-90-9NHS 

Scottish GP Fundholder

 

S

 

A-Z

 

B

 

0-9

 

0-9

 
 

ISD, Scotland

 

2nd character identifies the Health Board the GPFH reports to.
3rd character (always B) shows GPFH status.

 

Scottish Health Agency

 

S

 

D

 

0-9

 

0-9

 

0-9

 
 

ISD, Scotland

 

2nd character (D) identifies Scottish Office agencies

 

Scottish Health Board

 

S

 

A-Z

 

9

 

9

 

9

 
 

ISD, Scotland

 
 

Scottish Provider

 

S

 

A-Z

 

A,C,D

 

0-9

 

0-9

 
 

ISD, Scotland

 

2nd character identifies the Health Board the organisation reports to.
3rd character identifies the organisation type:
A= Health Unit
C = Hospital Trust
D = Nursing Home

 

  

Table 3: CODING FORMATS for ORGANISATIONS in OTHER HOME COUNTRIES

ORGANISATION CODES for Isle of Man Government Departments, Directorates and Sites are published by the Organisation Data Service and can be found:

Organisation Type

Character Position

Code allocated by:

Notes/Comments

 123456  

GP Practice - Alderney

 

A

 

L

 

D

 

0-9

 

0-9

 

0-9

 

NHS Prescription Services

 
 

GP Practice - Guernsey

 

G

 

U

 

E

 

0-9

 

0-9

 

0-9

 

NHS Prescription Services

 
 

GP Practice - Isle of Man (IOM)

 

Y

 

0-9

 

0-9

 

0-9

 

0-9

 

0-9

 

NHS Prescription Services

 
 

GP Practice - Jersey

 

J

 

E

 

R

 

0-9

 

0-9

 

0-9

 

NHS Prescription Services

 
 

Isle of Man (IOM) Government Department

 

Y

 

J

 

A-9

 
   

ODS

 

e.g. YJM

 

Primary Healthcare Directorate (Isle of Man)

 

Y

 

K

 

A-9

 
   

ODS

 

e.g. YK1

 

Note: A-9 indicates that characters A-Z and 0-9 are valid: except B, I, O, S, U and Z (to avoid ambiguity).

 

top


ORGANISATION SITE CODE

Change to Attribute: Changed Description

An ORGANISATION SITE CODE is a code which identifies an ORGANISATION SITE uniquely.

Note: Only ORGANISATION SITE CODES which have been notified to and issued by the Organisation Data Service may be used.

Notes:

ORGANISATION SITE CODING FRAMES

Character
Position

1

2

3

4

5

6

7

8

9

Format

 

a/n

 

a/n

 

a/n

 

a/n

 

a/n

 

a/n

 

a/n

 

a/n

 

a/n

 

A Frame

 

Organisation Type Identifier

 

Organisation Identifier

 

Site or Sub-Division Identifier

 
  

B Frame

 

Organisation Type Identifier

 

Organisation Identifier

 

Site or Sub-Division Identifier

 
    

C Frame

 

Organisation Type Identifier

 

Organisation Identifier

 

Site or Sub-Division Identifier

 
    

D Frame

 

Organisation Type
Identifier

 

Practice Identifier

 

Branch Surgery Identifier

 

E Frame

 

Organisation Type Identifier

 

Organisation Identifier

 

Site or Sub-Division Identifier

 
    

F Frame

 

Organisation Type
Identifier

 

Organisation Identifier

 
    

G Frame

 

Organisation Type
Identifier

 

Organisation Identifier

 

Site or Sub-Division Identifier

 
   

H Frame

 

Organisation Type Identifier

 

Organisation Identifier

 
    

I Frame

 

Organisation Type Identifier

 

Organisation Identifier

 
    

J Frame

 

Organisation Type Identifier

 

Organisation Identifier

 
    

K Frame

 

Organisation and Organisation Type Identifier

 

Organisation Site Identifier

 
    

NHS Organisation Sites:

A Frame:

Example
Local Service Provider Site e.g. LSP0101

  • LSP = Org Type Identifier
  • 01 = Organisation Identifier
  • 01 = Site or sub-division

B Frame:

Example
Strategic Health Authority Site e.g. Q3001

  • Q = Organisation Type Identifier
  • 30 = Organisation Identifier
  • 01 = Site or sub-division

Also:

Primary Care Trust Sitee.g. 5CT49
Care Trust Sitee.g. TAK01
Other Statutory Authority (OSA) Sitee.g. X1601
NHS Trust Sitee.g. RH802
Government Department Sitee.g. XDA01
Local Health Board (Wales) Sitee.g. 7A101
Welsh Local Health Board Site (all closed 30 September 2009) e.g. 6C401
Treatment Centree.g. 5CG12

C Frame:

Example
Independent Sector Healthcare Provider (ISHP) Site e.g. NV701

  • NV = Organisation Site Type Identifier
  • 7 = Organisation Identifier
  • 01 = equals site or sub-division

Also:

Primary Healthcare Directorate (Isle of Man) Sitee.g. YK101

D Frame

Example
GP Practice Branch Surgery: e.g. H81010002

  • H (and length of code) = Organisation Identifier
  • 81010 = Organisation Identifier (parent GP Practice)
  • 002 = Branch Surgery Identifier

E Frame

Example
Special Health Authority (SpHA) Site: e.g. T115A

  • T1 = Organisation Type Identifier
  • 15 = Organisation Identifier
  • A = Site or Sub-Division Identifier

F Frame

Example
Dispensary: e.g. FA002

  • F = Organisation Type Identifier
  • A002 = Organisation Identifier

G Frame

Example
Local Authority Site: e.g. V001AA

  • V = Organisation Type Identifier
  • 001 = Organisation Identifier
  • AA = Site or Sub-Division Identifier

Please Note: The Local Authority codes are not available for general use but must only be used to facilitate Spine Smartcard and Endpoint Registration.


H Frame

Example
Prison: e.g. YDE01

  • YDE = Organisation Type Identifier
  • 01 = Site or Sub-Division Identifier

I Frame

Example
Optical Site: e.g. TP01A,

  • TP = Organisation Type Identifier
  • 01A = Site or Sub-Division Identifier

J Frame

Example
Care Home Site: e.g. VN01A

  • VN = Organisation Type Identifier
  • 01A = Site or Sub-Division Identifier

K Frame

Example
Clinical Commissioning Group (CCG) Site From April 2013, e.g. 11AAA - 99YZZ

  • 11A = Organisation and Organisation Type Identifier
  • AA = Organisation Site Identifier

The structure and format of ORGANISATION SITE CODES maintained by the Organisation Data Service, NHS Prescription Services and other agencies are detailed in the tables below.

NHS ORGANISATION SITE CODES TABLES

Coding Formats

Table 1: CODING FORMATS FOR ORGANISATION SITES IN ENGLAND AND WALES

ORGANISATION SITE CODES for England and Wales are published by the Organisation Data Service and can be found:

Organisation Type

Frame Type

Character Position

Code allocated by:

Notes/Comments

 

See Coding Frames Table

 

1

 

2

 

3

 

4

 

5

 

6

 

7

 

8

 

9

 
  

Care Home Site

 

J

 

V

 

L, M or N

 

A-9

 

A-9

 

A-9

 
    

ODS

 

e.g. VN01A, VM01A, VL01A

 

Care Trust Site

 

B

 

T

 

A-Y

 

A-Y

 

A-9

 

A-9

 
    

ODS

 

First three characters denote owning Care Trust

e.g. TAK01

 
Clinical Commissioning Group (CCG) Site
From April 2013 

K

 

0-9

 

0-9

 

A-Y

 

A-Y

 

A-Y

 
    

ODS

 

From April 2013

First three characters denote owning Clinical Commissioning Group

e.g. 11AAA - 99YZZ

 

Dispensary

 

F

 

F

 

A-Y

 

A-9

 

0-9

 

0-9

 
    

NHS Prescription Services

 

e.g. FA002

 

Executive Agency Site

 

N/A

See Note

 

X

 

0-9

 

0-9

 

0-9

 

0-9

 
    

ODS

 

First three characters denote Executive Agency

e.g. X0901

 

Government Department Site

 

B

 

X

 

A-Y

 

A-Y

 

0-9

 

0-9

 
    

ODS

 

First three characters denote Government Department

e.g. XDA01

 

GP Practice Branch Surgery - England and Wales

 

D

 

A-H,
J-N,
P,
W &
Y

 

0-9

 

0-9

 

0-9

 

0-9

 

0-9

 

0-9

 

0-9

 

0-9

 

ODS

 

First 6 characters denote parent practice. Char 1 = W for Welsh GP Practice.

All other values represent English GP Practices

e.g. H81010002

 

Independent Sector Healthcare Provider (ISHP) Site

 

C

 

A, B, D, G, I, K, L, M , N, O, S, U, V, W

 

A-Y

 

A-Y, 0-9

 

A-Y, 0-9

 

A-Y, 0-9

 
    

ODS

 

First three characters denote owning Independent Sector Healthcare Provider (ISHP)

e.g. NV701

Note: The A-Y range includes all letters except Z

 

Local Authority (LA) Site

 

G

 

V

 

A-9

 

A-9

 

A-9

 

A-Y

 

A-Y

 
   

ODS

 

First four characters denote LA

e.g. V001AA

 
Local Health Board (Wales) Site

B

 

7

 

A-9

 

A-9

 

A-9

 

A-9

 
    

ODS

 

First three characters denote owning NHS Trust

e.g. 7A101

 

Local Service Provider (LSP) Site

 

A

 

L

 

S

 

P

 

0-9

 

0-9

 

0-9

 

0-9

 
  

ODS

 

First five characters denote owning Local Service Provider

e.g. LSP0101

 

NHS Trust Site

 

B

 

R

 

A-9

 

A-9

 

A-9

 

A-9

 
    

ODS

 

First three characters denote owning NHS Trust

e.g. RH802

 

Optical Site

 

I

 

T

 

P or Q

 

0-9

 

A-9

 

A-9

 
    

ODS

 

e.g. TP01A, TQ01A

 

Other Statutory Authority (OSA) Site

 

B

 

X

 

0-9

 

0-9

 

0-9

 

0-9

 
    

ODS

 

First three characters denote owning Other Statutory Authority

e.g. X1601 

 

Primary Care Trust (PCT) Site

 

B

 

5

 

A-9

 

A-9

 

A-9

 

A-9

 
    

ODS

 

First three characters denote owning Primary Care Trust

e.g. 5CT49

 

Prison

 

H

 

Y

 

D

 

E

 

A-9

 

A-9

 
    

ODS

 

e.g. YDE01

 

Special Health Authority (SpHA) Site

 

E

 

T

 

1

 

0-9

 

0-9

 

A-Y, 1-9

 
    

ODS

 

First three characters denote owning SpHA

e.g. T115A

 

Strategic Health Authority (SHA) Site

 

B

 

Q

 

A-9

 

A-9

 

A-9

 

A-9

 
    

ODS

 

First three characters denote owning SHA Trust

e.g. Q3001

 

Treatment Centre

 

B

 

5,
N or
R

 

A-9

 

A-9

 

A-9

 

A-9

 
    

ODS

 

First three characters denote owning NHS TrustPCT or Private Healthcare Provider

e.g. 5CG12, NT501, RBFTC

 

Welsh Local Health Board Site

 

B

 

6

 

A-Y

 

0-9

 

A-9

 

A-9

 
    

NHS Wales Informatics Service

 

First three characters denote owning Local Health Board (Wales)

e.g. 6C4A1

All Welsh Local Health Board Sites closed on 30 September 2009.

Local Health Board Sites introduced from 1 October 2009.

 

Welsh Local Health Board Site

 

B

 

6

 

A-Y

 

0-9

 

A-9

 

A-9

 
    

NHS Wales Informatics Service

 

First three characters denote owning Local Health Board (Wales)

e.g. 6C4A1

All Welsh Local Health Board Sites closed on 30 September 2009

Local Health Board Sites introduced from 1 October 2009

 

Note: Codes for Executive Agency, Executive Agency Programme, Executive Agency Site and Executive Agency Programme Department do not easily fit into the coding frames as shown above and are therefore not included. This is due to their unusual structure in that there are more hierarchical 'tiers' than with other organisations.

Executive Agency and Executive Agency Programme are both considered Organisation level entities, although each Programme does have a relationship to an Executive Agency. Executive Agency codes are three characters long. Executive Agency Programme codes are six, and their first three characters are the same as the Executive Agency they are associated to.

Department codes of eight characters long can then be allocated underneath a Programme code (sharing the first six characters). Executive Agency Site codes of five characters long can be allocated under an Executive Agency code (and share the first three characters).


Note: A-9 indicates that characters A-Z and 0-9 are valid: except B, I, O, S, U and Z (to avoid ambiguity). This applies to all ORGANISATION SITE CODES in the Coding Format Table above except Independent Sector Healthcare Provider (ISHP) sites.

  

Table 2: CODING FORMATS FOR ORGANISATION SITES IN OTHER HOME COUNTRIES

ORGANISATION SITE CODES for Isle of Man Government Departments, Directorates and Sites are published by the Organisation Data Service and can be found:

Organisation Type

Character Position

Code allocated by:

Notes/Comments

 12345  

Primary Healthcare Directorate (Isle of Man) Site

 

Y

 

K

 

A-9

 

A-9

 

A-9

 

ODS

 

First three characters denote parent IOM Directorate

e.g. YK101

 

Note: A-9 indicates that characters A-Z and 0-9 are valid: except B, I, O, S, U and Z (to avoid ambiguity).

 

top


PATIENT DIAGNOSIS TYPE FOR NHS HEALTH CHECK

Change to Attribute: Changed Description

The type of PATIENT diagnosis provided as a result of an NHS Health Check Assessment.The type of PATIENT DIAGNOSIS provided as a result of an NHS Health Check Assessment.

National Codes:

01Chronic Kidney Disease Stage 3
02Chronic Kidney Disease Stage 4
03Chronic Kidney Disease Stage 5
04Type 2 Diabetes
05Hypertension
06Non Diabetic Hyperglycaemia
 

top


ABSENCE WITHOUT LEAVE END DATE (RETIRED)  renamed from ABSENCE WITHOUT LEAVE END DATE

Change to Data Element: Changed Name, status to Retired, Description

Format/Length:see DATE 
HES Item: 
National Codes: 
Default Codes: 

Notes:
ABSENCE WITHOUT LEAVE END DATE is the same as attribute LEAVE END DATE where the LEAVE TYPE is National Code 'Absence Without Leave'.

ABSENCE WITHOUT LEAVE END DATE is the end date of a period of Mental Health Absence Without Leave for a PATIENT detained under the Mental Health Acts 1983.This item has been retired from the NHS Data Model and Dictionary and it is no longer required for the Mental Health Minimum Data Set.

 See the Clinical Data Sets Menu for a link to the latest version of the data set.

The last live version of this item is available in the September 2012 release of the NHS Data Model and Dictionary.

Access to this version can be obtained by emailing datastandards@nhs.net with "NHS Data Model and Dictionary - Archive Request" in the email subject line.

 

top


ABSENCE WITHOUT LEAVE END DATE (RETIRED)  renamed from ABSENCE WITHOUT LEAVE END DATE

Change to Data Element: Changed Name, status to Retired, Description

top


ABSENCE WITHOUT LEAVE START DATE (RETIRED)  renamed from ABSENCE WITHOUT LEAVE START DATE

Change to Data Element: Changed Name, status to Retired, Description

Format/Length:see DATE 
HES Item: 
National Codes: 
Default Codes: 

Notes:
ABSENCE WITHOUT LEAVE START DATE is the same as attribute LEAVE START DATE where the LEAVE TYPE is National Code 'Absence Without Leave'.

ABSENCE WITHOUT LEAVE START DATE is the Start Date of a period of Mental Health Absence Without Leave for a PATIENT detained under the Mental Health Acts 1983 as amended by the Mental Health Act 2007.This item has been retired from the NHS Data Model and Dictionary and it is no longer required for the Mental Health Minimum Data Set.

 See the Clinical Data Sets Menu for a link to the latest version of the data set.

The last live version of this item is available in the September 2012 release of the NHS Data Model and Dictionary.

Access to this version can be obtained by emailing datastandards@nhs.net with "NHS Data Model and Dictionary - Archive Request" in the email subject line.

 

top


ABSENCE WITHOUT LEAVE START DATE (RETIRED)  renamed from ABSENCE WITHOUT LEAVE START DATE

Change to Data Element: Changed Name, status to Retired, Description

top


ACTIVITY TREATMENT FUNCTION CODE

Change to Data Element: Changed Description

Format/Length:an3
HES Item:TRETSPEF
National Codes:See TREATMENT FUNCTION CODE
Default codes:199 - Non-UK provider; TREATMENT FUNCTION not known, treatment mainly surgical
 499 - Non-UK provider; TREATMENT FUNCTION not known, treatment mainly medical

Notes:
This is the TREATMENT FUNCTION under which the PATIENT is treated. It may be the same as the MAIN SPECIALTY CODE or a different TREATMENT FUNCTION which will be the CARE PROFESSIONAL's treatment interest.This item is being used for development purposes and has not yet been assured by the Information Standards Board for Health and Social Care.

Midwife Episodes and Nursing Episodes may use any appropriate ACTIVITY TREATMENT FUNCTION CODE.

The default codes 199 and 499 are only applicable for overseas health care providers.

ACTIVITY TREATMENT FUNCTION CODE replaces TREATMENT FUNCTION CODE, and should be used for all new and developing data sets and for XML messages.

 

top


ASSESSMENT DATE (FOR TRANSPLANT SUITABILITY)

Change to Data Element: Changed Description

Format/Length:See DATE 
HES Item: 
National Codes: 
Default Codes: 

Notes:
ASSESSMENT DATE (FOR TRANSPLANT SUITABILITY) is the same as attribute ACTIVITY DATE where the ACTIVITY DATE TIME TYPE is National Code 'Assessment Date For Transplant Suitability'.ASSESSMENT DATE (FOR TRANSPLANT SUITABILITY) is the same as attribute ACTIVITY DATE where the ACTIVITY DATE TYPE is National Code 'Assessment Date For Transplant Suitability'.

 

top


CDS RECORD IDENTIFIER

Change to Data Element: Changed Description

Format/length:an35
HES item: 
Format/Length:an35
HES Item: 
National Codes: 
Default Codes: 


Notes:
CDS RECORD IDENTIFIER may also be referred to as the CDS-RID.

When exchanging Commissioning Data Set data, this is an optional data element and when used is a unique number generated by the sender and inserted into the Commissioning Data Set data to enable senders and recipients to be able to cross-match and uniquely identify each and every Commissioning Data Set record.

The CDS RECORD IDENTIFIER consists of the following components:

REFRID COMPONENTFORMATCODES / VALUES
1CDS SENDER IDENTITY an5As generated in the CDS V6-2 Type 005B - CDS Transaction Header Group - Bulk Update Protocol or the CDS V6-2 Type 005N - CDS Transaction Header Group - Net Change Protocol 
2Not Usedan2Set = Blank
3CDS INTERCHANGE CONTROL REFERENCE an14
(n7) *
As generated in the CDS V6-2 Type 001 - CDS Interchange Header 
4CDS MESSAGE REFERENCE an14
(n7) *
As generated in the CDS V6-2 Type 003 - CDS Message Header 

* This data item is configured as an14 format element, but a maximum value of 9999999 is permitted in the format of n7.

Usage:

The CDS-RID is an optional reference assigned to each record by the Commissioning Data Set sender to aid the identification and cross-referencing of data between the sender and the receiver(s) of the Commissioning Data Set data.

CDS-XML Interchanges:

The CDS-RID data element is carried in the CDS Message Header (CDS V6-2 Type 003 - CDS Message Header). 

top


COMMISSIONER OR PROVIDER STATUS INDICATOR

Change to Data Element: Changed Description

Format/length:n2
HES item: 
Format/Length:n2
HES Item: 
National Codes: 
Default Codes: 


Notes:
This indicates whether a Central Information Requirement Data Set and the data it contains is a submission from the ORGANISATION in the role of commissioner of care or provider of care.

COMMISSIONER OR PROVIDER STATUS INDICATOR indicates whether a Central Information Requirement Data Set and the data it contains is a submission from the ORGANISATION in the role of commissioner of care or provider of care.

Permitted National Codes:

01Commissioner submission
02Provider submission
 

top


COMMISSIONER REFERENCE NUMBER

Change to Data Element: Changed Description

Format/length:an17
HES item: 
Format/Length:an17
HES Item: 
National Codes: 
Default Codes:8 (left justified padded with spaces) - Not applicable
9 (left justified padded with spaces) - Not known
 Notes:
COMMISSIONER REFERENCE NUMBER is the same as attribute COMMISSIONER REFERENCE NUMBER. 

top


COMMISSIONING SERIAL NUMBER

Change to Data Element: Changed Description

Format/length:an6
HES item:CSNUM
Format/Length:an6
HES Item:CSNUM
National Codes: 
Default Codes: 

Notes:
This is the same as attribute NHS SERVICE AGREEMENT NUMBER.COMMISSIONING SERIAL NUMBER is the same as attribute NHS SERVICE AGREEMENT NUMBER.

From 01/04/2001 this data item will be used to identify PATIENTS treated under Non-Contract Activities. NHS Trusts are required to insert the letters 'OAT' (mandated input as capitals) in the first three characters of the COMMISSIONING SERIAL NUMBER field of the Admitted Patient Care Commissioning Data Set. The remaining three characters will continue to be defined locally, see Data Set Change Notice 17/2000.

From 01/04/2005 an '=' (equals) as the last significant character in this six character field will indicate an episode that should be excluded from the Payment by Results tariff. The position of the last character depends on any preceding characters eg 1st character if field is otherwise blank, 4th character if following 'OAT', up to a maximum of 6th position. This provides a general exclusion facility for unusual circumstances or where more specific rules regarding coding in other fields cannot be implemented due to local software restrictions.

 

top


EARLIEST CLINICALLY APPROPRIATE DATE

Change to Data Element: Changed Description

Format/Length:See DATE 
HES Item: 
National Codes:
Default Codes: 


Notes:
EARLIEST CLINICALLY APPROPRIATE DATE is the earliest DATE that it was clinically appropriate for an ACTIVITY to take place.

For the Radiotherapy Data Set this is the same as the DECISION TO TREAT DATE unless there was an elective delay.

For the Community Information Data Set and Commissioning Data Sets (version 6-2 onwards), the EARLIEST CLINICALLY APPROPRIATE DATE may be used locally to inform waiting time calculations.  It can be used to account for periods of time where it is not appropriate to treat the PATIENT for clinical reasons, for example:

 

top


END TIME (SUPERVISED COMMUNITY TREATMENT RECALL)

Change to Data Element: Changed Description

Format/Length:See TIME
HES Item: 
National Codes: 
Default Codes: 

Notes:
END TIME (SUPERVISED COMMUNITY TREATMENT RECALL)  is the same as attribute ACTIVITY TIME where the ACTIVITY TIME TYPE is National Code 'End Time' of the Supervised Community Treatment Recall.,,,,  

top


LEAVE OF ABSENCE END DATE (RETIRED)  renamed from LEAVE OF ABSENCE END DATE

Change to Data Element: Changed Name, status to Retired, Description

Format/length:see LEAVE END DATE 
HES item: 
National Codes: 
Default Codes: 

Notes:
This is the same as attribute LEAVE END DATE where the LEAVE TYPE is National Code 03 Leave of Absence. This is the end date of a period of Mental Health Leave Of Absence for a PATIENT detained under the Mental Health Acts 1983 as amended by the Mental Health Act 2007. This item has been retired from the NHS Data Model and Dictionary and it is no longer required for the Mental Health Minimum Data Set.

See the Clinical Data Sets Menu for a link to the latest version of the data set.

The last live version of this item is available in the September 2012 release of the NHS Data Model and Dictionary.

Access to this version can be obtained by emailing datastandards@nhs.net with "NHS Data Model and Dictionary - Archive Request" in the email subject line.

 

top


LEAVE OF ABSENCE END DATE (RETIRED)  renamed from LEAVE OF ABSENCE END DATE

Change to Data Element: Changed Name, status to Retired, Description

top


LEAVE OF ABSENCE START DATE (RETIRED)  renamed from LEAVE OF ABSENCE START DATE

Change to Data Element: Changed Name, status to Retired, Description

Format/length:see DATE 
HES item: 
National Codes: 
Default Codes: 

Notes:
This is the same as attribute LEAVE START DATE where the LEAVE TYPE is National Code 03 Leave of Absence. This is the start date of a period of Mental Health Leave Of Absence for a PATIENT detained under the Mental Health Acts 1983 as amended by the Mental Health Act 2007. This item has been retired from the NHS Data Model and Dictionary and it is no longer required for the Mental Health Minimum Data Set.

See the Clinical Data Sets Menu for a link to the latest version of the data set.

The last live version of this item is available in the September 2012 release of the NHS Data Model and Dictionary.

Access to this version can be obtained by emailing datastandards@nhs.net with "NHS Data Model and Dictionary - Archive Request" in the email subject line.

 

top


LEAVE OF ABSENCE START DATE (RETIRED)  renamed from LEAVE OF ABSENCE START DATE

Change to Data Element: Changed Name, status to Retired, Description

top


OPERATION STATUS CODE

Change to Data Element: Changed Description

Format/Length:an1
HES Item:OPERSTAT
National Codes: 
Default Codes: 

Notes:
OPERATION STATUS CODES should be used once for each record to record states of knowledge regarding the operative procedure.

This item is being used for development purposes and has not yet been assured by the Information Standards Board for Health and Social Care.Permitted National Codes:

1One or more operative procedure carried out
8Not applicable i.e. no operative procedures performed or intended
9Not known i.e. finished episode/out-patient attendance but no data entered or the episode is unfinished and no data needs to be present. This would be a validation error only for a finished episode
 Use in the Future Outpatient CDS:
If it is not intended to perform a procedure at the future attendance, use value 8. Otherwise this data element should be omitted.

OPERATION STATUS CODE replaces OPERATION STATUS and should be used for all new and developing data sets and for XML messages.

 

top


PASSPORT NUMBER (OLD)

Change to Data Element: Changed Description

Format/Length:7 alphanumeric characters
HES Item: 
National Codes: 
Default Codes: 

Notes:
PASSPORT NUMBER (NEW) is the same as attribute PASSPORT NUMBER for an old style blue passport book.PASSPORT NUMBER (OLD) is the same as attribute PASSPORT NUMBER for an old style blue passport book. 

top


PERSON BIRTH DATE

Change to Data Element: Changed Description

Format/Length:See DATE 
HES Item: 
HES Item:DOB
National Codes: 
Default Codes: 

Notes:
PERSON BIRTH DATE is the same as attribute PERSON BIRTH DATE.

This is the e-Government Interoperability Framework (e-GIF) standard that should be used for all new and developing systems and for XML messages.

 

top


PERSON BIRTH DATE (BABY)

Change to Data Element: Changed Description

Format/Length:See PERSON BIRTH DATE 
HES Item: 
HES Item:DOBBABY
National Codes: 
Default Codes: 

Notes:
PERSON BIRTH DATE (BABY) is the same as data element PERSON BIRTH DATE for the baby. 

top


PERSON BIRTH DATE (MOTHER)

Change to Data Element: Changed Description

Format/Length:See PERSON BIRTH DATE 
HES Item: 
HES Item:MOTDOB
National Codes: 
Default Codes: 

Notes:
PERSON BIRTH DATE (MOTHER) is the same as data element PERSON BIRTH DATE for the mother. 

top


PERSON HEIGHT IN CENTIMETRES

Change to Data Element: Changed Description

Format/Length:max n3.n1
HES Item: 
National Codes: 
Default Codes: 


Notes:
PERSON HEIGHT IN CENTIMETRES records the Height of the PERSON in centimetres.

 

top


PERSON HEIGHT IN METRES

Change to Data Element: Changed Description

Format/Length:n1.max n2
HES Item: 
National Codes: 
Default Codes: 

Notes:
PERSON HEIGHT IN METRES records the Height of the PERSON in metres.

This corresponds to MEASURED OBSERVATION VALUE where the MEASURED PERSON OBSERVATION TYPE CODE is 'Height' and MEASUREMENT VALUE TYPE CODE is 'Metres'.

For the Systemic Anti-Cancer Therapy Data Set, PERSON HEIGHT IN METRES is the Height at the start of the Systemic Anti-Cancer Drug Regimen.

 

top


RENAL TREATMENT MODALITY NO TREATMENT REASON DATE

Change to Data Element: Changed linked Attribute

RENAL TREATMENT MODALITY NO TREATMENT REASON DATE
 
Attribute:
PERSON PROPERTY RECORDED DATE

top


NE  renamed from NE

Change to Package: Changed Name

top


OC  renamed from OF

Change to Package: Changed Name

top


For enquiries, please email datastandards@nhs.net